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Introduction 
 
Chapter 1: Hydroxylated pipecolic acids in nature and in bioactive 
compounds 
   
L-Pipecolic acids (Figure 1) are cyclic, naturally occurring nonproteinogenic α-amino acids 
which have been isolated from plants, fungi, microorganisms and human physiological fluids1. 
 The simplest of them, (1, Figure 1) is the major product of the degradation of lysine in human 
brain2a and it accumulates in the body fluids causing pipecolic acidemia in subjects suffering 
from Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease2b,c. 
L-pipecolic acid 1 is a component of a wide range of pharmacologically active compounds, such 
as for example, the immunosuppressive agents rapamycin1c,3 (Figure 2) and FK5061c,4 (Figure 2) 
the antitumor antibiotic sandramycin5 (Figure 2) and the local anesthetic analogue ropivacaine6 
(Figure 2). Monohydroxy-substituted derivatives 2-7 (Figure 1a) are natural compounds which 
could be considered expanded hydroxyproline and serine analogues; they play an important role 
in medicinal chemistry as molecular scaffolds for the preparation of conformationally restricted 
peptides and pharmaceutically active substances or because they are essential structural 
components of naturally occurring compounds possessing noteworthy biological activity1a-b. 
So, 3-hydroxypipecolic acid 2 (Figure 1a) is embedded in the natural antitumor antibiotic 
tetrazomine7 (Figure 2) and 4-hydroxypipecolic acid 4 (Figure 1a) is incorporated in the 
structures of the HIV-protease inhibitor palinavir8 (Figure 3) and some antagonists of the 
cholecistokine hormone9 (Figure 3). 4-Hydroxypipecolic acid 4 has also been used for the 
preparation of one of the most potent and selective N-methyl-D-aspartic acid (NMDA) receptor 
antagonists, CGS2028110 (Figure 3) and LY27254110 (Figure 3). 
Naturally occurring 4-hydroxypipecolic acid derivatives form the largest subgroup of substituted 
pipecolic acids and include the cyclodepsipeptide antibiotic virginiamycin S111 (Figure 3), 
isolated from Streptomyces virginiae, serotonine receptor antagonist damipipecoline12 (Figure 3) 
recently isolated from Axinella damicornis sponge, ovalin (Figure 3) from leguminose Milletia 
ovolifolia seeds13, tumor necrosys factor α-converting enzyme inhibitor14(Figure 3) and a 
sulphate compound possessing NMDA receptor agonistic activity15 (Figure 3) from legume 
Peltophorum africanum. Pseudoconhydrine (Figure 3) is an example of natural compound 
embedding a reduced 5-hydroxypipecolic acid skeleton16. 
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Pipecolic acids bearing two or three hydroxyl groups (8-12, Figure 1) are much less widespread 
in nature and were isolated from just a few sources. 4,5-Dihydroxypipecolic acid 8 was extracted 
from the leaves of Derris elliptica17a, isomer 11 from D. elliptica17a and Calliandra 
haematocephala
17b, where it has a role in the specific resistance of plants to fungi18, and 
compound 9 from the leaves of Calliandra angustifolia and the sap of C. confusa19. 
 
Figure 1a: L-series pipecolic acids 
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Figure 1b: D-series pipecolic acids 
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Figure 1: Natural (L-series)  and non-natural (D-series) hydroxypipecolic acids 
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Cis,cis compound 10 has been detected by GC-MS in extracts from Tetraberlinia polyfilla 
together with 9 and isolated from the leaves of C. pittieri20. Similarly, compound 12 is the only 
trihydroxypipecolic acid known from natural sources as it has been isolated from the seeds of 
Baphia racemosa
21. 
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Figure 2: Bioactive compounds embedding pipecolic acids  
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Figure 3  
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Figure 3: Bioactive compounds embedding pipecolic acids 
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Chapter 2: Previous syntheses of mono-hydroxypipecolic acids 
 
Because of their medicinal applications it is not surprising that there has been much interest in 
developing synthetic strategies to attain enantiopure 3-, 4-, and 5-hydroxypipecolic acids. 
 
2.1 Synthesis from amino acids 
 
The most common source for the starting materials for the asymmetric synthesis of pipecolic 
acid derivatives are linear proteinogenic α-amino acids. General strategies involve the 
functionalization of the side chain followed by cyclization reaction with the α-amino group. 
 
L-pipecolic acid and 3-hydroxypipecolic acid have been prepared from hydroxyproline and 
serine derivatives, using a ring closing metathesis as the key step22a,b. The strategy involves the 
formation of an alkene side chain from an hydroxy group. Allylation of the α-amine followed by 
RCM reaction gives the pipecolic acid rings. For example, serine derivative 13 (Scheme 1) was 
converted in two steps into alcohol 14. 
 
 Scheme 1 
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Schema 1: Reagents and conditions: (a) DMSO, (COCl)2, Et3N, CH2Cl2; (b) vinyl magnesium bromide, THF, 62% 
over two steps; (c) MOMCl, DIPEA, CH2Cl2, 82%; (d), NaH, allyl bromide, DMF, 90%; (e) Grubbs I catalyst, 
CH2Cl2, 84% 
 
This was subject to Swern oxidation and the resulting aldehyde was treated with 
vinylmagnesium bromide to give an inseparable mixture of syn- and anti- allylic alcohols 15 in a 
87:13 ratio, respectively. Protection of the secondary alcohol as methoxymethyl (MOM) ether 
Introduction: Chapter 2 
 10 
and allylation of the tert-butyloxycarbonyl (Boc)-derived amine gave the ring closing metathesis 
(RCM) precursor 16, which at this stage could be separated from the minor anti-diastereoisomer. 
Reaction of diene 16 with Grubb’s first generation catalyst gave dihydroxypiperidine 17 in 84% 
yield. Hydrogenation, oxidation of the resulting primary alcohol, followed by deprotection 
allowed the preparation of (2S,3R)-3-hydroxypipecolic acid 2 in good overall yield. 
 
A one-pot imine reduction and conjugate addition has been used for the preparation of 6-
substituted 2,6-trans-4-hydroxy-L-pipecolic acid23. Reaction of aspartic acid derivative 18 
(Scheme 2) with the anion of dimethyl methylphosphonate gave corresponding ester 19 in 84% 
yield. This was used in a Horner-Wadsworth-Emmons reaction with various alkyl and aryl 
substituted aldehydes to give a series of E enones 20. A four-steps, one pot reaction process 
involving removal of the trityl protecting group, formation of the imine 21 followed by 
chemoselective reduction and conjugate addition gave 4-oxo-L-pipecolic acid 22 in modest 
yield. Reduction of 22 and deprotection of the amine and carboxylic acid functional groups 
under standard conditions gave novel 6-substituted 4-hydroxy-pipecolic acid 23 in acceptable 
overall yield. 
 
Scheme 2 
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Scheme 2: Reagents and conditions: (a) (MeO)2P(O)Me, n-BuLi, THF, 84%; (b) RCHO, K2CO3, MeCN, 57-96%; 
(c) TFA, CH2Cl2 then PhCHO, Et3N, 4 Å MS;  (d), NaBH3CN, 29-53% over four steps 
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An highly efficient and common strategy for preparing functionalized pipecolic acid ring system 
involved the use of inter- and intramolecular reaction of amides with various carbonyl species. 
For example, Blaauw and co-workers applied this strategy with good results for the synthesis of 
(2S,2R)-5-hydroxypipecolic acid 7 and 6-substituted derivatives24 (Scheme 3). 
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Scheme 3: Reagents and conditions: (a) TsOH, DMF, toluene, 98%; (b) Oxone®, NaHCO3, MeOH, 98%; (c) H2, 
Pd/C; (d) 6M HCl, 93% over two steps; (e) Ac2O, Et3N,  DMAP, 99%; (f) TMS-R, Lewis acid, MeCN; (g) H2, Pd/C, 
82-92% over two steps 
 
Upon treatment with p-toluensulphonic acid in refluxing toluene of acetal 24 (Scheme 3) a 
smooth cyclization-elimination reaction occurred, providing enamine 25 in 98% yield. 
Epoxidation of 25 in presence of methanol, the key step of the synthesis, resulted to give the 
N,O-aminal 26 in 98% yield and with 94:4 diastereoselectivity in favour of the 2S,5R-
configurated product. Subsequent hydrogenation and hydrolysis of the methyl ester gave 
(2S,5R)-5-hydroxypipecolic acid 7 in high overall yield. N,O-aminal 26 proved to be a good 
precursor for the preparation of 6-substituted derivatives using N-acyliminium chemistry. After 
protection of the 5-hydroxy group, the N-acyliminium ion was formed by treatment with 
Introduction: Chapter 2 
 12 
Sn(OTf)2 as a Lewis acid. In situ reaction with a series of silyl nucleophiles gave the 2,6-cis-
substituted products 28 as single diastereoisomers in high yields. The formation of the 6S-
configured products is due to nucleophilic attack to the N-acyliminium ion in a pseudoaxial 
fashion. 
 
Ene-type reactions performed under acidic or Lewis acid conditions have been employed for the 
stereoselective synthesis of 4-hydroxypipecolic acids. 
For example, aldehyde 29 (Scheme 4), synthesized in six steps from L-homoserine 30, was 
subjected to a carbonyl-ene reaction in the presence of methylaluminum dichloride25. At room 
temperature this gave the cis,cis product which spontaneously lactonised to bicyclic pipecolic 
acid 31 in 79% yield. 
 
Scheme 4 
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Scheme 4: Reagents and conditions: (a) MeAlCl2, 79% 
 
Another strategy, in contrast to previous examples that used the cyclization of linear amino acids 
to form the pipecolic acid ring, involve ring expansion of cyclic amino acids26 (Scheme 5). 
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Scheme 5: Reagents and conditions: (a) ethyl diazoacetate, BF3·OEt2, Et2O, 90%; (b) NaCl, H2O (cat.), DMSO, 75% 
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Hydroxy proline derivative 32 underwent a ring expansion reaction with ethyl diazoacetate in the 
presence of boron trifluoride-diethyl ether. The reaction gave a mixture of the two regioisomers 
33 and 34, which after decarboxylation reaction afforded the 5-oxo and 4-oxo derivatives 35 and 
36, which could be separated via FCC. NaBH4 resulted as the better reducing agent to give C-4 
and C-5 hydroxyl cis and trans derivatives with the highest yield and diastereoselectivity.  
  
2.2 Synthesis from carbohydrates 
 
Carbohydrates have been used in combination with key ring forming reactions for the 
preparation of hydroxylated pipecolic acid derivatives, in similar fashion to amino acids. 
The chirality of the pyranoside or furanoside motif is generally used to introduce new 
stereogenic centres before the key cyclization step, or used directly as a component of the 
pipecolic acid ring. 
Carbohydrates have been converted into chiral dienes and utilized in RCM reactions27a,b,c. 
As an example, Chattopadhyay reported a stereodivergent route to both enantiomers of N-tosyl-
protected L-pipecolic acids27a in which they use aldehyde 37, prepared from D-mannytol27c as 
key building block (Scheme 6). 
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Scheme 6: Reagents and conditions: (a) allylamine, 4 Å MS, CH2Cl2, 91%; (b) allylzinc bromide, THF 66%; (c) 
TsCl, Et3N, CH2Cl2, 91%; (d) Grubbs I catalyst, CH2Cl2, 89%; (e) 6 M HCl, 91% (f) H2, Pd/C, EtOAc, 100%; (g) 
NaIO4, RuCl3 (cat.), CCl4, MeCN, H2O, 73% 
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Aldehyde 37 was allowed to react with allylamine under anhydrous conditions to give imine 38 
which was treated with allylzinc bromide producing the addition products 39 and 40, with 40 as 
the major product (19%-47%). The selectivity of the addition could be inverted using 
allylmagnesium bromide as nucleofile. Tosyl protection of  product 40 was followed by RCM 
reaction with a first generation Grubb’s catalyst which gave cyclic alkene 41 in good overall 
yield. Deprotection of the cyclohexylidene moiety in 41 led to the diol 42, followed by 
hydrogenation and oxidative cleavage of the diol unit, to give N-tosyl-L-pipecolic acid (N-Ts)-
ent-1. Starting from alkene 41, the synthesis of 4,5-dihydroxylated compound was also described 
in the same report (see later for description of this route). 
 
2.3 Chiral auxiliary based approaches 
 
The main strategy in chiral auxiliary based approaches involves the use of a chiral amine source 
which eventually becomes the amine group of the pipecolic acid ring. For example, nitrone 1,3-
dipolar cycloaddition was used for the synthesis of pipecolic acid derivatives28. 
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Scheme 7: Reagents and conditions: (a) Et3N, 4 Å MS, CH2Cl2, 68% (b) DIC, HOBt, Et2NPr2, CH2Cl2, 52% (c) 1-
buthenol, 46 43%, 47 43% (d) MsCl, Et3N, CH2Cl2 (e) H2, 10% Pd/C, MeOH (f) 6N HCl, ent-5 100% crude,  5 54% 
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The condensation of chiral amine (1R)-1-phenylethylhydroxylamine 43 (Scheme 7) with 
glyoxylic acid 44, followed by coupling with enantiopure amino acid produced nitrone 45, which 
is entirely present in (Z) configuration. This selectivity is due to the strong hydrogen bond that 
stabilizes the nitrone. Treatment of 45 with 1-butenol led to 1,3-dipolar cycloaddition reaction, 
giving a 1:1 mixture of the isoxazolidines 46 and 47, which were readly separated by 
chromatography on silica gel. Mesylation of isoxazolidines 46 and 47 led to the formation of 
epoxylated intermediates 48a and 48 that spontaneously open in derivative 49a and 49, which 
were respectively converted into trans-4-hydroxypipecolic acids 5a and 5. Using a similar 
reaction sequence, starting from cyclic enantiopure nitrone, the synthesis of cis-4-
hydroxypipecolic acid was also described28. 
 
2.4 Chiral synthons approaches 
 
Chiral synthons were used for the synthesis of hydroxylated pipecolic acid derivatives. 
Just as an example, for the synthesis of cis and trans 4-hydroxylated pipecolic acid 4 and ent-5, 
(3S)-4-ciano-3-hydroxybutanoate 50 (Scheme 8) from the chiral pool (ee 96%), was chosen as a 
starting material29. The configuration of the –OH group in the final molecule is maintained from 
the starting material29b. 
The hydroxyl-group in 50 was protected as tBu using a novel procedure30, which required the 
experimental conditions known to lead to the esterification of carboxylic acids, i.e. performing 
the reaction in tert-butyl acetate in the presence of a catalytic amount of HClO4. So,  by stirring a 
solution of the alcohol 50 in tert-butyl acetate at 25°C for 24 hours in the presence of acatalytic 
amount of perchloric acid, protected compound 51 was obtained in 94% yield after FCC. 
Compound 51 was involved in a Pt-catalyzed hydrogenation that gave lactam 52 in quantitative 
yield. Following protection of nitrogen as N-CO2Me (53) the corresponding vinyl phosphate was 
prepared by treatment of 53 with KHMDS followed by addition of diphenyl chlorophosphate. 
Palladium-catalyzed methoxy-carbonylation of the phosphate in anhydrous DMF at 1 atm CO 
(balloon) finally gave the key ester intermediate 54 in 81% yield after chromatography. 
The cis pipecolic derivative 55 was obtained by Pd-catalyzed hydrogenation of 54. In that 
conditions, 55 was obtained in a 20:1 ratio whit the trans derivative31. Finally, exhaustive 
hydrolysis of 55 gave cis 4 in 66% overall yield from 50. 
For the synthesis of trans isomer, the unsaturated ester 54 was reduced with Super Hydride 
(LiEt3BH). The reaction led to a 4:1 mixture of the desired trans and cis isomers, respectively. 
The two isomers were separated after deprotection of the -OH group and treatment of the 
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resulting alcohol mixture with PTSA in toluene at 100°C. In that condition, only the cis isomer 
lactonized (57), so the remaining trans 58 was isolated and finally converted in the desired ent-5. 
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Scheme 8: Reagents and conditions: (a) t-BuOAc, HClO4, 94% (b) H2, PtO2, MeOH, 100% (c) n-BuLi, MeOCOCl, 
THF, 88% (d) KHMDS, (PhO)2P(O)Cl, THF, 99% (e) Pd(OAC)2, Ph3P, CO, MeOH, Et3N, DMF, 81% (f) H2, 10% 
Pd/C, NaHCO3, MeOH, 100% (g) 2N HCl, 100% (h) LiEt3BH, THF, trans/cis 4:1, 93% (i) PTSA·H2O, MeCN, 
100% (l) PTSA, toluene, 58 63% (g) 2N HCl, 100% 
 
2.5 Catalytic Asymmetric Methods 
 
Asymmetric cathalysis was involved in several processes for the synthesis of pipecolic acid 
derivatives. 
Just as an example, for the synthesis of 4-hydroxypipecolic and 3-hydroxypipecolic Alegret used 
an epoxy-alcohol as source of chirality32, a substrate obtained in good yield and 93% ee by 
asymmetric Sharpless epoxylation of diene alcohol 59 (Scheme 9) with (+)-diethyltartrate. The 
regioselective (10:1) C-3 ring opening of 60 by allylamine, followed by N-Boc protection gave 
diol 61 in anti-configuration. Ring closing metathesis of 61 lead to diol 62, which was oxidized 
in a two-steps process to N-Boc protected baikjanin 63. Iodolactamization in standard conditions 
lead to 64 in 98% yield. Iodide elimination to give 65 followed by lacton hydrolysis lead to 
desired (N-Boc)-4. 
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Scheme 9 
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Scheme 9: Reagents and conditions: (a) t-Bu hydroperoxide, D-(-)-DIPT (cat) Ti(OiPr)4 (cat), 4 Å MS (b) 
allylamine, LiClO4, 83% (c) Boc2O, MeOH, 60% over two steps (d) Grubbs I catalyst, CH2Cl2, 70% (e) NaIO4, 
THF/H2O (f) NaClO2, tBuOH/THF, 62-75% over two steps (g) I2, KI, NaHCO3, H2O, CH2Cl2, 98% (h) Bu3SnH, 
AIBN (cat), C8H8, 76% (i) NaOH, dioxane/H2O 70% 
  
2.6 Enzymatic kinetic resolution 
 
Many hydrolytic enzymes have been used for the kinetic resolution of a variety of intermediates 
in the synthesis of enantio-enriched pipecolic acids, though the main class of enzymes used are 
lipases. For example, Takahata33 report the enzymatic kinetic resolution of racemic trans 
substrate (±)-67 (Scheme 10) obtained in two steps from allylglicine derivatives 66. 
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Scheme 10: Reagents and conditions: (a) lipase, vinyl acetate, i-Pr2O, 47% for 68, 47% for 67 (b) H2, Pd/C, EtOAc 
99% (c) 5 M HCl, 84% 
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The (2S, 3S)-67 isomer was converted in acetate derivative 68 using Bulkoldheria cepacia lipase, 
immobilized on ceramic particles. Under the best conditions this process gave the acetate in 97% 
ee and the remaining alcohol with 99% ee. 
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Chapter 3: Previous syntheses of 4,5-dihydroxylated pipecolic acids 
 
Perhaps due to their scarcity in nature, only a limited number of total syntheses of 
dihydroxypipecolic acids have been described. 
 
In 1976 Marlier report the synthesis of isomers 8, 9, 10 and 11. Mixture of compounds 10 and 11 
were obtained in by Marlier17a and later by Bleecker19 through stereoselective cis 
dihydroxylation of the natural compound L-baikiain with OsO4 in a tBuOH-H2O2. A tedious 
chromatographic separation procedure (included 8-day long eluition) and re-crystallization from 
Et2OH-H2O was required to separate and purify the two free acids, with an overall yield of 14% 
and 5% for 10 and 11, respectively17a. To obtain the trans isomers 8 and 9, N-Cbz protected L-
baikiain was oxidized with H2O2 in HCO2H. After N deprotection by hydrogenation on Pd/C the 
two isomers, obtained as a mixture, were isolated by the same chromatographic procedure as 
well for 10 and 11, giving 8 and 9 with 15% and 14% overall yield. 
 
In 1986 Fleet and co-workers reported the synthesis of 4,5 dihydroxy L-pipecolic acid 8 (Figure 
1) starting from isopropylidene derivative of D-glucoronolactone34 69 (Scheme 11). 
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Scheme 11: Reagents and conditions: (a) (CF3SO2)O, pyridine, CH2Cl2 (b) NaN3, DMF, 84% from 61 (c) H2, Pd/C, 
EtOAc (d) Cbz-Cl, NaHCO3, EtOAc/H2O, 72% over two steps (e) MeONa/ MeOH (f) NaBH4, MeOH, 91% over 
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two steps (g) MeSO2Cl, pyridine, 80%, (h) H2, Pd black, EtOAc, pyridine, quantitative yield (i) 0.1 M KOH, 
EtOH/H2O 1:1, 82%  
 
Reacting with (CF3SO2)2O in DCM in presence of pyridine, compound 69 gave the 
corresponding triflate 70 which was converted to the azide 71 with inversion of configuration in 
C-5. Palladium catalyzed hydrogenation followed by Cbz protection on the nitrogen atom gave 
compound 72. Treatment of 72 with a base (MeONa) caused the anticipated fragmentation to 
give, after reaction with sodium borohydride, the unsaturated diol 73. Compound 73 was 
selectivity protected on the primary –OH group as mesylate 74, than reduced in a palladium 
black catalyzed hydrogenation to give a single diastereoisomer of aminomesilate 75. The ring 
enclosure obtained by treatment with KOH gave dihydroxylated pipecolic acid 8, which was 
purified by ion exchange chromatography. 
In the same report34, the synthesis of 3,4,5-trihydroxy derivative 12, which was found to be a 
specific inhibitor of human liver β-D-glucuronidase35, was also described (Scheme 12). 
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Scheme 12: Reagents and conditions: (a) (CF3SO2)2O, pyridine, CH2Cl2 (b) Sodium trifluoroacetate (c) 
methanolysis 78% over three steps (d) (CF3SO2)2O, pyridine, CH2Cl2 (e) NaN3, DMF (f) H2, Pd/C, EtOAc (g) Cbz-
Cl, NaHCO3, EtOAc/H2O 44% from 60 (h) TFA/H2O (i) H2, palladium black, H2O/ AcOH, 60% over two steps  
 
In order to maintain the overall retention of configuration of C-5, the stereochemistry of C5-OH 
group in 69 was inverted to give the epimeric compound  76 (Scheme 12). 
Thus, alcohol 76 was converted in the corresponding gluco-azide 77, then hydrogenated and 
protected on the nitrogen as Cbz, giving carbamate 78. After removal of isopropylidene moiety 
by aqueous trifluoroacetic acid, the resulting lactol was involved in a catalytic hydrogenation on 
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palladium black, in aqueous acetic acid. In that conditions underwent intramolecular reductive 
amination and hydrolysis of the lactone, to give the trihydroxypipecolic acid 12. 
 
A total synthesis of 4,5-dihydroxypipecolic acid was developed by Thieme et al., based on the 
use of azomethine chiral auxiliaries and cyclization via nucleophylic bromide displacement36. 
The starting azomethines 79 (Scheme 13), treated with LDA and (4R,5R)-4,5-bis-
(bromomethyl)-2,2-dimethyl-1,3-dioxolane gave the envisaged alkylation products 80 with high 
yield and stereoselectivity (95:5). 
The configuration of the new stereogenic centre was governed by the configuration of the chiral 
auxiliary. In this case (S,S,S)-hydroxypinanone generates the (R) configuration in 80. The chiral 
auxiliary in 80 was smoothly split off by hydrolysis in the presence of citric acid to afford 2-(α-
aminoalkyl)-oxazole 81. 
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Scheme 13: Reagents and conditions: (a) LDA, (4R,5R)-4,5-bis-(bromomethyl)-2,2-dimethyl-1,3-dioxolane, THF, 
62-85% (b) citric acid, H2O/THF, 60-85% (c) Et2OH, NaHCO3 71-88%, (d) Cbz-Cl, K2CO3 dioxane/H2O, 97% (e) 
O2, rose bengal, UV light, CH2Cl2 (f) dioxane/H2O, 48% (g) H2, Pd/C, MeOH (h) HCl, THF   
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Treatment of 81 with NaHCO3 in ethanol induced the intramolecular cyclization, which afforded 
the optically active piperidine derivative 82 in 88% yield. Compound 82, after protection as N-
Cbz (83) reacted with oxygen under UV-light in the presence of Rose Bengal, for the cleavage of 
the C-C double bond of the oxazole ring, and following gave acid 84. Finally enantiopure 8 was 
obtained as chlorohydrate after N-deprotection and exhaustive hydrolysis. 
 
Starting from 85, (Scheme 14) Kuzuhara and Takahashi, provided a seven-steps stereoselective 
synthesis of enantiopure 4-deoxynojirimycin derivative 8637, and they used it as a precursor for 
the synthesis of trihydroxylated 1238 and dihydroxylated 8. 
After  benzylation of C3-OH in 86 that gave 87, the silyl group in C-6 was removed, and the free 
primary –OH group in 88 was converted into a carbonyl function by Jones oxidation at room 
temperature, than converted in benzyl ester with BnBr and Cs2CO3. Finally, palladium catalyzed 
hydrogenation gave inhibitor 12 in good overall yield. 
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Scheme 14: Reagents and conditions: (a) NaH, BnBr, n-BuNI, DMF, 66% (b) n-BuNF, AcOH, THF, 98% (c) Jones 
Reagent (d) BnBr, Cs2CO3, DMF, 69% over two steps (e) H2, 10% Pd/C, AcOH, EtOH, H2O, 53% (f) PhOCSCl, 
pyridine/CH2Cl2 (g) Bu3SnH, AIBN, toluene, 82% over two steps 
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The synthesis of dihydroxylated pipecolic acid 8 began with a deoxygenation reaction at C-3 
position of 86. This conversion was performed by converting the alcohol into a thiocarbonate 
derivative by the action of phenoxythiocarbonyl chloride, followed by deoxygenation via radical 
reaction with tributyltin hydride in the presence of azobis(isobutyronitryle) (AIBN) in toluene. 
With a similar strategies to as that from 87 to 12, the compound 89 was finally converted into 
enantiopure derivative 8. 
 
More recently Chattopadhyay reported a stereodivergent route to N-tosyl-proteced L-pipecolic 
and N-tosyl-4,5-cis dihydroxylated derivatives27 N-Ts-11 and N-Ts-10 (Scheme 15, Cfr Scheme 
6). 
Cyclic alkene 41 (Scheme 15) was subject to dihydroxylation with osmium tetroxide and N-
methylmorpholine-N-oxide (NMO) to give a 1:1 mixture of cis dihydroxylated diastereoisomers, 
that were separed by column chromatography. Each diastereoisomer was protected as O-Bn to 
give 91 and 92. The oxidation of the diol group in 91 and 92 with concomitant conversion of 
benyl group in benzoate gave pipecolic derivatives 94 and 96, which finally were converted in 
the N-tosilated cis and trans derivatives (N-Ts)-10 and (N-Ts)-11. However, no attempts of 
removing the N-Tosyl preotection were done. 
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Scheme 15: Reagents and conditions: (a) OsO4, NMO, acetone/H20 4:1 (b) NaH, BnBr, THF/DMSO 10:1, 91 31% 
over two steps, 92 25% over two steps (c) 6N HCl, THF, 93 81%, 95 82%, (d) NaIO4, RuCl3 (cat), CCl4/CHCN/H2O 
(1:1:1.5) 94 53%, 96 59% (e) 1M KOH, MeOH, (N-Ts)-11 71%, (N-Ts)-10 68% 
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So, whereas a limited number of syntheses of compound 8 exist, in the end no practical and 
scalable syntheses of compounds 9, 10 and 11 have instead been reported so far. 
In general, the scarce attention towards polyhydroxylated pipecolic acids is surprising, because 
just as monohydroxylated pipecolic acids 2-7 have been used as frames around which to build 
biologically active compounds, polyhydroxypipecolic acids 8-11 could be exploited in a similar 
fashion, with the advantage that the presence of a further hydroxy group can either provide 
further interactions with the target protein’s active site or be functionalized in order to attain 
higher potency and selectivity, as well as to modulate lipophilicity, a parameter that influences 
solubility, permeability through membranes, and clearance, i.e. biological processes relevant in 
drug discovery. 
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Chapter 4: Cyclopropanated amino acids as conformationally constrained 
molecular scaffold 
 
The scope of pipecolic acids can be futher expanded by the introduction of conformational 
restrictions. In fact, the practice of constraining natural amino acids in their conformationally 
rigid analogues has been highly successful in the design and synthesis of peptidomimetics and 
other bioactive molecules, with improved selectivity and methabolic stability39. For example, a 
particular three-dimensional arrangement of the peptide side chains can be obtained by 
appropriately constraining, biasing or fixing the side chain conformers, in order to get a 
particular foldamer of the molecule. This approach requires a set of  amino acids with particular 
steric constraints. Moreover the molecular rigidity that is attributed to cyclic molecules (like 
pipecolic acids), may be employed in reducing entropic costs that are associated with enzyme 
and receptor binding. In addition, the defined spatial arrangement of cyclic structures may be 
valuable in ascertaining information about the bioactive conformation, which can be used to 
modulate the binding properties, i. e. potency and selectivity. 
On this ground, cyclic amino acid analogues containing a cyclopropane skeleton, including 
proline and pipecolic acids40 (Figure 4), are of broad interest as biological probes, enzyme 
inhibitors and conformationally analogues of native amino acids41, as the three membered ring 
introduces specific steric constraints into the amino acids, possibly leading to changes in peptide 
conformation and reactivity. 
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Figure 4: selected examples of cyclopropanated proline and pipecolic amino acids 
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In fact, the cyclopropane ring exibit a certain “unsatured character” which results in a restriction 
torsion angles about the Cα-C=O bond to small values, due to the conjugation of the carbonyl 
group with the ring41. More specifically, the 1-aminocyclopropane carboxylic acid residue has 
been shown to exhibit a marked preference for the conformational space Φ,Ψ = ± 90°, 0°  i.e. for 
the position i +2 of type I and type 2 β-turns42, possibly leading to profound changes in the 
peptide conformation and reactivity. 
 
4.1 Previous synthesis of 2,3-methanopipecolic acids 
 
In literature are reported a variety of synthetic strategies for the synthesis of acyclic and five-
membered 2,3–methano amino acids, while only few methods have been reported for the 
synthesis of 2,3-methanopipecolic acids. 
In the first synthesis, described by Hercouet in 199643, lactone 97 (Scheme 16), obtained from L-
glutammic acid44 was converted to triol 98 by treatment with BMS in chloroform.  
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Scheme 16: Reagents and conditions: (a) BH3·Me2S, CHCl3, MeOH, 78% (b) SOCl2, CCl4, 72% (c) NaIO4, RuCl3 
·3H2O (cat), 96% (d) PhCH=NCH2CO2Me, NaH, DME, 99% (e) 1N/Et2O HCl, 86% (f) 1NaOH, then 6N HCl, 
Dowex 50x8, 59% 
 
Crude pentanetriol 98, reacted with SOCl2 in refluxing CCl4 afforded cyclic sulfite 99. This 
sulfite was oxidized to sulphate 100 via Sharpless reaction. Diastereospecific alkylation of 
methylbenzhylideneglycinate with 100 gave 101 as a single isomer with 99% yield. Product 101 
was hydrolyzed to get the aminoester 102 as hydrochloride, that cyclised in basic conditions 
(NaOH) to the desired piperidine 103, which was purified by ion exchange chromatography. 
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Following a different approach, Matsumura45 report the synthesis of 2,3 methanopipecolic acid 
starting from L-Lysine derivative 105 (Scheme 17). 
Cyclization of 105 to 106 occour via electrochemical anodic oxidation of 105 in methanol, 
followed by an acid-catalyzed cyclization, without isolation of the oxidation intermediate46. 
Treatment of 106 with KHMDS and diphenyldisulfide gave a phenylthiolated compound which 
was oxidized with m-CPBA to get 2,3-unsaturated derivative 107 in good overall yield and 88% 
ee. Cyclopropanation reaction was performed treating 107 with dimethylsulfoxonium methylide 
in DMSO. The reaction gave cyclopropanated 108 with very high facial selectivity (96:6% de). 
This selectivity could be explained in terms of steric and/or electrostatic repulsion between 
methoxy group of the molecule and dimetylsulfoxonium ylide. In fact, the ylide preferentially 
attack on the opposite face. The metoxy group in 108 was removed by reductive elimination with 
NaBH4 in formic acid to get 109, than the free acid 103 was obtained by hydrolysis with 
trimetylsilil iodide in CHCl3. 
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Scheme 17: Reagents and conditions: (a) anodic oxidation, MeOH, then H2SO4, 47% (b) KHMDS, PhSSPh, 90% 
(c) m-CPBA, 92% (d) Me3SOI, NaH, DMSO, 73% (e) NaBH4, HCO2H, 75% (f) Me3SiI, CHCl3, 50%  
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Scope of the work 
 
In the previous chapters we have described as the hydroxypipecolic acid scaffolds are emerging 
privileged structures involved in many important applications, in particular as constituents of 
pharmaceutically and biologically active compounds, as well as and conformational probes. 
Although an increasing number of works are devoted to the synthesis of mono- or 
polysubstituted pipecolic acid derivatives, the research of new synthetic routes to hydroxylated 
derivatives in enantiopure form remains a great centre of interest. 
On this ground, the aim of this research work is the development of new methodologies for the 
synthesis of enantiopure mono- and dihydroxylated pipecolic acid derivatives (Figure 5). In 
particular, the work will be focus on several complementary approaches to the synthesis of 4-
hydroxy-, 5-hydroxy- and 4,5-dihydroxypipecolic acids, in particular focusing, as for as it 
concerns the latter compounds, on the more neglected pipecolic acids 9-11 (Figure 2), and their 
enantiomers. Our approach will be based on the chemistry of lactam-derived enol phosphates 
developed in our lab, which we have recently shown to be suited to the preparation of 
enantiopure 4-hydroxypipecolic acids29. 
 
Moreover, with in mind the introduction of further constraints in hydroxypipecolic acids, we 
focused on the introduction of a cyclopropane ring in the position 2,3 of these molecules, in 
order to obtain mono- and dihydroxy methanopipecolic acid derivatives 110-113 and their  
enantiomers ent-110-113 (Figure 5) as a new class of conformationally constrained amino acid 
analogues to be employed as conformational probes and in the discovery of new drugs. 
 
For the above mentioned cyclopropanated derivatives, we envisage as a possible application the 
construction of RGD sequence-containing cyclopeptides, having in mind the synthesis of 
integrine ligands. This application is supported by preliminary calculation in MM2 which 
suggest the suitability of these scaffolds for building up cyclopeptides. 
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Figure 5 
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Figure 5: cyclopropanated hydroxypipecolic  acid derivatives 
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Results and discussion 
 
Chapter 1: General synthetic strategy 
 
Our approach to the synthesis of hydroxypipecolic acids (I, Scheme 18), as well as their 
cyclopropanated derivatives (II), was based on the transformation of hydroxylated lactams (V) 
into enecarbamate esters (III) through a Pd-catalyzed methoxycarbonylation of the 
corresponding enol phosphates (IV)47.  
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Scheme 18: general synthetic pathway for hydroxylated pipecolic acids and their cyclopropanated  analogues 
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Such enecarbamate esters were then converted into 4-hydroxypipecolic acids by exploiting the 
stereocontrol exerted by suitable OH group protections during the reduction step. 
Stereocontrolled cyclopropanation reactions were developed and applied on the same 
enecarbamate ester precursors, in order to obtain 2,3-methanopipecolic derivatives with very 
high optical purity. 
This methodology, of course, requires enantiopure hydroxylated lactams as starting material or, 
as an alternative, a racemate resolution at any stage of the synthesis. Both approaches were used 
by us during this research work for the synthesis of mono- and 4,5-dihydroxypipecolic acids48,49 
as well as their cyclopropanated derivatives50, and various piperidine alkaloids such as 
glycosidase inhibitors fagomine48 and 1-deoxymannojirimycin51. 
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Chapter 2: Synthesis of 4-hydroxypipecolic derivatives  
 
2.1 Sytnthesis of enecarbamate ester precursors from (3R)-4-ciano-3-hydroxybutanoate 
 
In our laboratory, a synthetic route for the synthesis of 4-hydroxylpipecolic acids, which started 
from enantio-enriched precursor 54, was previously developed. As shown in Scheme 8, the 
hydrogenation of lactam-derived precursor 54 on Pd/C lead to the formation of the cis-derivative 
55 in a 20 : 1 ratio with the undesired trans isomer. In that case, stereocontrol of the reduction on 
the double bond was attributed to the tBu.  
So, if such is the case, the use of a bulkier substituent (like a silyl group) on the hydroxy group 
should better directing the reduction towards the less hindered face of the double bond to furnish 
the target cis product with a higher facial selectivity than that obtained from 54. 
Unfortunately, as demonstred in a previus study29a, 4-silyloxy-substituted lactams (obtained with 
a similar route from 50 as that reported for 55, Scheme 19a), appear unsuitable for the 
preparation of the corresponding vinyl triflates and/or phosphates.   
In fact, the alkaline reaction conditions employed to generate phosphates or triflates (i.e 
treatment with KHMDS in THF at –78 °C), led to partial or complete elimination reaction 
products (Scheme 19a). 
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Scheme 19: Reagents and conditions: (a) KHMDS, (PhO)2P(O)Cl or PhNTf2, THF, -78°C 
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A possible reason for the particular tendency of enolates (or triflates) to give the elimination 
products is the strong A(1,2) strain generated between the olefinic proton on C-3 and the bulky 
equatorial silyloxy group after formation of the enolate (Scheme 19b). To reduce the strain, the 
4-silyloxy group should adopt an axial orientation, but this could be prone to elimination by an 
E2 mechanism under the reaction conditions. 
 
During my Ph-D, with the goal of establishing a general procedure for enantioselective synthesis 
of both enantiomers of 4-hydroxypiperidine derivatives, we worked on a different synthetic route 
to both antipodes of the 4-hydroxylated enecarbamate precursors. In this approach, the OH group 
and a suitable silyl protecting group will be inserted in a later stage of the synthesis, thus 
avoiding the problem of the elimination reaction. 
 
2.2 Synthesis of enecarbamate ester precursors from δ-valerolactam
50 
 
According to the general synthetic strategy which requires enantiopure enecarbamate precursors, 
we thus envisaged a chemo-enzymatic approach that would enable us to prepare racemic 118 
(Scheme 20) from commercial  δ-valerolactam 114 in a short synthetic sequence, followed by a 
lipase-catalyzed kinetic resolution of 118 to obtain both (R)- and (S)- enantiomers in enantiopure 
or enantio-enriched form. 
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Scheme 20: synthesis of enantio-enriched enamide ester precursors by EKR of 118 
 
So, a four-step conversion of N-CO2Me δ-valerolactam 115 into α,β-unsatured ester 117 
(Scheme 21) was realized by Pd-catalyzed methoxycarbonylation of vinyl phosphate 116 whit 
the same approach as shown in Scheme 19, which provided 118 in 70% overall yield. Allylic 
oxidation of 117 was carried out with N-bromosuccinimide (NBS) in the presence of a catalytic 
amount of azobisisobutyronitrile (AIBN), followed by hydrolysis with ZnCl2 in wet acetone 
(96%) which furnished (±)-118 in 66% yield. 
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Scheme 21: Reagents and conditions: (a) n-BuLi, MeOCOCl, THF, -78°C (b) KHMDS, (PhO)2P(O)Cl, THF, -78°C 
(c) Pd(OAC)2, Ph3P, CO, MeOH, Et3N, DMF, 55°C, 3h (d) AIBN, NBS, CCl4/CHCl3 9:1, reflux, 15 min (e) ZnCl2, 
96% aq. acetone, 25°C, 6h  
 
With sufficient amounts of racemic (±)-118, we were ready to study the kinetic resolution of this 
alcohol by means of lipases in organic media (Scheme 22, Table 1). 
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Scheme 22: Reagents and conditions: (a) MeONa, MeOH, 0°C, 3.5h 
 
From the various commercially available lipases, we initially opted to use Candida antarctica 
lipase B (CAL-B) supported on acrylic resin (trade name Novozym 435), because it has been 
used on a few occasions, either immobilized or free in solution, for the resolution of carbacyclic 
allylic alcohols that structurally resemble compound 11852. The enantiomeric ratio E ranged 
from 20 to 187 for substrate depending on the reaction conditions, thus allowing for an effective 
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resolution. For similar reasons, we employed Bulkolderia cepacia lipase53 (immobilized on 
diatomaceous earth and commercialized with the name of lipase AMANO IM), which has 
previously been exploited for the kinetic resolution of alcohols such as 3-ethyl-, 3-bromo-, and 
3-nitro-2-cyclohexen-1-ol54 , with E values from 49 to higher than 100. As in the case of simple 
secondary55 and cyclic allylic alcohols56 the R enantiomer of 118 was preferentially acylated in 
all experiments (Table 1). With CAL-B, we initially screened various acyl donors in anhydrous 
acetonitrile which was the best solvent for some 2-cycloexen-1-ols54a and, more conventionally, 
in toluene57. In both solvents, the best results were obtained with 4-chlorophenyl butyrate 
(PCPB)58 as the acyl donor. 
Interestingly, we determined a low E value of about 20 when vinyl acetate was used (entries 1 
and 5) which is almost identical to that measured for the kinetic resolution of seudenol catalyzed 
by free CAL-B56b. 
 
With 2,2,2-trifluoroethyl butyrate (TFEB), besides low E values, the reaction was slow and never 
reached 50% conversion (entries 2 and 6). With PCPB, we screened other solvents, and found 
that anhydrous THF was optimal (entry 10), which is in accordance with the observation that 
solvents with logP<2 are most suitable for polar substances59. In this case, by increasing the 
amount of enzyme and by using a 0.2 M subdtrate concentration, we eventually obtained an E 
value 135 that was only just suitable for effective kinetic resolution (entry 11). We also tested 
vinyl butyrate as the acyl donor under the same conditions, but found that the E value decreased 
(entry 12). 
 
Better results were obtained with lipase PS-AMANO-IM, although higher enzyme to substrate 
ratio (mg/mmol) were required to reach acceptable conversion in reasonable times. The best 
result (entry 14) was obtained by carrying out the resolution in the presence of PCPB in THF at 
0.8 M substrate concentration with 100 mg of lipase per mmol of (±)-118 (E = 162). Under the 
same conditions with both vinyl acetate (entry 16) and vinyl butyrate (entry 17)  this reaction 
was highly enantioselective, with measured E values of approximatively 160 and enantiomeric 
excesses for both enantiomers of 118 comparable to those of commercial ethyl (3R)- and (3S)-4-
ciano-3-hydroxybutanoate (96% ee) previously employed for the preparation of enantiopure (R)- 
and (S)-55 respectively (See Scheme 8). We thus applied the latter conditions to resolve a 
sufficient amount of 118 to proceed with the synthesis. 
After chromatographic separation of (R)-119 (45% yield, 95% ee) and (S)-118, pure (R)-118 was 
obtained by hydrolysis of ester (R)-119. 
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Table 1 
entry Acylant 
reagent[a]  
Solvent[b] t (h) c (%)[c] (R)-118 
ee (%)[d] 
(S)-118 
ee (%)[e] 
E[f] 
    CALB[g]    
1 VA CH3CN 21 45 83 64 21 
2 TFEB CH3CN 72 36
[h] 90 - 31[i] 
3 PCPB CH3CN 43 36
[h] 94 - 54[i] 
4[j] PCPB CH3CN 18 54 84 99 59 
5 VA toluene 16 64 56 99 17 
6 TFEB toluene 28 37[h] 82 47 16 
7[j] PCPB toluene 15 50 88 81 39 
8 PCPB CH2Cl2 72 12
[h] 85 13 16 
9 PCPB acetone 72 35[h] 95 51 65 
10[j] PCPB THF 23 47 94 84 92 
11[k] PCPB THF 4.5 47 96 85 135 
12[k,l] VB[m] THF 3 52 90 96 74 
    PS “Amano” IM[n]    
13 PCPB THF 40 40[h] 97 65 130 
14[o] PCPB THF 7 45 97 79 162 
15 VA THF 20 36[h] 94 54 56 
16[o] VA[p] THF 9 45 97 80 163 
17[l,o] VB[p] THF 6 49 96 93 168 
 
[a] VA: vinyl acetate, TFEB: 2,2,2-trifluoroethyl butyrate, PCPB: 4-Chlorophenyl butyrate, VB: vinyl butyrate. [b] 
Anhydrous solvents were used. [c] Conversion determined by GLC and 1H NMR. [d] Determined by 1H-NMR 
analysis of the Mosher ester after hydrolysis. [e] Determined by 1H NMR analysis of the Mosher ester. [f] E = 
enantiomeric ratio calculated as reported in ref 60 [g] Reaction carried out on 0.2-0.4 mmol of substrate at 30 °C, 
substrate concentration from 0.2 to 0.4 M, enzyme (mg)/substrate (mmol) ratio from 10 to 25, 2 equivalents of 
acylant reagent. [h] The reaction did not proceed further and it was stopped. [i] Calculated as ln[1-c(1+eep)]/ln[1-c(1-
eep)]. [j]
 Substrate concentration = 0.8 M. [k] Enzyme (mg)/substrate (mmol) ratio = 200. [l] Molecular sieves (4Å, 
130 mg/mmol) were used in this experiment. [m] 2.5 equivalents. [n] Reaction carried out on 0.2-0.4 mmol of 
substrate at 30 °C, substrate concentration = 0.8 M, enzyme (mg)/substrate (mmol) ratio = 20, 2 equivalents of 
acylant reagent. [o] Enzyme (mg) to substrate (mmol) ratio = 100. [p] 3.5 equivalents. 
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2.3 Synthesis of cis 4-hydroxypipecolic acid
48 
 
Now that the enantiopure precursor 118 was available, we could protect it with a large silyl 
group (TIPS, 81% yield) in order to obtain a higher selectivity for the subsequent Pd/C catalyzed 
hydrogenation to cis pipecolic acid. As previously reported for 429b, the synthesis of ent-4 was 
realized by hydrogenation of O-TIPS compound (S)-120 (Scheme 23), which provided 
diastereopure (2R,4S)-cis-121 in quantitative yield. In this case we managed to obtain a 
diastereomeric ratio higher than that previously obtained with the O-tBu protected compound 
(about 20 : 1, See Scheme 8) as we could not detect any trace of the trans compound in the 1H-
NMR spectrum of the crude reaction mixture. Exhaustive hydrolysis gave ent-4 as its 
hydrochloride salt in 100% yield61. With a similar approach we synthesized the natural 
enantiomer of 4. 
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Scheme 23: Reagents and conditions: (a) TIPSCl, imidazole, DMF, 40°C, 5h (b) H2, Pd/C, EtOAc, 25°C, 6h (c) 2N 
HCl, reflux 
 
2.4 Two-step enzymatic kinetic resolution
50 
 
We considered that conformationally restricted amino acids, in order to be introduced in a 
peptide sequence, must have higher enantiomeric excesses than those so far obtained for alcohols 
(R)-118 and (S)-118 (See Scheme 22, Table 1) and efforts should consequently be made to 
obtain such synthetic intermediates in enantiopure form. 
To this end, we first opted for a two-step lipase-catalyzed kinetic resolution of N-CO2Me 
protected compound (±)-118. However, because of the widespread use of the Cbz group for N-
protection in amino acids we also decided to study the enzymatic kinetic resolution of N-Cbz 
derivative (±)-125 by various lipases and then to subject the products to the stereoselective 
cyclopropanation. 
 
The two-steps kinetic resolution of (±)-118 was realized by stopping the enzyme-catalyzed 
esterification of the alcohol, carried out under the best conditions we found (See Table 1), with a 
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conversion around 40%. In this way, we should obtain the acylated product with high ee and 
only a little loss of material. 
The resolution (Scheme 24) was realized by stopping the esterification of the alcohol, carried out 
in the presence of PS “AMANO” IM lipase and vinyl butyrate as the acylating agent in dried 
THF (i. e. the best conditions found for the standard kinetic resolution), with 42% conversion 
(determined by GC and NMR of the crude reaction mixture). 
This allowed to obtain butyrate (R)- with very high enantiomeric purity (>99.5% ee, determined 
after hydrolysis) in a sufficient amount to proceed with the synthesis. The residual (S)-alcohol, 
obtained in 53% yield and 73% ee after chromatography, was subjected to the same EKR 
conditions, stopping the reaction after 22h when the conversion was 17%. After chromatography, 
enantiopure (S)-118 was obtained in 35% yield over the two steps. 
By this procedure, only a minimal amount of substrate was lost and both alcohols (R)-118 and 
(S)-118 were obtained with higher ee than by a single resolution. 
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Scheme 24: Reagents and conditions: (EKR I) vinyl butyrate, PS “AMANO” IM lipase, THF, 4Å MS, 30°C, 7h, 
42% conversion (EKR II) vinyl butyrate, PS “AMANO” IM lipase, THF, 4Å MS, 30°C, 22h, 17% conversion (a) 
MeONa, MeOH, 0°C, 3.5h 
 
Racemic N-Cbz-protected alcohol (±)-125 (Scheme 25) was conveniently prepared by the same 
procedure reported for (±)-118.  
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Scheme 25: Reagents and conditions: (a) n-BuLi, MeOCOCl, THF, -78°C (b) KHMDS, (PhO)2P(O)Cl, THF, -78°C 
(c) Pd(OAC)2, Ph3P, CO, MeOH, Et3N, DMF, 58°C, 4h (d) AIBN, NBS, CCl4/CHCl3 9:1, reflux, 15 min (e) ZnCl2, 
96% aq. acetone, 25°C, 6.5h 
 
N-Cbz-protected δ-valerolactam 122 was quantitatively converted into the corresponding enol 
phosphate 123 and this subjected to Pd-catalyzed methoxycarbonylation to give 124 in 87% 
yield over two steps after chromatography. Allylic oxidation finally afforded (±)-125 in 57% 
yield. 
 
As for N-CO2Me protected (±)-118, in order to determine the best conditions in terms of optical 
purity and yield of the products (see later for absolute configuration determination), a variety of 
lipases and solvents were applied to (±)-125. (Scheme 26, Tabella 2) Vinyl butyrate (VB, 
Tabella 2) and vinyl acetate (VA) were used as acylating reagents. 
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Scheme 26: Reagents and conditions: (a) MeONa, MeOH, 0°C, 3.5h 
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The kinetic resolution was carried out in the presence of various lipase at 30°C with an excess of 
either vinyl acetate or vinyl butyrate (3.5 eq) as the acylating reagent. Lipases from Aspergillus 
niger, Candida rugosa, Candida antarctica and Porcine Pancreatic lipase62 were tested under 
various conditions in toluene and tert-butyl methyl ether (TBME) with vinyl acetate but the 
reaction were either very slow or did not take place at all. 
 
Table 2 
entry 
Acylant 
reagent[a] 
Solvent[b] 
t 
(h) 
c (%)[c] 
(R)-125 
ee (%)[d] 
(S)-125 
ee (%)[e] 
    CALA[f]   
1 VB THF 4 - - - 
2 VA Toluene 90 17[g] - - 
3 VA Toluene 7 d 38.5[g] 40 30 
4 VA TBME 7 d 48 31 30 
    CALB[f]   
5 VB THF 4 52 85 94 
6 VB TBME 2.3 53 78 90 
    Amano[f]   
7 VB TBME 3.6 54 91.4 99.5 
8 VB THF 72 49 94 89 
    PS-“SolGel”-AK   
9 VB THF 4 - - - 
    ASN[f]   
10 VA Toluene 4 - - - 
    CRL[f]   
11 VA Toluene 96 6.5[g] - - 
    PPL[g]   
12 VA Toluene 96 2.3[g] - - 
 
Table 2: [a] VA: vinyl acetate, VB: vinyl butyrate. [b] Anhydrous solvents were used. [c] Conversion determined by 
GLC and 1H-NMR. [d] Determined by HPLC analysis of (R)-125 alcohol after hydrolysis. [e] Determined by HPLC 
analysis of (S)-125 [f] Reaction carried out on 0.2-0.4 mmol of substrate at 30 °C, substrate concentration 0.8 M, 
enzyme (mg)/substrate (mmol) ratio = 100, 3.5 equivalents of acylant reagent, molecular sieves (4Å, 130 mg/mmol) 
[g] The reaction did not proceed further and it was stopped. 
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The best results were obtained with PS “AMANO” IM in TBME with vinyl butyrate (E > 200). 
We employed that condition for a two-step kinetic resolution of  (±)-125 (Scheme 27) carried out 
in a similar manner to that (±)-118 resolution. 
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Scheme 27: Reagents and conditions: (EKR I) vinyl butyrate, PS “AMANO” IM lipase, TBME, 4Å MS, 30°C, 1.9h, 
44% conversion (EKR II) vinyl butyrate, PS “AMANO” IM lipase, THF, 4Å MS, 30°C, 1.4h, 16% conversion (a) 
MeONa, MeOH, O°C, 3.5h 
 
The first esterification reaction was stopped with 44% conversion (See Appendix 3) , and the 
remaining (S)-125 (51% yield and 73% ee) was subject to a second reaction, interrupted with 
16% conversion. This double step process gave the (S)-125 with 37% yield and 98.8% ee, and 
(R)-125 with 37% and 98.7% ee (See Appendix 2). 
 
2.5 Synthesis of cis 4-hydroxy-cyclopropanated derivatives: OH-directed cyclopropanation 
 
The OH-directed cyclopropanation of γ-hydroxy-α,β-unsaturated esters has been previously 
reported in a handful of cases, i.e. by samarium/mercury amalgam in conjunction with 
diiodomethane63 and by the Furukawa modification of the Simmons–Smith reaction64. In both 
cases, the hydroxyl group exerted complete stereocontrol, so we explored the use of both Sm– 
and Zn-carbenoids for the cyclopropanation of enantiopure 118, and the results are reported in 
Table 3. Disappointingly, the reaction under Molander’s conditions62b (entry 1) although 
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reaching complete conversion after 5 h, provided the target compound in a mixture with various 
unidentified byproducts. Moreover, the stereoselectivity was very low, with the unexpected 
predominance of the trans compound (trans/cis ratio of about 1.3 : 1). Considering the highly 
oxophilic nature of samarium and the excellent stereoselectivity reported by Cossy63a we can 
only assume that the N-protecting group somehow competes with the OH group for the 
coordination of samarium and the delivery of the carbenoid onto the double bond. In support of 
this hypothesis, the N-Boc-directed cyclopropanation of allylic carbamates with Zn-carbenoids 
has recently been described by Davies65. 
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Table 3 
entry R-OH
[a]
 Conditions 
Conversion 
(%)
[b]
 
 
Cis 
(%)
[c]
 
Trans 
(%)
[c] 
1 118                Sm/HgCl2, CH2I2, THF, -78°C→25°C, 5 h 100
[d] 43 57 
2 118 Et2Zn, CH2I2, CH2Cl2, -12°C→25°C, 24 h 87 
100 
(60)[e] 
- 
3 118 
Et2Zn, CH2I2, TFA, CH2Cl2,  
-78°C→25°C, 24 h 
72 
100 
(35)[e] 
- 
4 118 
Et2Zn, CH2I2, 2,4,6-trichlorphenol, CH2Cl2,  
-40°C→25°C, 4 h 
100 
100 
(86)[e] 
- 
5 125                
Et2Zn, CH2I2, 2,4,6-trichlorphenol, CH2Cl2,  
-40°C→25°C, 3.5 h 
100 
100 
(79)[e] 
- 
 
Table 3: [a] Reaction carried out on 0.2–0.9 mmol of substrate. [b] Reaction monitored by TLC. [c] Relative 
composition determined by 1H-NMR on the crude reaction mixture. [d] Starting material completely consumed but 
several unidentified products in the crude reaction mixture. [e] Yield after chromatography. 
 
We tried the Simmons–Smith reaction under three different sets of conditions (entries 2–4): (1) 
with the Wittig–Furukawa reagent66 Zn(CH2I)2 (2) with Charette’s carbenoid
67 Cl3C6H2OZnCH2I 
and (3) with Shi’s carbenoid68 CF3CO2ZnCH2I. 
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In spite of the latter being one the most reactive carbenoids, the reaction did not reach complete 
conversion after 24 h (entry 3), as also observed for the reaction with the Wittig–Furukawa 
reagent (entry 2). Although in all cases we observed the formation of the expected cis product 
only, the best result in terms of cyclopropanation rate and yield after chromatography was 
obtained with Et2Zn and CH2I2 in the presence of 2,4,6-trichlorophenol (entry 4). Under these 
conditions the reaction was complete in 4 h, providing the cis isomer (1R,5R,6S)-127 in 86% 
yield. 
These conditions were thus applied to N-Cbz protected alcohol (R)-125 to give diastereopure 
cyclopropanated (1R,5R,6S)-128 (entry 5) in good yield (79 %), as well as its enantiomer (S)-125 
to obtain (1S,5S,6R)-ent-128 (73 %). 
 
2.6 Synthesis of cyclopropanated trans derivatives  
 
Having assessed our approach to the synthesis of the cis-cyclopropanated derivatives 127 and 
128, the preparation of both trans cyclopropanated isomers had to be developed as the next step 
of the study. 
For the synthesis of these the trans isomers, we needed a bulky allylic protecting group that 
could direct the cyclopropanation onto the opposite face of the double bond. 
 
For 4-OTBS-, OTIPS-, and OtBu-protected derivatives of 118, were already observed good to 
high facial selectivity in heterogeneous catalytic hydrogenation and hydroboration reactions29,48, 
so we were confident that a similar selectivity could be obtained in cyclopropanation, either by 
exploiting Michael-type reactions of S-ylides or various carbenoids. 
 
However, not only did O-protected derivative 129 (R = TBS, Scheme 29, Table 4), react very 
slowly with Charette’s and Wittig–Furukawa’s carbenoids (53–55% conversion after 20–44 h, 
entries 1–2) but the cis isomer still, albeit only slightly, prevailed. This could be explained by a 
weak coordination of the Zn-carbenoid to the oxygen atom in the 4-position. 
In fact, when completely changing the reaction mechanism, i.e. using dimethylsulfoxonium 
methylide in DMSO at 25 °C, steric control by the 4-OR group took place, providing trans 
compounds 130, 131 and 133 in an approximately 3.8–7 : 1 ratio with their cis isomers (entries 
3–5) and in good yields (77–82%) after chromatography. This ratio could not be increased under 
different conditions, even when carrying out the reaction in DMF at –5 °C (entry 6). 
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Scheme 29: Reagents and conditions: (a) 3N HCl, CH3CN, 0°→25°C, 1h (b) MeONa, MeOH, 0°C 
 
Table 4 
entry R-OH
[a]
  Conditions 
Conversion 
(%)
[b]
 
Trans/Cis
[c]
 
 
1 129                Et2Zn, CH2I2, CH2Cl2, -12°C→25°C, 24 h 53 1 : 1.2 
2 129 
Et2Zn, CH2I2, 2,4,6-Trichlorphenol, CH2Cl2,  
-40°C→25°C, 44 h 
55 1: 1.3 
3 129 TMSOI[d], NaH, DMSO, 25°C, 2 h 
100 
(82)[e] 
4.7 : 1 
4 54 TMSOI[d], NaH, DMSO, 25°C, 1.5 h 
100 
(77)[e] 
3.8 : 1 
5 132                TMSOI[d], NaH, DMSO, 25°C, 2.2 h 
100 
(78)[e] 
7 :1 
6 129 TMSOI[d], NaH, DMF, -5°C, 24 h 
93 
(13)[e] [f] 
3.1 : 1 
7 54 TMSI[g], NaH, DMF, 25°C, 2 h 
82 
(14)[e] [f] 
4.8 : 1 
8 54 TMSI[g], NaH, DMSO, 25°C, 2 h 
89 
(5)[e] [f] 
- 
9 129 TMSCHN2, Pd(OAc)2, benzene, 30°C, 4 d 0 - 
 
Table 4: [a] Reaction carried out on 0.5-1 mmol of substrate, monitored by TLC. [b] Determined by 1H NMR. [c] 
Relative composition determined by 1H NMR on the crude reaction mixture. [d] TMSOI = Trimethylsulfoxonium 
iodide. [e] Yield after chromatography. [f] Low yield due to a great extent of degradation of the starting material. [g] 
TMSI = Trimethylsulfonium iodide. 
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The facial selectivity was much the same (trans/cis ratio = 4.8 : 1) when we used 
dimethylsulfonium methylide for the trans cyclopropanation in DMF (entry 7) at room 
temperature; however, the isolated yield was very low (14% after chromatography) under these 
conditions (and even worse when carrying out the reaction in DMSO, entry 8) because of the 
formation of a large amount of polar byproducts, which were lost in the work up or during 
chromatography. 
The Pd-catalyzed cyclopropanation (entry 9) carried out in the presence of 
trimethylsilyldiazomethane (TMSCHN2), as reported for an electron-poor olefin
69, failed 
completely. 
 
Despite the fact that the trans compounds were obtained in mixtures with their cis isomers, these 
could be easily separated by chromatography after OH deprotection (Scheme 29), which 
provided the enantiopure major trans compounds (1S,5R,6R)-127 in 69 and 67% yield from 
(1S,5R,6R)-130 and (1S,5R,6R)-131, respectively, and (1S,5R,6R)-128 in 73% yield from 
(1S,5R,6R)-133. The best conditions were as usually applied to the synthesis of enantiomer 
(1R,5S,6S)-ent-10 from (S)-132. 
 
Finally, to obtain these amino acid analogues in a form suitable for peptide coupling, we carried 
out the N-deprotection on both enantiomers of compounds cis and trans 128 by hydrogenolysis 
(Scheme 30) at room temperature over 10% Pd/C, which provided free amino esters  cis 110 and 
trans 110 both in quantitative yield70. 
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Scheme 30: Reagents and conditions:  (a) H2, 10% Pd/C, MeOH, 25°C, 3h 
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2.7 Determination of lipases enantiospecificity in EKR of racemic 4-hydroxylated N-Cbz 
protected enecarbamate esters 
 
Compound trans (1R,5S,6S)-110 was converted into the corresponding N-CO2Me protected 
derivative (1R,5S,6S)-127 (Scheme 31) whose positive optical rotation value is consistent to the 
stereospecificity of the lipase in the kinetic resolution of alcohol (±)-125 (for trans (1S,5R,6R)-
127 obtained from (R)-54 of known absolute configuration the [α]25D value is –4.43). 
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Scheme 31: Reagents and conditions: (a) H2, 10% Pd/C, MeOH, 25°C, 3h 
 
2.8 cis/trans stereochemical assignement in 4-hydroxy-cyclopropanated derivatives 
 
The relative cis and trans stereochemistry in compound 127 and 128 (Scheme 28) is easily 
assigned by the analysis of the coupling constants in the 1H-NMR spectrum and by NOE studies. 
In cis compound 5-H resonates at 4.35 ppm with a J = 10.1 Hz consistent with its axial 
orientation. This is confirmed by a NOESY 1D experiment (mixing time 800 ms) which shows a 
correlation between 5-H and axial 3-H proton. In trans compound 5-H resonates at 4.28 ppm as a 
broad singlet due to its equatorial position, as confirmed by the lack of NOE correlation between 
5-H and the protons at C3. In both isomers, the C-1 carbomethoxy group is axially oriented to 
remove the A(1,3) strain with the N-protecting group71. The 1H-NMR spectra of compounds 130, 
131 and 133 (Scheme 29) are quite complex due to the presence in solution of rotamers for both 
trans and cis isomers. However, at least one set of signals allow for the identification of the two 
isomers and the determination of the ratio, i.e. 3-H axial proton which is always 0.4-0.5 ppm 
more downfield-shifted in the trans isomer. In this, moreover, the 5-H is always a broad singlet 
due to the lack of trans diaxal couplings. 
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Chapter 3: Synthesis of 4,5-dihydroxypipecolic acids 
 
We started our study on 4,5-dihydroxylated pipecolic acids focusing on the 4,5-cis-dihydroxy 
compounds 10, 11 and related enantiomers ent-10 and ent-11. 
 
According to the above strategy, for the synthesis of cis 4,5-dihydroxypipecolic acid 10 and 11, 
cis 4,5-dihydroxylated lactam 137 would be required in enantipure form. Despite being a simple 
compound (and, in general, a potentially useful polyfunctionalized chiral synthon for diverse 
uses), the isolated enantiomers of the cis isomer 137 were unknown. 
 
3.1 Synthesis of the cis 4,5-dihydroxypiridine precursors: EKR strategy 
 
Encouraged by the good results obtained with 4-hydroxylated derivatives 118 and 125, we 
envisaged a lipase-catalyzed kinetic resolution of 4,5-dihydroxylated precursors. 
In 4-hydroxylated derivatives, the EKR was applied for the resolution of the enecarbamate 
substrates, but for the 4,5-dihydroxylated precursors we initially envisaged an enzymatic 
resolution at an “earlier” stage, i.e. on racemic 4,5-cis-dihydroxylated lactam 137 (Scheme 32). 
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Scheme 32: EKR-based strategy for enhantiopure 4,5-cis-dihydroxylated lactams precursors  
 
So, for the synthesis of the racemic 4,5-dihydroxylactam (±)-137, known unsaturated lactam 136 
(Scheme 33), which can be prepared in a multigram scale by coupling of 3-buthenol (134) with 
allylamine and following RCM of the coupling product 13572, was chosen as the starting 
material. 
In our laboratory were previously tried the Sharpless asymmetric dihyroxylation on lactam 136 
by using both α and β AD-mix. However, despite testing several experiments procedures and, in 
particular, a most promising one reported for the corresponding unsatured lactone73, it was never 
possible to obtain enantiomeric excesses higher than 14%74. 
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Scheme 33 
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Scheme 33: Reagents and conditions: (a) (COCl2), CH2Cl2, 25°C, 3 h (b) Grubbs I generation, CH2Cl2, reflux, 17 h 
(d) KMnO4 (31mM), NaOH (50 mM), H2O, 0°C, 1h  
 
Among the various options for the dihydroxylation of 136 to give new lactam (±)-137, the 
addition of an aqueous solution of KMnO4 to a vigorously stirred alkaline solution of the 
substrate  in water at 0°C worked best in terms of product recovery and yield after work-up75,76. 
Reagents concentrations, pH, and addition rate were critical to avoid either overoxidation or 
migration of the double bond to give the corresponding α,β-unsaturated lactam. 
 
3.1.1 EKR attempts on racemic lactam 137 
 
With a sufficient amount of (±)-137, we were ready for preliminary EKR studies. 
The first problem was the scarce solubility of this substrates in the solvents used above for EKR. 
So, we carried out the experiments dissolving racemic 137 in THF, which seemed to be the best 
solvent of 137. Three aliquots of substrate dissolved in THF (0.4 M) were reacted, respectively, 
in the presence of CAL-B, CAL-A and PS-AMANO-IM (100mg/mmol), with an excess of vinyl 
butyrate as acylant reagent. Unfortunately, probably due to the low solubility of the substrate in 
THF, in no cases we observed the conversion of the substrate to acylated products. Moreover, 
(±)-137 was unsoluble also in dioxane and acetonitrile. 
 
3.1.2 EKR application of 4,5-dihydroxylated enecarbamate derivative 
  
Due to the failure of the enzymatic strategy on racemic lactam 137, and envisaging a possible 
resolution in a “later” stage of the synthesis, we developed a synthetic route for the conversion of 
(±)-137 in the corresponding enecarbamate derivative trough the enol-phosphates chemistry, 
which should be then subjected to the enzymatic resolution (Scheme 34). 
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Scheme 34: EKR-based strategy for enhantiopure 4,5-cis-dihydroxylated enamide precursors  
 
This synthesis of the racemic enecarbamate precursor was previously developed for the N-Cbz 
derivative 147. This was subjected to the enzimatic resolution, then applied also to the N-CO2Me 
substrates 144, previously employed in a diastereodivergent synthesis of alkaloid 1,4-
dideoxymannojirimycin51. In Scheme 35 both routes where shown. 
So, crude (±)-137 was directly transformed into the isopropylidene-protected diol (±)-138 which 
was obtained in 63% yield over two steps after chromatography, and then protected as N-CO2Me 
or N-Cbz carbamates ((±)-139 and (±)-140, 81% and 84% yield, respectively). 
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Scheme 35: Reagents and conditions: (a) 2,2-dimetoxypropane, p-TsOH, MeOH, 55°C, 1h (b) MeOCOCl or 
BnOCOCl, n-BuLi, THF, -78°C (c) KHMDS, (PhO)2P(O)Cl, THF, -78°C (d) Pd(OAC)2, Ph3P, CO, MeOH, Et3N, 
DMF, 60°C, 2.5h (R = Me) or 5h (R = Bn) 
 
Quantitative generation of the corresponding enol phosphates (±)-141 and (±)-142 was 
accomplished by treatment of the lactams with KHMDS at -78°C in THF, followed by the 
addition of diphenylchlorophosphate. Pd-catalyzed metoxycarbonylation of the two phosphates 
was carried out according to the usual method, in anhydrous DMF and at 1 atm (CO balloon) and 
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finally gave the key ester intermediates (±)-143 and (±)-144 in 69 and 72% yield after two steps, 
respectively. In that conditions the N-Cbz phosphate reacted slowly than the N-CO2Me 
protected. In fact, phosphate (±)-142 was completely converted only after 5 h at 60°C, against 
the 2.5 h of the N-CO2Me phosphate (±)-141. 
 
During the synthesis we also tried to obtain isopropilidene-protected lactam 140 starting from 
diol 146 (Scheme 36), provided in scarce yield (16%) by N-Cbz protection of 136. The following 
OH protection as isopropylidene (2,2-dimethoxypropane and catalytic p-TsOH, MeOH 55°C) 
failed, affording only unidentified polar degradation products.   
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Scheme 36: Reagents and conditions: (a) n-BuLi, BnOCOCl, THF, -78°C (b) KMnO4 (31mM), NaOH (50 mM), 
H2O, 0°C, 1h  (c) 2,2-dimetoxypropane, p-TsOH, MeOH, 55°C, 1h 
 
In order to have the substrate ready for the enzymatic kinetic resolution, we performed the 
isopropylidene deprotection of (±)-144  in a TFA/CHCl3/H2O 5 : 1 : 0.1 mixture (Scheme 37).  
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Scheme 37: Reagents and conditions: (a)  TFA/CHCl3/H2O 5 : 1 : 0.1,  25°C, 11 min (b) TFA/CHCl3/H2O 5 : 1 : 0.1,  
25°C, 0.5 h  
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Under these conditions, compound (±)-144 reached complete conversion after 30 minutes, but 
the allylic hydroxyl group of the resulting cis alcohol 147 was prone to partial isomerisation due 
to the acid envirornment, forming also the undesired trans product (±)-148. Fortunately, this 
phenomena could be strongly limited by carrying out the reaction for shorter times (optimum 11 
min, stopped with 66% conversion). In that way, we managed to obtain only the required 
compound 147 in a 2 : 1 mixture with the unreacted substrate. The two compounds could be 
isolated by flash column chromatography, and (±)-144 subjected again to deprotection. 
 
With a sufficient amount of racemic 147, we were ready for EKR (Scheme 38, Table 5) 
experiments (see Appendix 6 for absolute configuration determination). 
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Scheme 38: Reagents and conditions: (a) MeONa, MeOH, 0°C, 3.5h 
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The kinetic resolution was carried out in the presence of the three lipases that gave the best 
results for the resolution of the 4-hydroxylated alcohols, i.e. Bulkorderia cepacia lipase (PS-
AMANO-IM) and Candida antarctica lipase B and A (CAL-B and CAL-A), with an excess of 
vinyl acetate, vinyl butyrate or vinyl stearate as the acylating reagent. As previously reported for 
the resolution of 4-hydroxylated compounds, the reactions were performed in various anhydrous 
solvents. 
 
Table 5 
entry 
Acylant 
reagent[a] 
Solvent[b] 
t 
(h) 
c (%)[c] 
4/5 
acylated 
ratio[c] 
151 
(%) 
147 
ee (%) 
ent-
147 
ee (%) 
E[f] 
    CALA[g]      
1 VA TBME 24 78 1.5 : 1 10 69[d] n.d. n.d 
2 VB TBME 5 46.8 1.7 : 1 1.1 1[d] n.d. n.d 
    CALB[g]      
3 VB TBME 47 52 3 : 1 < 0.5 70[d] 76[d] n.d 
4 VB THF 54 46 11 : 1 0.1 
72[d] 
57[e] 
86[d] 
72[e] 
29 
11 
5 VB Acetone 22 42 16 : 1 0.1 
59[d] 
51[e] 
89[d] 
79[e] 
31 
14 
6 VB Dioxane 70 53 11 : 1 - 69[e] 76[e] 15 
7 VB CH3CN 21 39 15 : 1 - 42
[e] 83[e] 16 
8 VB CH2Cl2 52 37 2.8 : 1 - 27
[e] 74[e] n.d 
9 VB Toluene 52 16 1.2 : 1 - 3[e] 45[e] n.d 
10 VS THF 67 36 2 : 1 - 21[e] n.d n.d 
    “Amano”      
11[h] VB THF 0.8 24 52 1 : 1.3 2.7 67[d] 57[d] n.d 
12[g] VB TBME 21 66 0.7 : 1 3.4 83[d] n.d. n.d 
 
Table 5: [a] VA: vinyl acetate, VB: vinyl butyrate, VS: vinyl stearate. [b] Anhydrous solvents were used. [c] 
Conversion determined by HPLC (column Acclaim 120 C18, see ref 77) and 1H-NMR. [d] Determined by HPLC 
analysis (column Cyclobond I2000, see ref 78). [e] Determined by HPLC analysis (column Lux Cellulose 4, see ref  
79). [f] Calculated as ln[1-c(1+eep)]/ln[1-c(1-eep)]. [g] Reaction carried out on 0.2-0.4 mmol of substrate at 30 °C, 
substrate concentration 0.2M, enzyme (mg)/substrate (mmol) ratio = 100, 3.5 equivalents of acylant reagent, 
molecular sieves (4Å, 130 mg/mmol). [h] Substrate concentration = 0.8 M 
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Because enzymes could acylate the hydroxy group at position 4, 5 or both (only in a few 
cases80), for each experiment we determined the regioselectivity of the enzymes and the 
enantiomeric excess of the acylated alcohols (after hydrolysis), as well as the ee of the unreacted 
diol. As in the case of simple 4-hydroxylate alcohols the (4S,5R) enantiomer of 147 was 
preferentially acylated in all experiments. 
Each enzyme showed a proper regioselectivity. CAL-B (entries 3-10) preferentially acylated the 
OH-group in position 4, as well as CAL-A (entries 1 and 2), while using PS-AMANO-IM the 5-
acylated isomer prevailed (entries 11 and 12). 
  
Unfortunately, the ratio between the 4-acylated and 5-acylated regioisomers at a certain 
conversion rate was not stable during the time and could not be easily determined. In fact, we 
observed a time-related decrease of 4-acylated/5-acylated ratio when the products were in 
solution. We explained it as a spontaneous migration of the acyl group from oxygen in position 4 
to position 5, as previously reported by Armesto et all. on quinic and shikimic acid derivatives81. 
This migration took place also during our efforts in chromatographyc separation of the 
regioisomers. 
 
So, although the ee of 5-acylated compound formed by migration was necessarily the same of 
that of the original 4-acylated regioisomer, we were not able to determine the relative amount of 
5-acylated isomer formed by direct action of the enzyme. Consequently, by measuring the ee of 
acylated products after hydrolysis (by HPLC), the enantioselectivity in position 5 or 4 could not 
be determined. 
 
In order to minimize this problem, we focused on the most regioselective enzyme CAL-B (entry 
3-10). Using vinyl butyrate as acylating agent, reaction time and enantiomeric excesses strongly 
depended on the employed solvent. In high-polarity solvents like acetone (entry 5), dioxane 
(entry 6) and acetonitrile (entry 7), reactions were faster and with an higher 4/5-acylated ratio 
with respect to what observed in low-polarity solvents (dichlormethane, toluene, entry 8 and 9). 
The experiment carried out with vinyl stearate (VS) acylating agent lead to the worst results 
(entry 10). 
Even under the best conditions we never managed to obtain products with sufficiently high ee 
(the enantiomeric ratio E was near 20 for the reaction performed in polar solvents), so this 
approach appeared unsuitable for the resolution of racemic 147 (although the results obtained in 
acetone and acetonitrile were promising and deserving further experiments). 
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3.2 Chemical resolution of racemic cis-4,5-dihydroxylated enecarbamate ester 147 
 
Due to the failure of the enzymatic approach, we envisioned a chemical resolution of racemic 
147 by esterification of racemic acid derivative 152 with enantiopure alcohols, having in mind a 
possible chromatographic separation of the two diastereoisomeric esters furnished by the 
reaction (Scheme 39). The experiments were carried out with enantiopure (-)-menthol and (S,S)-
hydrobenzoin. Unfortunately, even though various eluition mixture were tested, diasteromeric 
esters 153 and 154  resulted as to be unseparable by flash column chromatography. 
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Scheme 39: Reagents and conditions: (a) 1M LiOH, dioxane, 60°C, 21h (b) R*-OH, DCC, DMAP, CH2Cl2, 
0°C→25°C, 3 h (R-OH = menthol) or 21 h (R-OH = hydrobenzoin) 
 
3.3 Synthesis of the cis-4,5-dihydroxylated precursors from enantiopure lactones 
 
Due to the poor results of the enzymatic and chemical resolution of racemic 147, we envisaged a 
completely different route to build our synthetic precursors in enantiopure form, starting from 
enantiopure hydroxylated lactones from the chiral pool. 
For the synthesis of enantiopure 137 in enantiopure form, we envisaged a route which starts from 
enantiopure 2-deoxyribose 155. Being both enantiomers of 2-deoxyribose commercially 
available, we realized the synthesis of enantiopure cis 4,5-dihydroxy δ-valerolactam 137 
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(Scheme 40) from commercial 2-deoxy-D-ribose 155 , as well as the synthesis of  its enantiomer 
ent-137 from 2-deoxy-L-ribose ent-155. 
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Scheme 40: Reagents and conditions: (a) Br2, H2O, 25 °C, 5 d; (b) TsCl, pyridine, -15 °C, 2 h, then 0 °C, 5 h; (c) 
SOBr2, rt, 4.5 h; (d) NaN3, CH3CN, 18-C-6 or 15-C-5, reflux, 15-20 h; (e) H2 (1 atm), 10% Pd/C, MeOH, 24h (f) 
2,2-dimethoxypropane, p-TsOH, MeOH, 55 °C, 1 h; (g) CH3OCOCl, n-BuLi, –78 °C; (h) (PhO)2POCl, KHMDS, 
THF, –78 °C; (i) 10% Pd(OAc)2, 20% Ph3P, CO, MeOH, Et3N, DMF, 75 °C, 1 h; (e) H2 (1 
 
To this end, 2-deoxy-D-ribose 155 was initially subjected to treatment with Br2 in water for 5 
days, which provided 2-deoxy-D-ribonolactone 156 in excellent yield (88%) after 
chromatography82. This compound proved stable in aprotic solvents, but in protic mediums such 
as methanol it slowly equilibrates to give a minor isomer which could be the corresponding six-
membered lactone (i.e. the cis-4,5-dihydroxytetrahydropyran-2-one) or the intermediate aldonic 
acid, according to Han et al.82a,b. We found a ratio of about 2.5 : 1 in favor of the 2-deoxy-D-
ribonolactone, a ratio which did not change after heating at 50 °C83. The (partial) conversion of 
156 into the corresponding primary O-tosyl derivative 157 was realized as reported by treatment 
with TsCl in pyridine at -15 °C and then leaving at 0 °C for 5 h84 conditions which furnished 
compound 157 in 54% yield after chromatography. This was the best yield we obtained under 
these conditions, as prolonging the reaction times to completely convert 156 into 157 led to the 
partial tosylation of the secondary OH group, too. Similarly, several attempts at selectively 
converting the primary hydroxy group into a mesylate (MsCl, Et3N, in CH2Cl2 at -30 °C) always 
failed due to the concurrent mesylation of the secondary alcohol, followed by elimination of 
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methansulfonic acid during chromatography. Instead, bromination of compound 156 by 
treatment with thionyl bromide in anhydrous DMF at room temperature (4.5 h) occurred 
selectively at the primary position, but provided lactone (+)-158 in 47% yield after 
chromatography. However, it was possible, after the work-up of the reaction, to recover an 
amount of unreacted starting material (31%) which was chromatographed and reacted again with 
SOBr2 under the same conditions, thus providing bromolactone (+)-158 in 61% total yield
85. 
Transformation of both 157 and 158 into 2-deoxy-5-azido-D-ribonolactone 159 was 
accomplished by treatment with NaN3 in refluxing acetonitrile and in the presence of 18-crown-
6, which provided key intermediate 159 in 87% (from 157) and 95% (from 158). 
Eventually, hydrogenation of 159 at atmospheric pressure (balloon) over 10% Pd/C gave pure 
dihydroxylated lactam (4S,5R)-137 in 91% yield and whose 4,5-cis relative stereochemistry was 
confirmed by X-ray analysis (Figure 6). According to the same strategy, by converting 2-deoxy-
L-ribose (ent-155) into the corresponding bromine (47% over two steps), and this into azide 
(97%), we were also able to prepare its enantiomer (4R,5S)-ent-137 in 43% overall yield. 
 
Figure 6 
 
Figure 6: X-ray of (4S,5R)-137  nitrogen in blue, oxygen in red 
 
Lactam 137 was converted into enantiopure enecarbamate ester 143 according to the procedure 
we have disclosed for the synthesis of the corresponding racemic compound. Thus protection of 
(4S,5R)-137 as the acetonide (–)-138 (92%) (Scheme 41) , and then N-protection as carbamate (–
)-139 (84%) set the stage for the quantitative generation of the corresponding enol phosphate 141 
by treatment of the lactam with  KHMDS at –78 °C in THF followed by the addition of 
diphenylchlorophosphate. 
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Pd-catalyzed methoxycarbonylation of the phosphate in anhydrous DMF and at 1 atm (CO 
balloon) was carried out at 75° C in the presence of an excess of MeOH to give the key ester 
intermediates (+)-143 in 78% yield after two steps. 
Its enantiomer (-)-ent-143 was prepared according to the same procedure starting from (4R,5S)-
ent-137, with 51% overall yield. 
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Scheme 41: Reagents and conditions: (a) 2,2-dimethoxypropane, p-TsOH, MeOH, 55 °C, 1 h; (b) CH3OCOCl, n-
BuLi, –78 °C; (c) (PhO)2POCl, KHMDS, THF, –78 °C; (d) 10% Pd(OAc)2, 20% Ph3P, CO, MeOH, Et3N, DMF, 75 
°C, 1 h; 
 
3.4 Synthesis of 4,5-cis-dihydroxypipecolic acid 10 
 
To attain natural 4,5-cis-dihydroxypipecolic acid L-10, we subjected the enamine double bond of 
143 to heterogeneous catalytic hydrogenation over 10% Pd/C at 1 atm, which gave cis ester (-)-
160 (Scheme 42) in quantitative yield and complete facial selectivity (by 1H NMR). 
Exhaustive deprotection in refluxing aqueous 4 N HCl eventually concluded the first total 
synthesis of free L-pipecolic acid 10 which was obtained in high 27% overall yield in 9 steps and 
of which we could measure the optical rotation so far unknown17,19. 
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Scheme 42 
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Scheme 42: Reagents and conditions: (e) H2 (1 atm), 10% Pd/C, NaHCO3, EtOAc, 4 h; 4N HCL, reflux 4 h 
 
For the synthesis of the other 4,5-cis dihydroxylated pipecolic acid, that is compound 11, the 
enamine substrate ent-143 was subjected to a conjugate reduction by Super-Hydride (LiEt3BH) 
at -10 °C (Scheme 43). After quenching the anion with a saturated NaHCO3 solution, 
1H-NMR 
analysis of the crude reaction mixture revealed the formation of a 2.6 : 1 mixture between 
thermodynamically more stable ester (-)-161 and cis,cis isomer ent-160. The two 
diastereoisomers were easily separated by chromatography, thus obtaining pure 161 in 68% yield 
and its minor isomer ent-160 in 22% yield. On the basis of previous experience, the latter was 
subjected to epimerization by treatment with TBAF in THF29a which provided an approximately 
1:1 mixture of the two compounds (161 and ent-160) after 19 h at room temperature86. After 
another chromatography the total yield in target compound 161 was 78% over the two steps. 
Deprotection of 161 in refluxing 4N HCl eventually provided pure compound 11 in quantitative 
yield87, and analogous treatment of ent-160 provided the unnatural enantiomer of 2,4-cis 4,5-cis 
isomer ent-10. 
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Scheme 43: Reagents and conditions: (a) LiEt3BH, THF, -10 °C, 70 min; (b) 4N HCl, reflux, 24 h; (c) TBAF, THF, 
0 °C → rt, 18 h 
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3.5 Synthesis of the trans 4,5-dihydroxypipecolic precursors from enantiopure lactones 
 
For the synthesis of the 4,5-trans compound 9 we envisaged a route which starts from 
enantiopure 5-hydroxy-δ-valerolactam, whose synthesis has been reported by Herdeis from 
glutamic acid88, and in which the required 4-OH group would be installed on the heterocyclic 
skeleton at a later stage of the synthesis, relying on the preferential axial attack in the key allylic 
bromination step and the possible trans-directing effect exerted by the bulky silyloxy group in 
compound 169 (Scheme 28)89. 
Having in mind to employ the resulting 4,5-trans-dihydroxylated enecarbamate as substrates for 
the synthesis of pipecolic acids as well as their cyclopropanated derivatives (which requires a N- 
protecting group removable by hydrogenation) we performed the synthesis of both N-CO2Me 
protected and N-Cbz protected enecarbamate precursors 175 and 176, respectively (Scheme 44).  
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Scheme 44: Reagents and conditions: (a) MsCl, Et3N, CH2Cl2, -30°C→25°C, 2h (b) NaN3, 18-crown-6, MeCN, 
reflux, 10h (c) H2, 10% Pd/C, MeOH, 25°C, 21h (d) TBSCl, imidazole, DMF, 38°C, Xh (e) MeOCOCl or 
BnOCOCl, n-BuLi, -78°C (f) KHMDS, (PhO)2P(O)Cl, THF, -78°C (g) Pd(OAC)2, Ph3P, CO, MeOH, Et3N, DMF, 
70°C, 2.5h (h) AIBN, NBS, CCl4/CHCl3 9:1, reflux, 1.5 h (i) Silver acetate, AcOH, 15 min, 25 °C; (l) MeONa, 
MeOH, 0 °C, 1 h 
 
Their synthesis was realized starting from 5-OH protected lactam 164, (Scheme 43) which was 
prepared from commercial (S)-(+)-γ-hydroxymethyl-γ-butyrolactone 162 as reported by 
Results and discussion: Chapter 3 
 60 
Herdeis88, trough cyclization of azide 163 and silyl protection of the resulting alcohol. After N-
protection as methyl carbamate or benzyl carbamate, compounds 165 and 166 were converted 
into the corresponding enol phosphates 167 and 168, then into enecarbamate esters 169 and 170 
(82% and 60% yield, respectively) as usual. The allylic bromination of both precursors was 
carried out by treatment with N-bromosuccinimide (NBS) in the presence of catalytic 
azobisisobutyronitrile (AIBN) in a refluxing mixture of CCl4/CHCl3
90. 
 
Interestingly, whereas the reaction on the corresponding 5-unsubstituted enamide ester was 
complete in 15 min, under the same conditions thorough consumption of our substrates occurred 
only after 1.5 h. 
 
On the other hand, we were glad to observe that allyl bromide 171 was obtained as a single trans 
diastereomer and with the two groups (Br and OTBS) axially oriented. This assignment was 
made on the basis of the very low coupling constant values (less than 4 Hz) of protons 4-H and 
5-H of 171, which resonates at 4.32 and 4.22 ppm almost as broad singlets, and the lack of nOe 
correlations between 6-Hax and any of the two protons mentioned above. Our failed attempts to 
convert bromide 171 into a 4,5-cis diol derivative by a SN2 displacement of the bromine with an 
O-nucleophile (e.g. with AcOK in anhydrous DCM in the presence of 18-crown-6 at 25 °C or 
with AcOLi in DMF at 45 °C) can be explained by the steric impediment exerted by the large, 
axially oriented, OTBS group. Instead, cationic processes were all successful to provide 4,5-
trans diol derivative, in particular treatment of bromide with silver acetate (2 equiv.) in acetic 
acid furnished (-)-173 with the highest yield (75% over two steps)91.  
Again, the trans stereochemical assignment of compound 173 is based on the analysis of the 
coupling constants in its 1H-NMR spectrum: both 4-H (4.95 ppm) and 5-H (3-91 ppm) protons 
possess very low coupling constants (less than 3 Hz) which is in accordance with their equatorial 
position. Moreover, there is no nOe enhancement of 4-H and 5-H when selecting 6-Hax in 
NOESY 1D experiments. 
The trans selectivity in both radical and cationic processes to give 173 and 174, respectively, can 
be only in part accounted for on the basis of steric reasons, as instead stereoelectronic effects 
could play a major role in stabilizing the transition state89. The axial introduction of the bromine 
on the half-chair conformation with the axial OTBS group at C-5 permits the maintenance of 
maximum π-overlap in the allylic radical during the reaction and, moreover, there could be a 
possible further stabilization by hyperconjugative delocalization of the forming Br-C σ-bond 
with the σ*orbital of C-OTBS bond (Figure 7). 
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Figure 7  
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Figure 7: stereochemistry in the allylic oxidation (a) of compound 169 and SN1 substitution (b) of 171 
 
The procedure with silver acetate in acetic acid was also applied on trans N-Cbz bromide 172, 
providing 174 in 40% yield over two steps. 
The acetyl group in 173 and 174 was following removed to give alcohols 175 and 176 (both with 
73% yield). 
 
3.6 Synthesis of 4,5-trans-dihydroxypipecolic acids 
 
For the synthesis of the 4,5-trans compound 9, the N-CO2Me protected enecarbamate ester 175 
was hydrogenated as usual yielding a 3.1 : 1 mixture (by 1H-NMR) of 2,4-trans-4,5-trans 
compound (–)-178 and 2,4-cis-4,5-trans isomer 177 (Scheme 45). 
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Scheme 45: Reagents and conditions: (a) H2 (1 atm), 10% Pd/C, NaHCO3, EtOAc, 20 h; (b) 4N HCl, reflux, 24 h 
 
As expected, the effect of bulky silyloxy group was prevailing in dictating which face of the 
double bond would be adsorbed on the Pd-catalyst, although the stereoselectivity was lower than 
we had hoped. In any case, major isomer 178 was easily separated by chromatography (71% 
yield) and fully deprotected in refluxing aqueous 4 N HCl to give target pipecolic acid 9 in 
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quantitative yield. Unfortunately, it was not possible to isolate the minor isomer 177 if not in 
mixture with small amounts of 178. 
 
3.7 NOESY study on 4,5-dihydroxypipecolic acids 
 
Because of the lack of high field NMR studies on these 4,5-dihydroxypipecolic acids, besides 
recording NMR spectra, we also performed NOESY 1D and 2D experiments to assess the spatial 
orientation of the three substituents on the piperidine ring. As shown in Figura 8,  in all cases the 
carboxylic group at 2-position is equatorially oriented, as shown by the ever present nOe cross-
peak between 2-H (axially oriented) and 6-Hax, thus dictating the spatial orientation of the two 
hydroxyl groups. In compound 9, the two protons at C-4 and C-5 resonate at 4.04 and 3.94 ppm 
almost as broad singlets with very low coupling constants (J < 3.5 Hz), consistent with their 
equatorial position. 
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Figure 8: stereochemistry assignement by nOe 
 
In compound 10, a nOe correlation exists also between 2-H and 4-H, showing the equatorial 
orientation of the 4-OH group. In this compound, only 5-H appears as a broad singlet at 4.16 
ppm consistent with the axial position of the 5-OH group. The reverse apply for compound 11, 
for which we found a nOe correlation between 3-Hax and 5-H, and it is the equatorially oriented 
4-H (4.13 ppm) which has very low coupling constant values now. The equatorial orientation of 
5-OH is further confirmed by the high value for the 3J between 5-H and 6-Hax (10 Hz), consistent 
with the axial orientation of 5-H. 
 
3.8 Synthesis of 4,5–dihydroxy-cyclopropanated derivatives 
 
In a similar fashion to reported for 4-hydroxy-enecarbamates 118 and 125, also the N-Cbz 
enecarbamate ester 176 was converted into the cis and trans cyclopropanated (whith respect to 
the orientation of the allylic OH group) derivatives, by exploiting the stereocontrol exerted by 
nude or bulky protected allylic OH group. 
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3.8.1 Synthesis of cyclopropanated derivatives: OH-directed cyclopropanation 
 
The best strategies that were suitable to attain the 4-monohydroxy cis and trans cyclopropanated 
derivatives were applied to the enantiopure 4,5-dihydroxylated substrate 176. 
In particular, the OH-directed cyclopropanation by Charette’s Zn-carbenoid (i. e. Et2Zn and 
CH2I2 in the presence of 2,4,6-trichlorophenol) resulted as to be the better route to attain the cis 
product 179 (Scheme 46) with absolute diastereoselectivity (by 1H-NMR) and very high yield 
after chromatography (95%). 
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Scheme 46: Reagents and conditions: (a) Et2Zn, CH2I2, 2,4,6-trichlorphenol, CH2Cl2, -40°C→25°C, 22 h; (b) 3N 
HCl, CH3CN, 0°C→25°C, 1 h; (c) H2 (1 atm), 10% Pd/C, EtOAc, 20 h 
 
The attribution of the relative cis stereochemistry in compound 179 was easily assigned by NOE 
studies. In particular, NOESY 1D experiments (mixing time 800 ms) showed a correlation 
between 5-H and the axial 3-H proton, as well as a correlation between endo 7-H and 4-H, 
consistent with the proposed structure.  
 
After removal of the TBS group with 3N HCl in ACN which gave intermediate 180 (73%), 
hydrogenation on Pd/C finally provided derivative cis-112 in quantitative yield. 
 
3.8.2 Synthesis of cyclopropanated derivatives: bulky group-directed cyclopropanation 
 
For the synthesis of the trans derivative trans-112, we exploited the reaction of 
dimetilsulfoxonium methilyde on 4,5-disilyloxy-protected 181 (Scheme 47), obtained in 99% 
yield after TBS protection of the free hydroxy group in 176. Reaction with ylide provided, just 
like the same reaction with the in 4-hydroxylated derivative, a mixture of the desired trans 182 
and cis derivatives (66% yield), with a 6 : 1 ratio (by 1H-NMR). 
In this case, the attribution of trans stereochemistry was assigned by the lack of NOE correlation 
between 5-H and the protons at C3. 
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Scheme 47 
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Scheme 47: Reagents and conditions: (a) TBSCl, imidazole, DMF, 38°C, 2.5 h; (b) trimethylsulfoxonium iodide, 
NaH, DMSO, 25°C, 4 h; (c) 3N HCl, CH3CN, CH3CN, 0°C→25°C, 2 h; (d) H2 (1 atm), 10% Pd/C, EtOAc, 20 h 
 
Unfortunately, while trans 4-hydroxy-cyclopropanated derivative could be separated from the cis 
compound after hydrolysis of the silyloxy group, the two unprotected diastereoisomers 183 and 
180 resulted unseparable by chromatography.  
 
Despite this result, we continued the synthesis with deprotection of the nitrogen by 
hydrogenation on Pd/C which provided trans-112 in 83% in a 6 : 1 diastereomeric ratio. 
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Chapter 4: synthesis of 5-hydroxylated pipecolic derivatives 
 
4.1 Synthesis of 5-hydroxypipecolic acids
49 
 
Having assessed our approach to the synthesis of three of the four natural 4,5-dihydroxypipecolic 
acids 9-11, we were tempted to exploit 5-silyloxy-protected compound 169 for the preparation of 
both cis and trans 5-hydroxypipecolic acid 6 and 7, although the synthesis of these compounds 
has been already reported by a few authors in the past92. 
Thus, hydrogenation of 169 (Scheme 48) provided cis compound 184 (95% yield, 
stereochemical attribution based on nOe correlation between 3-Hax and 5-H and a large 
3
J value 
between 6-Hax and 5-H in a compound with the 2-CO2Me group axially-oriented – see infra) in a 
8 : 1 ratio with its trans isomer. 
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Scheme 48: Reagents and conditions: (a) H2 (1 atm), 10% Pd/C, NaHCO3, EtOAc, 20 h; (b) 3N HCl, CH3CN, 25°C, 
2h; (c) 4N HCl, reflux, 24 h 
 
The facial selectivity of this experiment is much higher than we obtained for hydrogenation of 
175 under the same conditions (See Scheme 35). This suggests a slight steric hindrance exerted 
by the 4-OH in 175, as similarly observed when hydrogenating under the same conditions 4-
hydroxy-substituted compounds29a. 
The minor diastereoisomer was removed from the mixture by chromatography after OH-
deprotection to give diastereopure, known compound cis 18592g-h,93. After N-deprotection in 
refluxing 4 N HCl, pure cis 5-hydroxypipecolic acid 6 was obtained in 43% overall yield from 
precursor 164. 
 
Conjugate reduction of the double bond in ent-169 (Scheme 49) was as expected poorly 
stereoselective, providing the thermodynamically less stable trans isomer 186 in a 1 : 1.5 ratio 
with cis compound ent-184. 
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Scheme 49: Reagents and conditions: (a) LiEt3BH, THF, -10°C, 70 min (b) 3N HCl, CH3CN, 0°C→25 °C, 2 h; (c) 
4N HCl, reflux, 24 h; 
 
This ratio is easily explained considering the forced axial orientation of the 2-CO2Me group 
necessary to remove the A(1,3) strain with the N-protection94. In such a case, in trans compound 
186 the 5-OTBS group is consequently axially oriented and thus less favored for the 1,3-diaxial 
repulsive interaction with 3-H. As above, deprotection gave free alcohols ent-185 and 187 
which, after chromatographic separation, were converted into ent-6 (100%) and natural pipecolic 
acid 7 (100%). 
 
4.2 Synthesis of cis 5-hydroxy-cyclopropanated derivatives 
 
In addition to preparing 5-hydroxypipecolic acids, we tried to use the 5-hydroxylated substrates 
for the synthesis of cyclopropanated derivatives. 
We thus investigated the application of the Zn-carbenoids previously applied to 4-mono and 4,5-
dihydroxylated substrates, for OH-directed cyclopropanation of the homoallylic alcohol 188 
(Scheme 42), obtained after OH deprotection on N-Cbz precursor 170. 
In the “mild” reaction conditions used above for 118 and 125 (-15°C or -40°C than room 
temperature), alcohol 188 reacted very slow either with Charette’s and Furukawa’s Zn-
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carbenoids (<50% conversion, determined by 1H-NMR after, respectively, 96 an 72 h at room 
temperature).  
Despite this low conversion rate, which could be explained by the not optimal spacial 
relationship between the homoallylic hydroxy group and the alkene95, we were glad to observe 
that the hydroxy group still exerted complete stereocontrol, leading to the cis isomer 189 only 
(Scheme 50). 
In order to reach the reaction to complete conversion in a shorter time96 we first tried to increase 
the carbenoid concentration (3 eq of Et2Zn and 6 eq of CH2I2, instead of 2 and 4, respectively), 
then to carry out the reaction in CH2Cl2 in refluxing conditions. 
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Scheme 50: Reagents and conditions: (a) 3N HCl, CH3CN, 0°C → 25°C, 1.5 h; (b) Et2Zn, CH2I2, CH2Cl2, -15°C → 
reflux, 16h,   
 
In that conditions, the reaction was complete reached to complete conversion in 16 h, providing 
cis-189 with complete diastereoselectivity, and in 41% yield after chromatography. Finally, the 
Cbz group was removed as usual, affording compound cis (R)-111 in 96% yield. 
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Conclusion 
 
In conclusion with this work we believe we have demonstrated the flexibility and easiness of our 
approach to the synthesis of polyhydroxylated pipecolic acids and their cyclopropanated 
derivatives based on the chemistry of lactam-derived enol phosphates. Starting from commercial, 
inexpensive material, in a few steps we were able to prepare all isomers of 4,5-
dihydroxypipecolic acids and the simpler 4- hydroxy and 5-hydroxy derivatives. As a furher 
application of this chemistry, starting from the same common α,β-unsaturated enantiopure 
precursors we developed a methodology to attain their 2,3-cyclopropanated derivatives, which 
are a new kind of conformationally constrained hydroxypipecolic acids, potentially useful for the 
preparation of new drugs. 
 
The synthesis of mono-hydroxylated and 4,5-dihydroxylated pipecolic acids, as well as their 
cyclopropanated derivatives, required the synthesis of enantiopure enecarbamate esters as 
substrates for the stereoselective elaboration of the double bond. 
 
For the synthesis of 4-hydroxylated enecarbamate ester precursors 118 and 125 the key step in 
the process was the Pd-catalyzed methoxycarbonylation of racemic enol phosphates generated 
from elaboration of δ-valerolactam. Both enantiomers of the resulting 4-hydroxylated 
enecarbamate ester  precursors 118 and 125 were obtained with high optical purity (ee 98.5 - 
99.5%) by enantioselective enzymatic kinetic resolution of the corresponding racemic 
compounds. 
 
Stereoselective hydrogenation on the O-silyl protected derivative, followed by exhaustive 
hydrolysis generate the cis-4-hydroxypipecolic acid ent-4 with a higher de with respect to that 
previously obtained from OtBu-protected compounds29a. 
Enecarbamate substrates were also involved in cyclopropanation reactions, in which the 
stereochemical control was ensured by the 4-OH group itself, either free or protected. Charette’s 
Zn-carbenoid for the OH-directed cyclopropanation and Michael-type addition of 
dimethylsulfoxonium methylide in DMSO for the synthesis of the trans products provided the 
2,3-methanopipecolic acid derivatives with the highest yield and facial selectivity. The 
compounds so obtained are rigidified homoserine analogues which could find applications in 
medicinal chemistry as conformational probes and in drug discovery. 
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The synthesis of 4,5-cis 4,5-dihydroxypipecolic acids required the preparation from 2-deoxy-D- 
(and L) ribose of enantiopure cis 4,5-dihydroxy-δ-valerolactam 137, which is a new compound 
and we believe useful as a starting material for the synthesis of other natural products. The key 
step in the process was the Pd-catalyzed methoxycarbonylation of the enol phosphate generated 
from 138, which provided an enecarbamate ester easily converted by stereoselective reduction 
either to 10 or 11 (obtained in 27 and 17% yield, respectively, over ten steps). 
Although in this work we did not specifically focused on the preparation of the unnatural 
enantiomers of 10 and 11, we have in any case set the stage for their synthesis as we have 
prepared the enantiopure precursor 138 from both  2-deoxy-D- and L-ribose. 
 
The synthesis of the 4,5-trans 4,5-dihydroxypipecolic acid was instead realized through a highly 
stereoselective allylic bromination of the enecarbamate ester obtained by methoxycarbonylation 
of the enol phosphate derived from a known 5-hydroxy-δ-valerolactam derivative. After 
substitution to give the 4-hydroxy-N-CO2Me protected derivative 175, the reduction of the 
double bond and subsequent hydrolysis provided target compound 9 (in 22% yield over 8 steps). 
As for 4,5-cis dihydroxypipecolic acids, unnatural enantiomers of 9 and 6-7  can be prepared by 
the same route as their precursor (R)-(-)-γ-hydroxymethyl-γ-butyrolactone is commercially 
available. As our approach allows the synthesis of several hundred mg of final compound, the 
potential of these 4,5-dihydroxypipecolic acids as conformationally constrained scaffolds in 
medicinal chemistry could now be assessed. 
 
Moreover, starting from N-Cbz protected substrates 176 and 170, we obtained their cis 
cyclopropanated derivatives in high optical purity employing Charette’s and Furukawa’s Zn-
carbenoids for the OH-directed reaction of 176 and 170, respectively, followed by N 
deprotection. Dimethylsulfoxonium methilyde in DMSO were employed for the synthesis of 
compound trans-112 (even though this was obtained in a 6:1 ratio with the cis diastereoisomer). 
As well as the 4-hydroxylated derivatives described above, the compounds so obtained are 
rigidified amino acid analogues which could find applications in medicinal chemistry as 
conformational probes and in drug discovery. 
 
During my research work, besides the targets discussed above, their precursors, in racemic or 
enantiopure form, were also employed for the synthesis of alkaloids like fagomine48 and 1-
deoxymannojirimycin51. 
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Appendix 
 
Appendix 1: Chiral HPLC analysis of alcohol 118  
 
Substrate concentration = 1 mM in MeOH. Vinj = 0.1 µL. Eluant: MeOH-H2O, 35:65, isocratic 
elution; flow = 0.2 mL/min. λ = 254 nm 
Column: Cyclobond I 2000 
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17_GEN_11_AC #2 [modified by HPLC] UV_VIS_1
mAU
min
1 - 20,587
2 - 21,560
WVL:254 nm
 
No.  Ret.Time  Peak Name  Height       Area     Rel.Area      Amount   Type  
 min                          mAU         mAU*mim  %   
1   20,59       n.a.             5,225         2,310     99,76     n.a.     BMB* 
2   21,56       n.a.             0,028         0,005     0,24       n.a.     BMB* 
N
CO2Me
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(S)-2
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No.  Ret.Time  Peak Name  Height         Area              Rel.Area  Amount     Type  
 min                          mAU           mAU*min     %   
1   20,87       n.a.             0,040           0,012         0,23      n.a.       BMB* 
2   21,82       n.a.             10,523         5,116         99,77      n.a.       BMB 
N
CO2Me
CO2Me
OH
(S)-118
(R)-118
Appendix 
 72 
Appendix 2: Chiral HPLC analysis of alcohol 125  
 
Substrate concentration = 5 mM in MeOH. Vinj = 2.0 µL.  Eluant: Hexane-IPA, 40:60, isocratic 
elution; flow = 0.5 mL/min. λ = 254 nm 
Column: Lux Cellulose-4 
Rt = 11.68 min (R) and 17.32 min (S) 
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No.  Ret.Time  Peak Name  Height             Area   Rel.Area     Amount      Type  
 min    mAU             mAU*min %   
1   11,68       n.a.  121,741  39,847  50,47          n.a               BMB 
2   17,32       n.a.  68,963  39,105  49,53          n.a.              BMB 
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30_mag_11_AC_Alcool_N_Cbz #4 [modified by HPLC] UV_VIS_2
mAU
min
1 - 11,660
2 - 17,287
WVL:254 nm
 
 
No.  Ret.Time  Peak Name  Height   Area   Rel.Area      Amount    Type  
 min               mAU               mAU*min  %   
1   11,66       n.a.  121,714   39,532   99,33          n.a.   BMB 
2   17,29       n.a.   0,676               0,266    0,67            n.a.           BMB* 
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30_mag_11_AC_Alcool_N_Cbz #6 [modified by HPLC] UV_VIS_2
mAU
min
1 - 11,667
2 - 17,273
WVL:254 nm
 
 
No.  Ret.Time  Peak Name  Height  Area   Rel.Area  Amount      Type  
 min     mAU             mAU*min %   
1   11,67       n.a.   0,341              0,086   0,09           n.a. BMB* 
2   17,27       n.a.   170,723  96,256  99,91         n.a. BMB 
   
N
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Appendix 3: GLC control of the kinetic resolution of alcohol (±)-125 
 
Column SBPTM-1 15 m × 0.53 mm (id), 3 µm film 
Injector 250 °C 
Detector (FID) 300 °C 
Flow 2.34 mL/min 
Column temperature 250 °C.   
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Appendix 4: HPLC control of the kinetic resolution of diol (±)-147 (entry 6, 70h) 
 
Substrate concentration = 5 mM in MeOH. Eluition program: from 55% ACN for 2.5’ to 90% 
ACN for 3’ in 3.5’, then 55% ACN for 2.5’ in 0’; λ=254 
Column: Acclaim 120 C18 
Rt-147 = 3.81 min, Rt-5-butyrate = 7.05 min, Rt-4-butyrate = 7.69 min 
0,0 1,3 2,5 3,8 5,0 6,3 7,5 8,8 10,0 11,5
-50
100
200
300
450
27_mag_11_EKR_70h #1 [modified by HPLC] UV_VIS_2
mAU
min
1 - m - 3,807
2 - 7,053
3 - 7,693
WVL:254 nm
 
No.  Ret.Time  Peak Name  Height  Area   Rel.Area  Amount Type  
 min    mAU  mAU*min %   
1   3,81       m  373,549  33,906  47,05     n.a. BMB 
2   7,05       n.a.  35,239  3,312   4,60      n.a. BMB* 
3   7,69       n.a.  391,517  34,847  48,35     n.a. BMB 
Total:     800,304  72,065  100,00     0,00 
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Appendix 5: Chiral HPLC analysis of diol 147 
 
Substrate concentration = 5 mM in MeOH. Eluant: n-hexane/IPA 50:50; isocratic elution, λ=254 
Column: Lux Cellulose 4 
Rt 147 = 20.97, Rt ent-147 = 22.97 min 
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31_mag_11_IT07_10 #5 [modified by HPLC] UV_VIS_2
mAU
min
1 - 19,773
2 - 21,320
WVL:254 nm
 
No.  Ret.Time  Peak Name  Height  Area   Rel.Area  Amount Type  
 min    mAU  mAU*min %   
1   19,77       n.a.  13,532  7,825   15,76     n.a. BMB* 
2   21,32       n.a.  60,671  41,832  84,24     n.a. BMB* 
Total:     74,203  49,657  100,00     0,000 
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31_mag_11_IT07_10 #7 [modified by HPLC] UV_VIS_2
mAU
min
1 - 18,807
2 - 20,360
WVL:254 nm
 
No.  Ret.Time  Peak Name  Height  Area   Rel.Area  Amount Type  
 min    mAU  mAU*min %   
1   18,81       n.a.  54,436  31,447  88,15     n.a. BMb* 
2   20,36       n.a.  6,991   4,229   11,85     n.a. bMB* 
Total:     61,427  35,676  100,00     0,000
N
Cbz
CO2Me
OH
147
HO
ent-147
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Appendix 6: Determination of lipases enantiospecificity in EKR of racemic cis-4,5-
dihydroxylated enamide esters 
 
Since Scheme 40, both enantiomer of cis-lactam 137 were available, so we could determine the 
enantioselectivity of the lipases in the racemic resolution of 147 by assignement of the absolute 
configuration of the EKR products. 
Diol (-)-147, directly obtained from the EKR (i.e the non-acylated isomer) was converted into 
the corresponding enamide ester (-)-144  (Scheme 51) whose negative optical rotation value is 
consistent to the stereospecificity of the lipase in the kinetic resolution of diol (±)-147 (for 
compound (4S,5R)-144 obtained from enantiopure 138 of known absolute configuration the 
[α]22D value is +33.5). 
  
Scheme 51 
138
N
H
O
O
O
144 (52% over three steps)
[a]D
22 +33.5 (c 1.02, CHCl3)
N
O
O
Cbz
CO2Me
a, b, c
N
OH
HO
CO2Me
Cbz
d ent-144 (62%)
[a]D
25 -25.3 (c 0.21, CHCl3)
(4R,5S)-ent-147 (from EKR)  
Scheme 51: Reagents and conditions: (a) BnOCOCl, n-BuLi, –78 °C; (b) (PhO)2POCl, KHMDS, THF, –78 °C; (c) 
10% Pd(OAc)2, 20% Ph3P, CO, MeOH, Et3N, DMF, 75 °C, 1 h (d) 2,2-dimethoxypropane, p-TsOH, MeOH, 55 °C, 
1.5 h 
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Experimental 
 
General. Melting points are uncorrected. Chromatographic separations were performed under 
pressure on silica gel by flash-column techniques; Rf values refer to TLC carried out on 25-mm 
silica gel plates (Merck F254), with the same eluent as indicated for the column chromatography. 
THF was distilled from Na/benzophenone. CH2Cl2 and n-hexane were distilled from CaH2. 
Commercial anhydrous DMSO, DMF and MeOH were used. Commercial TBDME was used. 
CAL-B was purchased from Sigma-Aldrich and has a reported activity ≥ 10.000 U/g. Enzyme 
PS-AMANO-IM Lipase was a gift from Amano Enzyme Inc., and has a reported activity ≥ 500 
U/g 1H-NMR and 13C-NMR spectra were recorded with a Mercury 400 instrument in CDCl3 
solution, unless otherwise stated. Solvent reference line were set at 7.26 ppm (CDCl3), 4.79 ppm 
(D2O) and 3.31 ppm (CD3OD). Mass spectra were carried out by direct inlet on a LCQ FleetTM 
Ion Trap LC/MS system (Thermo Fisher Scientific) with an electrospray ionization (ESI) 
interface in the positive mode. Microanalyses were carried out with a Perkin-Elmer 2400/2 
elemental analyser. Optical rotations were determined with a JASCO DIP-370 instrument. HPLC 
analyses were carried out on a Dionex Ultimate 3000 instrument. 
HPLC column for monitoring enzymatic reactions on racemic 147 was Acclaim 120 C18, 250 x 
4.60 nm, 5 µm; eluition program: from 55% ACN for 2.5’ to 90% ACN for 3’ in 3.5’, then 55% 
ACN for 2.5’ in 0’; λ=254, 223 nm; (Rt-diol = 3.81 min, Rt-5-butyrate = 7.05 min, Rt-4-butyrate = 7.69 
min, Rt-4,5-dibutyrate = 10.23 min, Rt-5-acetate = 4.99 min, Rt-4-acetate = 5.55 min, Rt-4,5-diacetate = 7.75 
min). 
HPLC columns for calculate the enantiomeric ratio of diols were:  
Lux Cellulose 4, 250 x 4.60 nm, 5 µm, eluition program: 50% IPA – 50% n-hexane, λ=254, 223 
nm, (Rt 147 = 20.97, Rt ent-147 = 22.97 min) and Cyclobond I2000, 250 x 4.60 nm, 5 µm, 
eluition program: 85% H2O – 15% MeOH, λ=254, 223 nm, (Rt 147 = 20.09, Rt ent-147 = 21.29 
min). 
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51
NC CO2Et
OtBu
 
Ethyl (R)-3-tert-Butoxy-4-cyanobutanoate [(-)-51]. To a solution of (R)-50 (1.257 g, 8.0 
mmol) in tBuOAc (100 mL) was added dropwise HClO4 (48 µL, 0.8 mmol) and the mixture was 
left at 25 °C under stirring. After 24 h, a saturated Na2CO3 aqueous solution (50 mL) was added, 
the mixture was extracted with EtOAc (3 × 30 mL) and the combined organic layers were 
washed with NaHCO3 (satd) (50 mL) and dried over K2CO3. After filtration and evaporation of 
the solvent, compound 51 (1.65 g, 97%) was obtained as a pale yellow liquid which can directly 
be used in the next step. Chromatography (EtOAc-n-hexane, 1:3, Rf 0.3), gave 51 as a pale 
yellow oil (1.602 g, 94%). [α]20D = –9.0 (c 2.00, CHCl3). 
1H NMR (CDCl3, 200 MHz) δ 4.15-
4.03 (m, 1 H + 2 H), 2.62-2.54 (m, 4 H), 1.26-1.15 (m, 9 H + 3 H); 13C NMR (CDCl3, 50.33 
MHz) δ 170.4 (s), 117.5 (s), 75.1 (s), 64.3 (d), 60.7 (t), 41.2 (t), 28.1 (q, 3 C), 25.4 (t), 14.1 (q); 
MS m/z (%) 198 (M+ -15, 15), 140 (35), 112 (28), 57 (100). Anal. Calcd for C11H19NO3: C, 
61.95; H, 8.98; N, 6.57. Found: C, 61.98; H, 8.77; N, 6.28. 
 
 
N
H
O
52
O
t
Bu
 
(R)-4-tert-Butoxypiperidin-2-one [(+)-52]. To a stirred solution of 51 (506 mg, 2.38 mmol), in 
MeOH (10 mL) was added PtO2 (54 mg, 0.2 mmol) under N2 atmosphere. The mixture was 
flushed with H2 and then left under static pressure of H2 (balloon) at 25 °C. After 48 h the 
reaction was complete (by TLC). The catalyst was filtered, washing with MeOH, and the 
solution was concentrated under vacuum, to give pure 52 (408 mg, 100%) as a white solid. The 
same reaction can be carried out in absolute EtOH, in which case is complete in 24 h. (+)-52: 
m.p.= 102.5-103.5 °C. [α]20D = +17.4 (c 0.35, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 5.78 (br s, 
1 H), 3.96-3.89 (m, 1 H), 3.50-3.43 (m, 1 H), 3.34-3.20 (m, 1 H), 2.55 (dd, J = 17.6, 5.0 Hz, 1 
H), 2.34 (dd,  J = 17.6, 6.4 Hz, 1 H), 1.91-1.83 (m, 1 H), 1.79-1.71 (m, 1 H), 1.12 (s, 9 H); 13C 
NMR (CDCl3, 100.4 MHz) δ 171.6 (s), 74.0 (s), 64.0 (d), 40.7 (t), 38.4 (t), 30.2 (t), 28.3 (q, 3 C). 
MS m/z (%) 156 (M+-15, 3), 115 (48), 98 (28), 87 (18), 72 (21),  59 (100). Anal. Calcd for 
C9H17NO2: C, 63.13; H, 10.01; N, 8.18. Found: C, 63.03; H, 10.00; N, 8.09. 
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N O
53
O
t
Bu
CO2Me
 
Methyl (R)-4-tert-Butoxy-2-oxopiperidine-1-carboxylate [(+)-53]. To a cooled (-78 °C) 
solution of lactam 52 (372 mg, 2.17 mmol) in anhydrous THF (9 mL) under N2 atmosphere, was 
added dropwise a 1.6 M solution of nBuLi (1.49 mL, 2.39 mmol, 1.1 equiv) in hexane. After 40 
min, methyl chloroformate (185 µL, 2.39 mmol, 1.1 equiv) was added dropwise, the cooling bath 
was removed, and the reaction mixture was allowed to warm to 0 °C. Stirring was continued for 
another 2 h and then a NaHCO3 (satd) aqueous solution (6 mL) was slowly added, followed by 
water (15 mL). The mixture extracted with Et2O (3 × 20 mL) and dried over Na2SO4. After 
filtration and evaporation of the solvent, 53 was obtained as a yellowish solid which was 
chromatographed (CH2Cl2-MeOH, 40:1, + 0.1% Et3N, Rf 0.32) to give pure 53 (438 mg, 88%) as 
a white solid: m.p. =  55-56 °C. [α]20D = +15.5 (c 0.47, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 
3.99-3.93 (m, 1 H), 3.89 (ddd, J = 12.8, 8.2, 4.7 Hz,  1 H), 3.86 (s, 3 H), 3.67 (ddd, J = 12.8, 7.3, 
4.7 Hz, 1 H), 2.69 (dd, J = 16.8, 5.1 Hz, 1 H), 2.53 (dd,  J = 16.8, 6.6 Hz, 1 H), 2.06-1.93 (m, 1 
H),  1.86-1.76 (m, 1 H), 1.18 (s, 9 H); 13C NMR (CDCl3, 100.4 MHz) δ 169.9 (s), 154.8 (s), 74.2 
(s), 63.7 (d), 53.9 (q), 43.8 (t), 42.7 (t), 31.2 (t), 28.2 (q, 3 C). MS m/z (%) 229 (M+, 3), 173 (30), 
156 (25), 102 (22), 88 (20), 57(100). Anal. Calcd for C11H19NO4
: C, 57.62; H, 8.35; N, 6.11. 
Found: C, 57.41; H, 8.13; N, 6.02. 
 
54
N
O
t
Bu
CO2Me
CO2Me
 
Dimethyl (R)-4-tert-Butoxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(+)-54]. To a 
solution of KHMDS (4.7 mL of a 0.5 M solution in toluene, 2.35 mmol) in THF (12.5 mL), 
cooled at –78 °C and under nitrogen atmosphere, was added a solution of 53 (430 mg, 1.88 
mmol) in THF (5 mL) and the resulting mixture was stirred for 1.5 h. Afterward a solution of 
(PhO)2P(O)Cl (487 µL, 2.35 mmol) in THF (4 mL) was added, leaving under stirring for 1 h at –
78 °C before allowing the temperature to rise to 0 °C. Then, a 10% NaOH aqueous solution (38 
mL) was added, the mixture was extracted with Et2O (3 × 30 mL), washed with 10% NaOH (24 
mL), and dried over anhydrous K2CO3 for 30 min. After filtration and evaporation of the solvent 
(without heating and leaving a small volume of solvent), the crude phosphate was 
chromatographed (EtOAc-n-hexane, 30:70, + 1% Et3N, Rf 0.27) on a short layer of silica gel (3.5 
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cm of silica gel in a column with internal diameter of 3 cm) to give the phosphate (856 mg, 99%) 
as a pale yellow oil. 
Phosphate: 1H NMR (CDCl3, 200 MHz) δ 7.32-7.17 (m, 10 H), 4.92 (br s, 1 H), 3.65-3.60 (m, 1 
H), 3.52 (s, 3 H), 3.49-3.21 (m, 2 H), 1.82-1.64 (m, 2 H), 1.14 (s, 9 H); 13C NMR (CDCl3, 50.33 
MHz) δ 154.1 (s), 150.4 (s), 141.1 (s), 129.7 (d, 4 C), 125.3 (d, 2 C), 120.1 (d, 4 C), 102.2 (d), 
74.1 (s), 61.9 (d), 53.1 (q), 42.9 (t), 32.7 (t), 28.1 (q, 3 C). 
Phosphate (856 mg, 1.86 mmol) was immediately dissolved in DMF (4.8 mL), Pd(OAc)2 (42 
mg, 0.186 mmol) and Ph3P (97 mg, 0.372 mmol) were added and the solution was stirred 10 min 
under a CO atmosphere (balloon). Then Et3N (516 µL, 3.72 mmol) and MeOH (3 mL, 74.4 
mmol) were added and stirring was continued at 55 °C (external bath) for 3 h under static CO 
pressure. The solution was filtered through Celite, and the MeOH was evaporated. The residue 
was diluted with water (40 mL), extracted with Et2O (3 × 40 mL) and dried over Na2SO4. After 
filtration and evaporation of the solvent, the oily residue was chromatographed (EtOAc-n-
hexane, 1:2, +1% Et3N,  Rf 0.33) to give (+)-54 (408 mg, 81%) as a thick pale yellow oil. 
(+)-54. [α]23D = +157 (c 0.54, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 5.87 (d, J = 3.9 Hz, 1 H), 
4.07-4.16 (m, 1 H), 3.97 (dt, J = 12.9, 4.3 Hz, 1 H), 3.76 (s, 3 H), 3.71 (s, 3 H), 3.28 (ddd, J = 
12.9, 8.9, 4.7 Hz, 1 H), 1.89-1.81 (m, 2 H), 1.21 (s, 9 H); 13C NMR (CDCl3, 50.33 MHz) δ 164.7 
(s), 153.8 (s), 132.3 (s), 122.5 (d), 74.1 (s), 60.6 (d), 52.8 (q), 51.8 (q), 40.5 (t), 32.4 (t), 27.8 (q, 
3 C); MS m/z (%) 271 (M+, 18), 198 (87), 183 (100), 94 (82), 80 (42), 57 (79). Anal. Calcd for 
C13H21NO5
: C, 57.55; H, 7.80; N, 5.16. Found: C, 57.41; H, 7.67; N, 5.01. 
 
115
N O
CO2Me
 
Methyl 2-oxopiperidine-1-carboxylate (115) 
To a solution of methyl 2-oxopiperidine-1-carboxylate 114 (991 mg, 10 mmol) in THF (92 mL), 
cooled to -78 °C, n-BuLi (6.3 mL, 1.6 M solution in hexane, 10 mmol) was slowly added. The 
mixture was stirred at –78 °C for 15 min and then methyl chloroformate (850 µL, 11 mmol) was 
added drop-wise. After 10 min the solution was allowed to reach 0 °C, saturated aqueous 
NaHCO3 (50 mL) was added and the organic layer was separated. The aqueous layer was 
extracted with CH2Cl2 (2 x 40 mL) and the combined organic extracts were dried over Na2SO4 
and evaporated. The residue was purified by flash chromatography (n-hexane/EtOAc 1:1, Rf 
0.27) to give 115 (1.30 g, 8.27 mmol, 83%) as a white solid. 
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115. 
1H NMR (CDCl3, 400 MHz) δ = 3.84 (s, 3 H, OCH3), 3.74–3.71 (m, 2 H, 6-H), 2.54–2.50 
(m, 2 H, 3-H), 1.85–1.80 (m, 4 H, 4-H and 5-H) ppm. 13C NMR (CDCl3, 100.4 MHz) δ = 171.2 
(s, CO), 155.0 (s, CO), 53.8 (q, OCH3), 46.5 (t, C-6), 34.8 (t, C-3), 22.6 (t, C-4), 20.3 (t, C-5) 
ppm. ESI-MS m/z (%) = 158 (9) [M + 1]+, 126 (100), 82 (49). 
 
116
N O(O)(OPh)2
CO2Me
 
Methyl 6-[(diphenoxyphosphoryl)oxy]-3,4-dihydropyridine-1(2H)-carboxylate (116) 
To a solution of KHMDS (20.8 mL of a 0.5 M solution in toluene, 10.38 mmol) in THF (54.8 
mL), cooled at –78 °C and under nitrogen atmosphere, was added a solution of 115 (1.30 g, 8.3 
mmol) in THF (21.7 mL) and the resulting mixture was stirred for 1.5 h. Afterward a solution of 
(PhO)2P(O)Cl (2.1 mL, 10.38 mmol) in THF (17.1 mL) was added, leaving under stirring for 1 h 
at –78 °C before allowing the temperature to rise to 0 °C. Then, a 10% NaOH aqueous solution 
(160 mL) was added, the mixture was extracted with Et2O (3 × 130 mL), washed with 10% 
NaOH (100 mL) and water (100 mL), and dried over anhydrous K2CO3 for 1 hour. After 
filtration and evaporation of the solvent (without heating and leaving a small volume of solvent), 
the crude phosphate was chromatographed (EtOAc/n-hexane, 1:3, + 1% Et3N, Rf 0.19) on a short 
layer of silica gel (4 cm of silica gel in a column with internal diameter of 4 cm) to give 116 
(3.20 g, 99%) as a pale yellow oil. 
116. 
1H NMR (CDCl3, 400 MHz) δ = 7.37–7.32 (m, 4 H, CHarom), 7.26–7.17 (m, 6 H, CHarom),  
5.10 (q, J = 2.9 Hz, 1 H, 3-H), 3.64–3.61 (m, 2 H, 6-H), 3.56 (s, 3 H, OCH3), 2.18–2.04 (m, 2 H, 
4-H), 1.76–1.69 (m, 2 H, 5-H) ppm. 13C NMR (CDCl3, 100.4 MHz) δ = 154.7 (s, CO), 150.5 (s, 
2 C, Carom), 140.0 (s, C-2), 129.8 (d, 4 C, Carom), 125.5 (d, 2 C, Carom), 120.1 (d, 4 C, Carom), 100.4 
(d, C-3), 53.1 (q, OCH3), 45.7 (t, C-6), 22.6 (t, C-4), 21.6 (t, C-5) ppm. ESI-MS m/z (%) = 390 
(6) [M + 1]+, 346 (100), 265 (21). 
C19H20NO6P (389) requires C 58.61; H 5.18; N 3.60. Found: C 58.34; H 5.00; N 3.27 
 
117
N
CO2Me
CO2Me
 
Dimethyl 5,6-dihydropyridine-1,2(4H)-dicarboxylate (117)  
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Phosphate 116 (2.87 g, 7.38 mmol) was immediately dissolved in DMF (19.4 mL), Pd(OAc)2 
(166 mg, 0.738 mmol) and Ph3P (388 mg, 1.48 mmol) were added and the solution was stirred 
10 min under a CO atmosphere (balloon). Then Et3N (2.0 mL, 14.76 mmol) and MeOH (12.0 
mL, 295.2 mmol) were added and stirring was continued at 55 °C (external bath) for 3 h under 
static CO pressure. The solution was diluted with water (200 mL), extracted with Et2O (6 × 150 
mL) and dried over Na2SO4. After filtration and evaporation of the solvent, the oily residue was 
chromatographed (EtOAc/n-hexane, 1:2,  Rf 0.20) to give 117 (1.29 g, 88%) as a thick pale 
yellow oil. 
117. 
1H NMR (CDCl3, 200 MHz) δ = 6.04 (t, J = 4.0 Hz, 1 H, 3-H), 3.73 (s, 3 H, OCH3), 3.67 (s, 
3 H, OCH3), 3.61–3.55 (m, 2 H, 6-H), 2.25–2.16 (m, 2 H, 4-H), 1.84–1.72 (m, 2 H, 5-H) ppm. 
13C NMR (CDCl3, 50.33 MHz) δ = 164.9 (s, CO), 154.3 (s, CO), 132.2 (s, C-2), 122.8 (d, C-3), 
53.1 (q, OCH3), 52.0 (q, OCH3), 43.6 (t, C-6), 22.9 (t, C-4), 22.7 (t, C-5) ppm. MS m/z (%) = 
199 (29) [M]+, 167 (11), 140 (30), 80 (20), 68 (29), 59 (100).  
C9H13NO4 (199) requires C 54.26; H 6.58; N 7.03. Found: C 54.29; H 6.33; N 6.86 
 
(±)-118
N CO2Me
CO2Me
OH
 
Dimethyl 4-Hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(±)-118] 
A solution of 117 (1.29 g, 6.49 mmol), N-bromosuccinimide (1.47 g, 8.24 mmol) and a catalytic 
amount of azobisisobutyronitrile (90 mg, 0.55 mmol) in a 9:1 mixture of CCl4 and CHCl3 (224 
mL) was refluxed with vigorous stirring for 15 min. After cooling, the reaction mixture was 
diluted with CHCl3 (180 mL), washed with water (200 mL) and evaporated. The yellow oil thus 
obtained was dissolved in 96% aqueous acetone (113 mL) and ZnCl2 (3.67 g, 26.93 mmol) was 
added to the solution portionwise over 4 h. After 6 h, the reaction mixture was diluted with 
CHCl3 (130 mL), washed with water (300 mL), saturated aqueous NaHCO3 (300 mL) and brine 
(300 mL) and dried over Na2SO4. After filtration and evaporation of the solvent, the crude 
product was chromatographed (EtOAc/n-hexane, 2:1, + 0.5% Et3N, Rf 0.33) to give (±)-118 (920 
mg, 66%) as a thick pale yellow oil. 
(±)-118. 1H NMR (CDCl3, 400 MHz) δ = 5.96 (dd, J = 3.9, 1.0 Hz, 1 H, 3-H), 4.31–4.27 (m, 1 
H, 4-H), 4.05 (dt, J = 13.1, 4.1 Hz, 1 H, 6-H), 3.79 (s, 3 H, OCH3), 3.73 (s, 3 H, OCH3), 3.30 
(ddd, J = 13.2, 9.2, 5.5 Hz, 1 H, 6-H’), 1.96–1.85 (m, 2 H, 5-H) ppm. 13C NMR (CDCl3, 100.4 
MHz) δ = 165.1 (s, CO), 154.0 (s, CO), 133.6 (s, C-2), 120.4 (d, C-3), 61.2 (d, C-4), 53.4 (q, 
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OCH3), 52.5 (q, OCH3), 40.1 (t, C-6), 32.1 (t, C-5) ppm. MS m/z (%) = 215 (38) [M]
+, 183 (79), 
155 (59), 127 (47), 114 (49), 97 (74), 59 (100).  
C9H13NO5 (215) requires C 50.23; H 6.09; N 6.51. Found: C 50.48; H 5.79; N 6.22. 
 
N
(±)-118 (S)-118
EKR
N CO2Me
CO2Me
OH
CO2Me
CO2Me
OH
+
N CO2Me
CO2Me
O
O
R
(R)-119  
Kinetic Resolution with PS “AMANO” IM lipase  
Dimethyl (R)-4-(Butyryloxy)-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(+)-119] and (S)-
4-Hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(–)-118]  
To a solution of (±)-118 (538 mg, 2.5 mmol) in THF (3.1 mL) at 30 °C, was added lipase PS 
“AMANO” IM (250 mg) under N2 atmosphere. After 20 minutes, vinyl butyrate (1.1 mL) was 
added and the reaction was left under vigorous stirring and monitored by GC. After 6.5 h, the 
conversion reached 50% and the reaction was stopped by filtration over a thin layer of celite. 
After evaporation, the crude product was chromatographed (EtOAc/n-hexane, 1:2) to give (R)-
119 (Rf 0.60, 321 mg, 45%, 95% ee) and (S)-118 (Rf 0.15, 226 mg, 42%, 94% ee). 
(R)-119 [α]25D = +206 (c 0.82, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ = 5.91 (d, J = 4.1 Hz, 1 
H, 3-H), 5.31 (pseudo q, J = 3.9 Hz, 1 H, 4-H), 4.10 (dt, J = 13.1, 4.1 Hz, 1 H, 6-H), 3.79 (s, 3 H, 
OCH3), 3.74 (s, 3 H, OCH3), 3.28 (ddd, J = 13.1, 8.8, 6.2 Hz, 1 H, 6-H’), 2.27 (t, J = 7.0 Hz, 2 H, 
OCH2), 1.94–1.98 (m, 2 H, 5-H), 1.60–1.68 (m, 2 H, CH2), 0.94 (t, J = 7.3 Hz, 3 H, CH3) ppm. 
13C NMR (CDCl3, 100.4 MHz) δ = 172.7 (s, CO), 164.7 (s, CO), 153.9 (s, CO), 135.2 (s, C-2), 
116.6 (d, C-3), 63.2 (d, C-4), 53.5 (q, OCH3), 52.5 (q, OCH3), 40.5 (t, C-6), 36.2 (t, 
CH2CH2CH2), 29.3 (t, C-5), 18.4 (t, CH2CH3), 13.6 (q, CH3). MS m/z (%) 286 (12) [M
 + 1]+, 253 
(21), 198  (59), 183 (77), 152 (58), 94 (100).  
C13H19NO6 (285) requires C 54.73; H 6.71; N 4.91. Found: C 54.58; H 6.93; N 5.12. 
(S)-118. [α]25D = –132 (c 0.78, CHCl3). Spectroscopic data as reported above for racemic 
compound (±)-118. 
 
Dimethyl (R)-4-Hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(+)-118]  
To a solution of (+)-119 (215 mg, 0.75 mmol) in dry MeOH (7.2 mL) cooled in an ice bath, 
MeONa (40.5 mg, 0.75 mmol) was added and it was stirred 5 h at 0 °C under N2 atmosphere. 
Then glacial acetic acid (0.340 mL) was added and the MeOH was evaporated. The residue was 
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diluted with water (70 mL), extracted with EtOAc (4 × 70 mL) and dried over Na2SO4. After 
filtration and evaporation of the solvent, the crude product was chromatographed (EtOAc/n-
hexane, 1:1, + 0.5% Et3N, Rf 0.15) to give (R)-118 (153 mg, 95%) as a thick pale yellow oil.  
(R)-118. [α]25D = +134 (c 0.67, CHCl3). Spectroscopic data as reported above for racemic 
compound (±)-118. 
 
120
N
CO2Me
OTIPS
CO2Me
 
Dimethyl (S)-4-Triisopropylsilyloxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(–)-120] 
To a stirred solution of (S)-118 (207 mg, 0.975 mmol) in anhydrous DMF (2.6 mL) were added 
imidazole (148 mg, 2.17 mmol) and TIPSCl (306 µL, 1.45 mmol) and it was stirred 5 h at 40 °C 
(external bath) under N2 atmosphere. After cooling to room temperature, water (25 mL) was 
added and the solution extracted with Et2O (4 × 25 mL). The combined organic layers were 
washed with brine (25 mL) and dried over Na2SO4. After filtration and evaporation of the 
solvent, the oily residue was chromatographed (EtOAc/n-hexane, 1:4, Rf 0.19) to give (S)-120 
(327 mg, 91%) as a thick colorless oil. 
(S)-120. [α]20D = −125.2 (c 0.97, CHCl3).  1H NMR (CDCl3, 400 MHz) δ = 5.92 (dd, J = 3.9, 0.8 
Hz, 1 H, 3-H), 4.35  (pseudo q, J = 3.9 Hz. 1 H, 4-H), 3.98 (dt, J = 12.9, 4.1 Hz, 1 H, 6-H), 3.79 
(s, 3 H, OCH3), 3.72 (s, 3 H, OCH3), 3.34 (ddd, J = 12.9, 10.3, 3.5 Hz, 1 H, 6-H’), 1.94–1.83 
(m, 2 H, 5-H), 1.06 (s, 18 H + 3 H, TIPS) ppm. 13C NMR (CDCl3, 100.4 MHz) δ = 165.3 (s, 
CO), 154.2 (s, CO), 132.4 (s, C-2), 122.2 (d, C-3), 62.0 (d, C-4), 53.3 (q, OCH3), 52.3 (q, 
OCH3), 40.3 (t, C-6), 33.2 (t, C-5), 18.0 (q, 6 C, CH3 of TIPS), 12.2 (d, 3 C, CH of TIPS)  ppm. 
ESI-MS m/z (%) = 394 (11) [M + 23]+, 296 (22), 220 (100), 62 (14).  C18H33NO5Si (371) 
requires C 58.19; H 8.95; N 3.77. Found: C 57.86; H 8.98; N 3.83. 
 
121
N CO2Me
CO2Me
OTIPS
 
Dimethyl 4-Triisopropyloxypiperidine-1,2-dicarboxylate [(+)-121]: To a stirred suspension of 
NaHCO3 (16 mg, 0.19 mmol) in anhydrous EtOAc (1.5 mL), Pd/C 10% (13.1 mg, 0.012 mmol) 
was added and it was stirred 30 min under a H2 atmosphere (balloon). Then, a solution of (S)-120 
(26.2 mg, 0.077 mmol) in anhydrous EtOAc (680 µL) were added and it was stirred 6 h at room 
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temperature. The reaction was stopped by filtration over a thin layer of celite and the solvent was 
evaporated, to give (2R,4S)-121 (26 mg, 100%) as a thick colorless oil. 
121. [α]23D = +11.6 (c 1.06, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ = 4.80 (br d, J = 6.6 Hz, 
major rotamer, 2-H) and 4.64 (br d, J = 6.6 Hz, minor rotamer, 2-H), 4.19 (br quintet, J = 2.5 Hz, 
1 H, 4-H), 3.96 (br d, J = 12.0 Hz, minor rotamer, 6-Heq) and 3.83 (br d, J = 10.9 Hz, major 
rotamer, 6-Heq), 3.72 and 3.69 (s, 3 H + 3 H, two rotamers, OCH3), 3.56–3.44 (m, 1 H, 6-Hax),  
2.50–2.40 (br m, 1 H, 3-Heq), 1.86 (br dd, J = 13.7, 7.2 Hz, 1 H, 3-Hax), 1.78–1.55 (m, 2 H, 5-H), 
1.04 (s, 18 H + 3 H, TIPS) ppm. 13C NMR (CDCl3, 100.4 MHz) δ = 171.9 (s, CO) 157.1 and 
156.6 (s, two rotamers, CO), 63.8 (d, C-4), 52.8 (d, C-2), 51.9 (q, OCH3), 51.2 and 50.9 (q, two 
rotamers, OCH3), 35.9 and 35.7 (t, two rotamers, C-6), 33.9 and 33.8 (t, two rotamers, C-3), 32.4 
and 32.2 (t, two rotamers, C-5), 18.0 and 17.9 (q, 6 C, CH3 of TIPS), 12.2 (q, 3 C, CH of TIPS) 
ppm.  ESI-MS m/z (%) = 374 (6) [M + 1]+, 314 (100). C18H35NO5Si (373) requires C 57.87; H 
9.44; N 3.75. Found: C 57.73; H 9.52; N 3.89. 
 
N
(±)-118 (S)-118
EKR I
N CO2Me
CO2Me
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CO2Me
CO2Me
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N CO2Me
CO2Me
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(R)-119
(S)-118
N CO2Me
CO2Me
OH
(R)-118
N CO2Me
CO2Me
OH
EKR II
 
Two-step lipase-catalyzed kinetic resolution of (±)-118: 
Dimethyl (R)-4-(Butyryloxy)-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(+)-119] and (S)-
4-Hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(–)-118].  
4 Å MS (153 mg) were added to a solution of (±)-118 (253 mg, 1.18 mmol) in THF (1.5 mL) at 
30 °C, followed by lipase PS “AMANO” IM (118 mg), under N2 atmosphere. After 20 min, 
vinyl butyrate (523 µL, 4.12 mmol) was added and the reaction was left under vigorous stirring 
and monitored by GC. After 7 h, the conversion reached 42% and the reaction was stopped by 
filtration over a thin layer of Celite. After evaporation, the crude product was chromatographed 
(first with EtOAc-n-hexane, 1:2, then EtOAc-n-hexane, 2:1 to collect the alcohol) to give (R)-
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119 (Rf 0.60, 122 mg, 38%, 99.5% ee) and (S)-118 (Rf 0.3, 134 mg, 53%, 69% ee). (S)-118 was  
dissolved again in  THF (0.8 mL) at 30 °C, 4 Å MS (80 mg) were added, followed by lipase PS 
“AMANO” IM (62 mg) under N2 atmosphere. After 20 min, vinyl butyrate (236 µL, 1.86 mmol) 
was added and the reaction was left under stirring and monitored by GC. After 22 h, the 
conversion reached 17% and the reaction was stopped by filtration over a thin layer of celite. 
After evaporation, the crude product was chromatographed (EtOAc-n-hexane, 1:2) to give (S)-
118 (Rf 0.15, 226 mg, 89%, 99.5% ee).  
(R)-119.[1b] [α]25D = +215.0 (c 0.78, CHCl3). Spectroscopic data as reported above for (±)-118. 
(S)-118.[1b] [α]25D = –139.7 (c 0.68, CHCl3). Spectroscopic data as reported above for (±)-118. 
Compound (R)-119 was deprotected as reported above, giving (R)-118 in 96% yield 
(R)-118. [α]25D = +139.2 (c 0.71, CHCl3).  Spectroscopic data as reported above for (±)-118 
 
123
N
Cbz
OP(O)(OPh)2
 
1-Benzyl 2-Methyl 5,6-Dihydropyridine-1,2(4H)-dicarboxylate (123) 
To a solution of KHMDS (20.8 mL of a 0.5 M solution in toluene, 10.4 mmol) in THF (54 mL), 
cooled at –78 °C and under nitrogen atmosphere, was added a solution of N-Cbz-protected δ-
valerolactam 122 (1.96 g, 8.39 mmol) in THF (20 mL) and the resulting mixture was stirred for 
1.5 h. Afterward a solution of (PhO)2P(O)Cl (2.15 mL, 10.36 mmol) in THF (16.0 mL) was 
slowly added, leaving under stirring for 1 h at –78 °C before allowing the temperature to rise to 0 
°C. Then, a 10% NaOH aqueous solution (165 mL) was added, the mixture was extracted with 
Et2O (3 × 95 mL), the combined organic layers washed with 10% NaOH (60 mL) and dried over 
anhydrous K2CO3 for 30 min. After filtration and evaporation of the solvent (without heating and 
leaving a small volume of solvent), the crude phosphate was chromatographed (EtOAc-n-
hexane, 1:2.5, + 1% Et3N, Rf 0.25) on a short layer of silica gel (4.5 cm of silica gel in a column 
with internal diameter of 3 cm) to give the enol phosphate 123 as pale yellow oil (3.875 g, 99%). 
123. 1H NMR (400 MHz, CDCl3): 7.38-7.26 (m, 10 H), 7.25-7.13 (m, 5 H), 5.14 (pseudo q, J = 
3.9 Hz, 1 H, 3-H), 5.08 (s, 2 H, CH2Ph), 3.70-3.61 (m, 2 H, 6-H), 2.24-2.11 (m, 2 H, 4-H), 1.81-
1.69, 2 H, 5-H). 13C NMR (CDCl3, 100.4 MHz) δ = 154.0 (s, CO), 150.4 (s, 2 C), 139.9 (s, C-2), 
135.9 (s), 129.7 (d, 4 C), 128.4 (d, 2C), 128.0 (d), 127.9 (d, 2 C), 125.4 (d, 2 C), 120.0 (d, 4 C), 
100.5 (d, C-3), 67.8 (t, CH2Ph), 45.7 (t, C-6), 22.6 (t, C-4), 21.6 (t, C-5) ppm. ESI-MS m/z (%): 
953 (100) [2M+ + 23], 488 (10) [M+ + 23], 466 (8) [M+ + 1]. 
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124
N
Cbz
CO2Me
 
1-Benzyl 2-Methyl 5,6-Dihydropyridine-1,2(4H)-dicarboxylate (124) 
Phosphate 123 was immediately dissolved in DMF (20 mL) and to the resulting solution were 
added Pd(OAc)2 (189 mg, 0.84 mmol) and Ph3P (439 mg, 1.67 mmol) under nitrogen 
atmosphere. The solution was stirred 10 min under a CO atmosphere (balloon), then Et3N (2.3 
mL, 16.7 mmol) and MeOH (7.0 mL, 335 mmol) were added and stirring was continued at 58 °C 
(external bath) for 4 h under static CO pressure and then left at room temperature overnight. The 
solution was diluted with water (150 mL), extracted with Et2O (5 × 100 mL) and dried over 
Na2SO4. After filtration and evaporation of the solvent, the oily residue was chromatographed 
(EtOAc-n-hexane, 1:4,  Rf 0.28) to give 124 (2.03 g, 88%) as a thick pale yellow oil. 
124. 1H NMR (CDCl3, 400 MHz) δ = 7.40-7.28 (m, 5 H, Ph), 6.07 (t, J = 3.9 Hz, 1 H, 3-H), 5.14 
(s, 2 H, CH2Ph), 3.67-3.64 (m, 2 H, 6-H),  3.56 (br s, 3 H, OCH3), 2.27-2.22 (m, 2 H, 4-H), 1.86-
1.81 (m, 2 H, 5-H) ppm. 13C NMR (CDCl3, 100.4 MHz) δ = 165.1 (s, CO), 154.0 (s, CO), 135.8 
(s), 132.4 (s, C-2), 128.5 (d, 2 C), 128.2 (d), 128.1 (d, 2 C), 123.1 (d, C-3), 68.0 (t, CH2Ph), 51.9 
(q, OCH3), 43.7 (t, C-6), 22.9 (t, C-4), 22.7 (t, C-5) ppm. MS m/z (%) = 276 (2) [M + 1]
+, 232 
(100). C15H17NO4 (275.30) requires C 65.44; H 6.22; N 5.09. Found: C 65.27; H 6.11; N 5.01. 
 
(±)-125
N CO2Me
Cbz
OH
 
 
1-Benzyl 2-Methyl 4-Hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate (±)-125 
A solution of 124 (663 mg, 2.41 mmol), N-bromosuccinimide (545 mg, 3.06 mmol) and a 
catalytic amount of azobisisobutyronitrile (34 mg, 0.21 mmol) in a 9:1 mixture of anhydrous 
CCl4 and CHCl3 (83 mL) was refluxed with vigorous stirring for 15 min. After cooling, the 
reaction mixture was diluted with CHCl3 (65 mL), washed with water (70 mL) and evaporated to 
give the 4-Br derivative as a yellow oil. 
4-Br derivative. 1H NMR (CDCl3, 200 MHz) δ = 7.40-7.20 (m, 5 H, Ph), 6.04 (d, J = 4.4 Hz, 1 
H, 3-H), 5.20 (part A of an AB system, J = 12.1 Hz, 1 H, CH2Ph), 5.09 (part B of an AB system, 
J = 12.1 Hz, 1 H, CH2Ph), 4.88-4.81 (m, 1 H, CHBr), 4.32-4.20 (m, 1 H, 6-H), 3.56 (s, 3 H, 
OCH3), 3.65-3.20 (m, 1 H, 3-H’), 2.50-2.20 (m, 2 H, 5-H) ppm. 
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This oil was dissolved in 96% aqueous acetone (68 mL), six drops of water were added, and 
ZnCl2 (1.362 g, 10 mmol) was added portionwise to the resulting solution over 4 h. After further 
2.5 h, the reaction mixture was diluted with CHCl3 (60 mL), washed with water (100 mL), 
saturated aqueous NaHCO3 (100 mL) and brine (65 mL) and dried over Na2SO4. After filtration 
and evaporation of the solvent, the crude product was chromatographed (EtOAc-n-hexane, 2:1, 
Rf 0.40) to give (±)-125 (399 mg, 57%) as a thick pale yellow oil. 
(±)-125. 1H NMR (CDCl3, 400 MHz) δ = 7.40-7.30 (m, 5 H, Ph), 5.94 (dd, J = 3.9, 0.6 Hz, 1 H, 
3-H), 5.18 (part A of an AB system, J = 12.1 Hz, 1 H, CH2Ph), 5.09 (part B of an AB system, J = 
12.1 Hz, 1 H, CH2Ph),  4.31–4.27 (m, 1 H, 4-H), 4.08 (dt, J = 13.3, 4.3 Hz, 1 H, 6-H), 3.56 (br s, 
3 H, OCH3), 3.31 (ddd, J = 13.3, 9.4, 4.7 Hz, 1 H, 6-H’), 1.94–1.90 (m, 2 H, 5-H) ppm. 
13C 
NMR (CDCl3, 100.4 MHz) δ = 165.0 (s, CO), 153.4 (s, CO), 135.4 (s), 133.6 (s, C-2), 128.5 (d, 
2 C), 128.4 (d), 128.3 (d, 2 C), 120.7 (d, C-3), 68.3 (t, CH2Ph), 61.3 (d, C-4), 52.2 (q, OCH3), 
40.2 (t, C-6), 32.2 (t, C-5) ppm. MS m/z (%) = 291 (1) [M]+, 259 (100). 
C15H17NO5 (291.30) requires C 61.85; H 5.88; N 4.81. Found: C 62.01; H 5.68; N 4.57. 
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Lipase-catalyzed Kinetic Resolution of (±)-125: 
1-Benzyl 2-Methyl (S)-4-Hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(–)-125] and 
1-Benzyl 2-Methyl (R)-4-(Butyryloxy)-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(+)-126].  
4 Å MS (78 mg) were added to a solution of (±)-125 (176 mg, 0.604 mmol) in TBME (1.5 mL) 
at 30 °C, followed by lipase PS “AMANO” IM (60 mg), under N2 atmosphere. After 20 min, 
vinyl butyrate (268 µL, 2.11 mmol) was added and the reaction was left under vigorous stirring 
and monitored by GC. After  1.7 h, the conversion reached 44% and the reaction was stopped by 
filtration over a thin layer of Celite. After evaporation, the crude product was chromatographed 
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(EtOAc–n-hexane, 1:2) to give (R)-125 (Rf 0.54, 87 mg, 40%) and (S)-126 (Rf 0.12, 90 mg, 51%, 
73% ee). (S)-125 was dissolved again in TBME (0.8 mL) at 30 °C, 4 Å MS (39 mg) were added 
followed by lipase PS “AMANO” IM (30 mg) under N2 atmosphere. After 20 min, vinyl 
butyrate (132 µL) was added and the reaction was left under stirring and monitored by GC. After 
2.2 h, the conversion reached 16% and the reaction was stopped by filtration over a thin layer of 
celite. After evaporation, the crude product was chromatographed to give (S)-125 (65 mg, 37%, 
99.8% ee).  
(S)-125. [α]25D =  –230.1 (c 0.50, CHCl3).  Spectroscopic data as reported above for (±)-125.  
(R)-126. [α]25D =  +189.9 (c 0.89, CHCl3).  
1H NMR (CDCl3, 400 MHz) δ = 7.40-7.28 (m, 5 H, 
Ph), 5.90 (d, J = 4.3, Hz, 1 H, 3-H), 5.31 (pseudo q, J = 3.9 Hz, 1 H, 4-H), 5.19 (part A of an AB 
system, J = 12.1 Hz, 1 H, CH2Ph), 5.10 (part B of an AB system, J = 12.1 Hz, 1 H, CH2Ph),  
4.17 (dt, J = 13.1, 4.1 Hz, 1 H, 6-H), 3.56 (br s, 3 H, OCH3), 3.29 (ddd, J = 13.1, 9.4, 5.6 Hz, 1 
H, 6-H’), 2.27 (t, J = 7.4 Hz, 2 H, COCH2), 2.00–1.94 (m, 2 H, 5-H), 1.68-1.59 (m, 2 H, 
CH2CH3), 0.94 (t, J = 7.4 Hz, CH2CH3) ppm. 
13C NMR (CDCl3, 100.4 MHz) δ = 172.6 (s, CO), 
164.6 (s, CO), 153.3 (s, CO), 135.3 (s), 135.2 (s, C-2), 128.5 (d, 2 C), 128.4 (d), 128.3 (d, 2 C), 
116.7 (d, C-3), 68.5 (t, CH2Ph), 63.3 (d, C-4), 52.3 (q, OCH3), 40.6 (t, C-6), 36.2 (t, COCH2), 
29.3 (t, C-5), 18.4 (t, CH2CH3), 13.6 (q, CH2CH3)  ppm. MS m/z (%) = 384 (12) [M + 23]
+, 296 
(100), 162 (18). 
C19H23NO6 (361.39) requires C 63.15; H 6.41; N 3.88. Found: C 63.03; H 6.44; N 3.65. 
 
1-Benzyl 2-Methyl (R)-4-Hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(+)-125]  
To a solution of (R)-126 (87 mg, 0.24 mmol) in dry MeOH (1 mL), cooled in an ice bath, was 
added MeONa (13 mg, 0.24 mmol), and the mixture stirred for 3.5 h at 0 °C under N2 
atmosphere. Then glacial acetic acid (14 µL) was added and the solvent was evaporated. The 
residue was diluted with water (20 mL), extracted with EtOAc (4 × 20 mL) and dried over 
Na2SO4. After filtration and evaporation of the solvent, the crude product was chromatographed 
(EtOAc-n-hexane, 1:1, Rf 0.24) to give (R)-125 (66 mg, 95%, 98.7% ee) as a colorless oil.  
 (R)-125. [α]25D = +228.7 (c 0.54, CHCl3).  Spectroscopic data as reported above for (±)-125. 
  
N CO2Me
CO2Me
OH
(1R,4R,5S)-cis-127  
Dimethyl (1R,5R,6S)-5-Hydroxy-2-azabicyclo[4.1.0]heptane-1,2-dicarboxylate [cis (+)-127] 
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To a solution of 2,4,6-trichlorophenol (248 mg, 1.26 mmol) in anhydrous CH2Cl2 (12.6 mL), 
cooled to –40 °C, was added Et2Zn (1.26 mL of a 1 M solution in hexane, 1.26 mmol) under 
nitrogen atmosphere. The mixture was left under stirring for 15 min, then CH2I2 (101 µL, 1.26 
mmol) was added dropwise and, after another 15 min at –40 °C, a solution of alcohol (R)-118 
(136 mg, 0.63 mmol) in CH2Cl2 (0.8 mL) was added dropwise. The cooling bath was removed 
and reaction mixture was left under stirring for 4 h. The suspension was then cooled in a ice bath 
and a 10% solution of citric acid (5 mL) was added dropwise under vigorous stirring. The 
cooling bath was removed and when the solution became clear, the layers were separated, the 
aqueous layer extracted with  CH2Cl2 (6 × 5  mL) and the combined organic layers washed with 
a 10% solution of Na2CO3 (2 × 40 mL) and dried over Na2SO4. After chromatography (Et2O, Rf 
0.12), compound (1R,5R,6S)-127 (124 mg, 86%) was obtained as a colorless oil.   
(1R,5R,6S)-127. [α]25D = +51.3 (c 0.93, CHCl3). 
1H NMR (CDCl3, 400 MHz) (1.7:1 mixture of 
rotamers) δ = 4.35 (dt, J = 10.1, 6.2 Hz, 1 H, H-5),  4.02 (dt, J = 13.5, 3.9 Hz, 1 H, 3-H, major 
rotamer), 3.86 (dt, J = 14.0, 4.3 Hz, 1 H, 3-H, minor rotamer), 3.73 (s, 3 H, OCH3, minor 
rotamer), 3.71 and 3.70 (s, 3 H + 3 H, OCH3, both rotamers), 2.81 (td, J = 14.0, 1.8 Hz, 1 H, 3-
H’, minor rotamer), 2.73 (td, J = 13.5, 2.0 Hz, 1 H, 3-H’, major rotamer), 2.05-1.89 (m, 2 H, 4-H 
and 6-H, and 1 H, minor rotamer), 1.87 (dd, J = 9.9, 5.3 Hz, 1 H, 7-H, major rotamer), 1.78 (br s, 
1 H, OH), 1.27-1.16 (m, 1 H, 4-H’, major rotamer, and 1 H, minor rotamer), 1.09 (dd, J =  7.6, 
5.3 Hz, 1 H, 7-H’, minor rotamer), 1.06 (dd, J = 7.6, 5.3 Hz, 1 H, 7-H’, major rotamer) ppm. 13C 
NMR (CDCl3, 100.4 MHz) (mixture of rotamers) δ = 172.2 and 171.7 (s, CO), 156.9 and 156.3 
(s, CO), 64.2 and 64.1 (d, C-5), 53.0 and 52.8 (q, OCH3), 52.5 (q, OCH3), 41.9 and 41.3 (s, C-1), 
41.1 and 40.9 (t, C-3), 30.8 and 30.3 (d, C-6),  29.0 and 28.7 (t, C-4), 19.7 and 19.1 (t, C-7) ppm. 
MS m/z (%) = 230 (8) [M + 1]+, 197 (100). 
C10H15NO5 (229.23) requires C 52.40; H 6.60; N 6.11. Found: C 52.09; H 6.72; N 5.98. 
 
N CO2Me
Cbz
OH
(1R,4R,6S)-cis-128  
2-Benzyl 1-Methyl (1R,5R,6S)-5-Hydroxy-2-azabicyclo[4.1.0]heptane-1,2-dicarboxylate [cis 
(+)-128] 
Prepared as reported above for cis (+)-127 but the reaction was stopped after 3.5 h. Starting from 
(R)-125 (47 mg, 0.16 mmol), compound (1R,5R,6S)-128 (36 mg) was obtained after 
chromatography (Et2O, Rf 0.24) as a colorless oil (72%). 
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(1R,5R,6S)-128. [α]25D =  +31.2 (c 0.72, CHCl3). 
1H NMR (CDCl3, 400 MHz) (2.4:1 mixture of 
rotamers) δ = 7.36-7.25 (m, 5 H, Ph),  5.26 (d, J = 12.5 Hz, 1 H, CH2Ph, major rotamer), 5.15 
(AB system, J = 12.5 Hz, 2 H, CH2Ph, minor rotamer), 5.05 (d, J = 12.5 Hz, 1 H, CH2Ph, major 
rotamer), 4.38-4.29 (m, 1 H, 5-H),  4.03 (dt, J = 13.5, 3.7 Hz, 1 H, 3-H, major rotamer), 3.91 (dt, 
J = 13.5, 3.7 Hz, 1 H, 3-H, minor rotamer), 3.69 (s, 3 H, OCH3, minor rotamer), 3.51 (s, 3 H, 
OCH3, major rotamer), 2.83 (td, J = 13.8, 1.8 Hz, 1 H, 3-H’, minor rotamer), 2.74 (td, J = 14.2, 
2.1 Hz, 1 H, 3-H’, major rotamer), 2.12-2.00 (br, 1 H, OH), 2.06-1.90 (m, 2 H, 4-H and 6-H, and 
1 H, minor rotamer), 1.87 (dd, J = 9.9, 5.1 Hz, 1 H, 7-H, major rotamer), 1.28-1.16 (m, 1 H, 4-
H’, major rotamer, and 1 H, minor rotamer), 1.07 (dd, J =  7.6, 5.1 Hz, 1 H, 7-H’, minor 
rotamer), 1.08 (dd, J = 7.6, 5.1 Hz, 1 H, 7-H’, major rotamer) ppm. 13C NMR (CDCl3, 100.4 
MHz) (mixture of rotamers) δ = 172.1 and 171.7 (s, CO), 156.2 and 155.7 (s, CO), 136.5 (s, Ph), 
128.5 and 128.4 (d, 2 C, Ph), 127.9 and 127.8 (d, Ph), 127.6 (d, 2 C), 67.4 and 67.3 (t, CH2Ph), 
64.1 and 63.1 (d, C-5), 52.5 and 52.3 (q, OCH3), 41.9 and 41.4 (s, C-1), 41.2 and 41.0 (t, C-3), 
30.7 and 30.3 (d, C-6),  29.0 and 28.7 (t, C-4), 19.7 and 19.1 (t, C-7) ppm. MS m/z (%) = 306 
(100%) [M + 1]+. 
C16H19NO5 (305.33) requires C 62.94; H 6.27; N 4.59. Found: C 62.66; H 6.12; N 4.27. 
 
N CO2Me
Cbz
132
OTBS
 
1-Benzyl 2-Methyl (R)-4-tert-Butyldimethylsilanyloxy-5,6-dihydropyridine-1,2(4H)-
dicarboxylate [(+)-132]  
To a stirred solution of (R)-125 (62 mg, 0.21 mmol) in anhydrous DMF (0.7 mL) were added 
imidazole (43 mg, 0.63 mmol) and TBSCl (63 mg, 0.42 mmol) and it was stirred 2 h at 38 °C 
(external bath) under N2 atmosphere. After cooling to room temperature, water (5 mL) was 
added and the solution extracted with Et2O (5 × 4 mL). The combined organic layers were 
washed with brine (5 mL) and dried over Na2SO4. After filtration and evaporation of the solvent, 
the oily residue was chromatographed (EtOAc-n-hexane, 1:5, Rf 0.45) to give (R)-132 (84 mg, 
99%) as a thick colorless oil.  
(R)-132. [α]20D = +126.0 (c 0.82, CHCl3).  
1H NMR (CDCl3, 400 MHz) δ = 7.40-7.28 (m, 5 H, 
Ph), 5.85 (d, J = 3.7 Hz, 1 H, 3-H), 5.18 (part A of an AB system, J = 12.1 Hz, 1 H), 5.09 (part B 
of an AB system, J = 12.1 Hz, 1 H), 4.24  (pseudo q, J = 3.9 Hz. 1 H, 4-H), 4.02 (dt, J = 12.9, 
4.5 Hz, 1 H, 6-H), 3.55 (br s, 3 H, OCH3), 3.39-3.29 (m, 1 H, 6-H’), 1.90–1.81 (m, 2 H, 5-H), 
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0.88 (s, 9 H, TBS), 0.08 (s, 6 H TBS) ppm. 13C NMR (CDCl3, 100.4 MHz) δ = 165.2 (s, CO), 
153.6 (s, CO), 135.6 (s, Ph), 132.5 (s, C-2), 128.5 (d, 2 C, Ph), 128.3 (d, Ph), 128.2 (d, 2 C, Ph), 
122.6 (d, C-3), 68.2 (t, CH2Ph), 62.0 (d, C-4), 52.1 (q, OCH3), 40.4 (t, C-6), 33.1 (t, C-5), 25.8 
(q, 3 C, TBS), 18.0 (s, TBS), –4.59 (q, TBS),  –4.74 (q, TBS)  ppm. MS m/z (%) = 405 (62) 
[M]+, 361 (100).  
C21H31NO5Si (405.56) requires C 62.19; H 7.70; N 3.45. Found: C 62.44; H 7.38; N 3.43. 
 
N CO2Me
CO2Me
OH
trans-127  
Dimethyl (1S,5R,6R)-5-Hydroxy-2-azabicyclo[4.1.0]heptane-1,2-dicarboxylate [trans (–)-
127] 
Cyclopropanation by dimethylsulfoxonium methylide of (R)-129. Dry DMSO (0.9 mL) was 
added to NaH (60% in weight in mineral oil, 24 mg, 0.6 mmol) previously washed with dry n-
hexane (2 × 1.5 mL) under nitrogen atmosphere. To the resulting suspension was added 
trimethylsulfoxonium iodide (122 mg, 0.56 mmol) in three portions and the mixture was left 30 
min under stirring  at room temperature. After cooling with a water bath at 15 °C, a solution of 
(R)-129 (122 mg, 0.37 mmol) in DMSO (500 µL) was added dropwise. The water bath was 
removed and the reaction mixture was left under stirring for 2 h. Water (12 mL) was added and 
the mixture extracted with Et2O (7 × 9 mL), dried over Na2SO4, filtered and concentrated. 
Chromatography (EtOAc-n-hexane, 1:5, Rf 0.24) gave compound 130 (104 mg, 82%) as a 4.7:1 
mixture of trans and cis isomers.  
Trans isomer: 1H NMR (CDCl3, 400 MHz)  (1.8:1 mixture of rotamers) δ  = 4.12-4.09 (m, 1 H, 
5-H), 3.78 (dt, J = 12.9, 4.2 Hz, 1 H, 3-H, major rotamer), 3.71 (s, 3 H, OCH3, minor rotamer), 
3.69 and 3.68 (s, 3 H + 3 H, OCH3, both rotamers), 3.62 (dt, J = 12.3, 4.1 Hz, 1 H, 3-H, minor 
rotamer), 3.23 (ddd, J = 12.3, 10.7, 2.7 Hz, 1 H, 3-H’, minor rotamer), 3.14 (ddd, J = 12.9, 10.9, 
2.9 Hz, 1 H, 3-H’, major rotamer), 1.91 (dd, J = 10.3, 5.5 Hz, 1 H, 7-H, minor rotamer), 1.85 
(dd, J = 10.3, 5.3 Hz, 1 H, 7-H, major rotamer), 1.76-1.57 (m, 2 H, 6-H and 4-H), 1.51-1.39 (m, 
1 H, 4-H’), 0.88 (s, 9 H, TBS), 0.73 (dd, J =  7.8, 5.5 Hz, 1 H, 7-H’, minor rotamer), 0.70 (dd, J 
= 8.2, 5.5 Hz, 1 H, 7-H’, major rotamer), 0.084 (s, 6 H, TBS) ppm. 
The mixture of trans and cis 130 (79 mg, 0.22 mmol) was dissolved in acetonitrile (10 mL) and, 
after cooling at 0 °C, a 3 N solution of HCl (10 mL) was added dropwise. The cooling bath was 
removed and the mixture left under stirring 1 h. A satd solution of NaHCO3 (20 mL) was slowly 
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added until pH 7, the aqueous layer extracted with EtOAc (6 × 20 mL) and the combined organic 
layers dried over Na2SO4, filtered and concentrated. Chromatography (Et2O, Rf 0.23) gave 
(1S,5R,6R)-127 (35 mg, 69%) as a colorless oil. 
Cyclopropanation by dimethylsulfoxonium methylide of (R)-54. The reaction was carried out 
as reported above for (R)-129. Starting from (R)-54 (87 mg, 0.32 mmol), chromatography 
(EtOAc-n-hexane, 1:4, Rf 0.22) of the crude reaction mixture gave compound 131 (70 mg, 77%) 
as a 3.8:1 mixture of trans and cis isomers.  
Trans isomer: 1H NMR (CDCl3, 400 MHz)  (2.3:1 mixture of rotamers) δ  = 3.78-3.65 (s + m, 7 
H, OCH3 and 5-H), 3.28 (ddd, J = 12.5, 8.2, 4.3 Hz, 1 H, 3-H’, minor rotamer), 3.21 (ddd, J = 
12.9, 8.6, 4.3 Hz, 3-H’, major rotamer), 1.92 (dd, J = 10.1, 5.5 Hz, 1 H, 7-H, minor rotamer), 
1.85 (dd, J = 9.8, 5.1 Hz, 1 H, 7-H, major rotamer), 1.78-1.68 (m, 1 H, 6-H), 1.68-1.60 (m, 1 H, 
4-H), 1.58-1.49 (m, 1 H, 4-H’), 1.21 (s, 9 H), 0.75 (dd, J =  7.8, 5.1 Hz, 1 H, 7-H’, minor 
rotamer), 0.72 (dd, J = 7.8, 5.1 Hz, 1 H, 7-H’, major rotamer) ppm. 
The mixture of trans and cis 131 (70 mg, 0.25 mmol) was dissolved in acetonitrile (3.2 mL) and 
pTsOH·H2O (58 mg, 0.3 mmol) was added under stirring at room temperature. After 21 h, 
another portion of pTsOH·H2O (24 mg) was added and the mixture left under stirring for another 
6 h. The mixture was filtered on a short layer of a Celite/NaHCO3 (1:1) mixture and 
concentrated. Chromatography (Et2O, Rf 0.23) gave trans (1S,5R,6R)-127 (38 mg, 67%) as a 
colorless oil.  
(1S,5R,6R)-(–)-127. [α]25D = –4.43 (c 0.47, CHCl3). 
1H NMR (CDCl3, 400 MHz) (2:1 mixture of 
rotamers) δ  = 4.28 (br s, 1 H, H-5),  3.86 (dt, J = 13.3, 3.9 Hz, 1 H, 3-H, major rotamer), 3.73 (s, 
3 H, OCH3, minor rotamer), 3.71 and 3.70 (s, 3 H + 3 H, OCH3, both rotamers, and 1 H, 3-H, 
minor rotamer), 3.19 (td, J = 13.6, 2.1 Hz, 1 H, 3-H’, minor rotamer), 3.09 (td, J = 13.3, 2.3 Hz, 
1 H, 3-H’, major rotamer), 1.97 (dd, J = 10.5, 5.5 Hz, 1 H, 7-H, minor rotamer), 1.93-1.87 (m, 1 
H, 7-H, major rotamer, and 1 H, 6-H, minor rotamer), 1.87-1.67 (m, 1 H, 6-H, major rotamer, 
and 1 H, 4-H), 1.58-1.46 (m, 1 H, 4-H’), 0.78 (dd, J =  8.0, 5.5 Hz, 1 H, 7-H’, minor rotamer), 
0.75 (dd, J = 8.0, 5.3 Hz, 1 H, 7-H’, major rotamer) ppm. 13C NMR (CDCl3, 100.4 MHz) 
(mixture of rotamers) δ = 172.5 (s, CO), 157.0 (s, CO), 63.2 and 63.1 (d, C-5), 52.9 and 52.8 (q, 
OCH3), 52.5 (q, OCH3), 39.0 and 38.6 (s, C-1), 36.5 and 35.9 (t, C-3), 31.1 and 31.0 (d, C-6),  
30.9.0 and 30.8 (t, C-4), 20.5 and 20.0 (t, C-7) ppm. MS m/z (%) = 230 (9) [M + 1]+, 211 (29), 
197 (100), 80 (16). 
C10H15NO5 (229.23) requires C 52.40; H 6.60; N 6.11. Found: C 52.22; H 6.57; N 5.81. 
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N CO2Me
Cbz
OH
trans-128  
2-Benzyl 1-Methyl (1S,5R,6R)-5-Hydroxy-2-azabicyclo[4.1.0]heptane-1,2-dicarboxylate 
[trans (–)-128] 
The reaction was carried out as reported above for (R)-129. Starting from (R)-132 (78 mg, 0.19 
mmol), chromatography (EtOAc-n-hexane, 1:6, Rf 0.22) of the crude reaction mixture gave 
compound 133 (62 mg, 78%) as a 7 : 1 mixture of trans and cis isomers.  
Trans isomer: 1H NMR (CDCl3, 400 MHz)  (2.5:1 mixture of rotamers) δ  = 7.37-7.26 (m, 5 H, 
Ph), 5.25 (part A of an AB system, J = 12.5 Hz, 1 H, major rotamer), 5.20 (part A of an AB 
system, J = 12.3 Hz, 1 H, minor rotamer),  5.14 (part B of an AB system, J = 12.3 Hz, 1 H, 
minor rotamer), 5.05 (part B of an AB system, J = 12.5 Hz, 1 H, major rotamer), 4.16-4.10 (m, 1 
H, 5-H), 3.81 (dt, J = 12.9, 4.3 Hz, 1 H, 3-H, major rotamer), 3.71 (s, 3 H, OCH3, minor 
rotamer), 3.53 (s, 3 H, OCH3, major rotamers), 3.27 (ddd, J = 12.9, 10.5, 2.7 Hz, 1 H, 3-H’, 
minor rotamer), 3.17 (ddd, J = 12.9, 10.9, 2.7 Hz, 1 H, 3-H’, major rotamer), 1.94 (dd, J = 10.3, 
5.7 Hz, 1 H, 7-H, minor rotamer), 1.87 (dd, J = 10.3, 5.7 Hz, 1 H, 7-H, major rotamer), 1.78-1.58 
(m, 2 H, 6-H and 4-H), 1.52-1.40 (m, 1 H, 4-H’), 0.87 (s, 9 H), 0.76 (dd, J =  8.0, 5.7 Hz, 1 H, 7-
H’, minor rotamer), 0.72 (dd, J = 8.0, 5.7 Hz, 1 H, 7-H’, major rotamer), 0.08 (s, 3 H, TBS, 
major rotamer), 0.07 (s, 3 H, TBS, major rotamer) ppm. 
The mixture of trans and cis 133 was deprotected as reported above for compound 130, 
obtaining after chromatography (Et2O–n-hexane, 11:1, Rf 0.2) compound trans (–)-128 (29  mg, 
73%) as a colorless oil.  
(1S,5R,6R)-(–)-128. [α]25D = –2.98 (c 1.01, CHCl3).  
1H NMR (CDCl3, 400 MHz) (2.6:1 mixture 
of rotamers) δ  = 7.37-7.26 (m, 5 H, Ph), 5.26 (part A of an AB system, J = 12.5 Hz, 1 H, major 
rotamer), 5.19 (part A of an AB system, J = 12.5 Hz, 1 H, minor rotamer),  5.14 (part B of an AB 
system, J = 12.5 Hz, 1 H, minor rotamer), 5.06 (part B of an AB system, J = 12.5 Hz, 1 H, major 
rotamer), 4.31–4.25 (m, 1 H, 5-H), 3.89 (dt, J = 13.2, 3.7 Hz, 1 H, 3-H, major rotamer), 3.77 (dt, 
J = 13.3, 3.7 Hz, 1 H, 3-H, minor rotamer), 3.71 (s, 3 H, OCH3, minor rotamers), 3.53 (s, 3 H, 
OCH3, major rotamers), 3.21 (td, J = 13.3, 2.1 Hz, 1 H, 3-H’, minor rotamer), 3.11 (td, J = 13.2, 
2.57 Hz, 1 H, 3-H’, major rotamer), 1.98 (dd, J = 10.5, 5.5 Hz, 1 H, 7-H, minor rotamer), 1.92 
(dd, J = 10.5, 5.5 Hz, 1 H, 7-H, major rotamer), 1.85-1.68 (m, 2 H, 6-H and 4-H), 1.59-1.48 (m, 
1 H, 4-H’),  0.80 (dd, J =  8.0, 5.5 Hz, 1 H, 7-H’, minor rotamer), 0.76 (dd, J = 8.0, 5.5 Hz, 1 H, 
7-H’, major rotamer) ppm. 13C NMR (CDCl3, 100.4 MHz) (mixture of rotamers) δ = 172.4 and 
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171.9 (s, CO), 156.2 (s, CO), 136.6 (s, Ph), 128.5 (d, 2 C, Ph), 127.9 (d, Ph), 127.6 (d, 2 C, Ph), 
67.4 and 67.2 (t, CH2Ph), 63.1 (d, C-5), 52.5 and 52.3 (q, OCH3), 39.1 and 38.6 (s, C-1), 36.6 
and 35.9 (t, C-3), 31.1 and 31.0 (d, C-6),  30.9 and 30.8 (t, C-4), 20.5 and 20.0 (t, C-7) ppm. 
MS/MS m/z (%) = 306 (9) [M + 1]+, 262 (100), 244 (6), 198 (9), 170 (9), 154 (8), 91 (2). 
C16H19NO5 (305.33) requires C 62.94; H 6.27; N 4.59. Found: C 62.73; H 6.11; N 4.19. 
 
N
H
CO2Me
OH
(1R,5R,6S)-cis-110  
Methyl (1R,5R,6S)-5-Hydroxy-2-azabicyclo[4.1.0]heptane-1-carboxylate   [cis (+)-110] 
To a solution of alcohol (1R,5R,6S)-128 (210 mg, 0.69 mmol) in ethyl acetate (19 mL) was 
added, under nitrogen atmosphere, 10% Pd/C (52 mg) and the resulting suspension stirred under 
an H2 atmosphere (balloon) at room temperature for 3 h. After filtration over a Celite layer and 
evaporation of the solvent, pure amino ester cis (+)-110 (118 mg) was obtained in quantitative 
yield as a colorless oil. 
cis-110. [α]25D = +80.9 (c 0.78, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ = 4.32-4.25 (m, 1 H, 5-
H), 3.72 (s, 3 H, OCH3), 2.84 (dt, J = 12.7, 4.1 Hz, 1 H, 3-H), 2.57 (td, J = 12.7, 2.3 Hz, 1 H, 3-
H’), 2.10-2.03 (m, 1 H, 4-H), 1.90-1.76 (m, 3 H, 6-H, OH, and NH), 1.57 (dd, J = 9.8, 4.7 Hz, 1 
H, 7-H), 1.24-1.13 (m, 1 H, 4-H’), 1.05 (dd, J = 7.4, 4.7 Hz, 1 H, 7-H’) ppm. 13C NMR (CDCl3, 
100.4 MHz) δ = 174.7 (s, CO), 64.6 (d, C-5), 52.5 (q, OCH3), 42.6 (s, C-1), 41.7 (t, C-3), 31.4 
(d, C-6),  28.1 (t, C-4), 21.8 (t, C-7) ppm. MS/MS m/z (%) = 172 (1%) [M + 1]+, 154 (100), 122 
(25), 94 (25). 
C8H13NO3 (171.19) requires C 56.13; H 7.65; N 8.18. Found: C 56.44; H 7.38; N 7.97 
 
N
H
CO2Me
OH
(1S,5R,6R)-trans-110  
Methyl (1S,5R,6R)-5-Hydroxy-2-azabicyclo[4.1.0]heptane-1-carboxylate   [trans (–)-110] 
Reaction carried out as reported for cis (+)-110. Starting from (1S,5R,6R)-128 (29 mg, 0.095 
mmol), compound trans (–)-110 (16.3 mg) was obtained in 100% yield as a colorless oil. 
trans-110. [α]25D = –21.8 (c 0.76, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ = 4.37-4.34 (br s, 1 H, 
5-H), 3.71 (s, 3 H, OCH3), 2.95 (td, J = 12.7, 3.1 Hz, 1 H, 3-H), 2.61 (dt, J = 12.7, 3.7 Hz, 1 H, 
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3-H’), 2.14-1.98 (m, 2 H, OH and NH), 1.83 (dd, J =  10.5, 7.8 Hz, 1 H, 7-H), 1.65-1.50 (m, 3 H, 
6-H, 4-H and 4-H’), 0.74 (dd, J = 7.8, 4.7 Hz, 1 H, 7-H’) ppm. 13C NMR (CDCl3, 100.4 MHz) δ 
= 175.0 (s, CO), 63.5 (d, C-5), 52.5 (q, OCH3), 39.4 (s, C-1), 36.3 (t, C-3), 31.1 (d, C-6),  29.0 (t, 
C-4), 22.3 (t, C-7) ppm. MS/MS m/z (%) = 172 (3%) [M + 1]+, 154 (100). 
C8H13NO3 (171.19) requires C 56.13; H 7.65; N 8.18. Found: C 56.38; H 7.44; N 8.01 
 
Conversion of trans (1R,5S,6S)-110 into (1R,5S,6S)-127. 
To a solution of trans (1R,5S,6S)-110 (15 mg, 0.088 mmol) in dry CH2Cl2 (880 µL) cooled at 0 
°C, were added dropwise Et3N (16 µL, 0.114 mmol) and methyl chloroformate (9 µL, 0.114 
mmol). The resulting mixture was stirred for 20 min before adding further Et3N (16 µL, 0.114 
mmol) and methyl chloroformate (9 µL, 0.114 mmol). The solution was then stirred at 25 °C for 
1 h, then diluted with CH2Cl2 (3 mL), washed with brine (2.5 mL) and dried over Na2SO4. After 
evaporation of the solvent, the crude was dissolved in MeOH (200 µL) and K2CO3 (1 mg) was 
added leaving under stirring for 1 h. The solution was concentrated and chromatographed (Et2O, 
Rf 0.24) to give compound trans (1S,5R,6R)-127 (8 mg, 40%) as a colorless oil and [α]
25
D = 
+4.61 (c 0.41, CHCl3).  
 
(±)-137
N
H
OH
HO
O
 
(±)-4,5-Dihydroxypiperidin-2-one [(±)-137]. 
A solution of 3,6-dihydro-1H-pyridin-2-one 136 (507 mg, 5.22 mmol) in MeOH (8 mL) was 
cooled in an ice bath and aqueous 50 mM NaOH (40 mL) was added, followed by aqueous 31 
mM KMnO4 (129 mL), that was added dropwise in 30'. The resulting brown solution was stirred 
for 10' and, after removal of the ice bath, MeOH was added (80 mL). After 30', the suspension 
was filtered through a Celite pad to remove the dark brown salts and the filtrate was 
concentrated, neutralized with 1 N HCl (5.5 mL) and concentrated in vacuo to give lactam 9 
(680 mg) which was used in the next step without prior purification. 
A sample of the crude reaction mixture was purified by flash chromatography (eluant: EtOAc-
MeOH, 3:2; Rf 0.33) for the characterization, affording pure (±)-137 as a white powder. 
(±)-137. m.p. 144.0–144.9 °C. 1H NMR (D2O, 400 MHz) δ (ppm): 4.21–4.15 (m, 2 H, 4-H, 5-H), 
3.46 (dd, J = 13.0, 4.3 Hz, 1 H, 6-H'), 3.37 (dd, J = 13.0, 5.1 Hz, 1 H, 6-H''), 2.68 (dd, J = 17.5, 
5.5 Hz, 1 H, 3-H'), 2.50 (dd, J = 17.5, 7.8 Hz, 1 H, 3-H''). 13C NMR (D2O, 100.4 MHz) δ (ppm): 
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173.3 (s, C2), 66.0 (d, C4), 65.3 (d, C5), 43.6 (t, C6), 34.7 (t, C3). MS/MS (ESI) of [M+1]+ m/z 
%: 132 (M++1, 12), 114 (M+-OH, 100), 96 (27). Anal. Calcd for C5H9NO3·1/10H2O: C, 45.18; 
H, 6.98; N, 10.54. Found: C, 44.96, H, 6.46; N, 10.26. 
 
N
H
(±)-138
O
O
O
 
(±)-4,5-O-Isopropylidene-4,5-dihydroxypiperidin-3-one ((±)-138). 
The crude lactam (±)-137 was taken up into methanol (3 mL) and a catalytic amount of p-
toluenesulfonic acid was added (169 mg, 0.89 mmol) followed by 2,2-dimethoxypropane (17.3 
mL, 140 mmol). The mixture was warmed at 55°C for 1 h and, after cooling, diluted with MeOH 
(9 mL) and neutralized by K2CO3 (62 mg, 0.45 mmol). After filtration on a Celite pad and 
evaporation of the solvent, crude (±)-138 was obtained as a yellow solid, which was purified by 
flash chromatography (eluant: CH2Cl2–MeOH, 20:1; Rf 0.17), affording pure (±)-138 as a white 
powder (563 mg, 63% over two steps). 
(±)-138. m.p. 137.2–138.3 °C. 1H NMR (400 MHz) δ (ppm): 5.85 (br s, 1 H, NH), 4.69 (ddd, J = 
7.2, 4.1, 2.7 Hz, 1 H, 4-H), 4.45-4.41 (m, 1 H, 5-H), 3.38 (ddd, J = 14.3, 5.9, 2.3 Hz, 1 H, 6-H'), 
3.28 (dt, J = 14.3, 2.5 Hz, 1 H, 6-H''), 2.66 (ddd, J = 15.6, 2.7, 1.4 Hz, 1 H, 3-H'), 2.37 (dd, J = 
15.6, 4.1 Hz, 1 H, 3-H''), 1.45 (s, 3 H, CH3), 1.34 (s, 3 H, CH3). 
13C NMR (100.4 MHz) δ (ppm): 
171.2 (s, C2), 109.0 (s, C(CH3)2), 72.6 (d, C4), 72.3 (d, C5), 43.9 (t, C6), 36.4 (t, C3), 26.1 (q, 
CH3), 24.1 (q, CH3). MS/MS (ESI) of [M+1]
+ m/z %: 172 (M++1, 13), 154 (1), 114 (100), 96 
(27). Anal. Calcd for C8H13NO3·⅛H2O: C, 55.40; H, 7.70; N, 8.08. Found: C, 55.86, H, 8.30; N, 
8.30. 
 
(±)-139
N O
O
O
CO2Me
 
(±)-4,5-O-Isopropylidene-4,5-dihydroxy-2-oxopiperidine-1-carboxylic Acid Methyl Ester 
((±)-139).  
A solution of lactam (±)-138 (888 mg, 5.19 mmol) in dry THF (52 mL) was cooled at –78 °C 
and a 1.6 M solution of n-BuLi (3.30 mL, 5.19 mmol) was slowly added, keeping the 
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temperature below –70°C during the addition. The mixture was stirred for 15 min and then 
methyl chloroformate (402 µL, 5.19 mmol) was added dropwise and, after 10 min, the cooling 
bath was removed and the temperature allowed to warm to 0 °C. Saturated NaHCO3 (24 mL) and 
water (24 mL) were added and the product extracted with dichloromethane (3 × 20 mL). The 
combined organic extracts were dried over Na2SO4, filtered and evaporated in vacuo to give 
crude (±)-139. After purification by flash chromatography (eluant: n-hexane-EtOAc, 1:2; Rf 
0.32) pure (±)-139 was obtained as a white solid (998 mg, 84%). 
(±)-139. m.p. 138.5–139.3 °C. 1H NMR (400 MHz) δ (ppm): 4.64 (ddd, J = 7.6, 3.5, 2.7 Hz, 1 
H, 4-H), 4.54-4.49 (m, 2 H, 5-H, 6-H'), 3.88 (s, 3 H, OCH3), 3.30 (dd, J = 15.0, 2.3 Hz, 1 H, 6-
H"), 2.85 (dd, J = 16.0, 2.7 Hz, 1 H, 3-H'), 2.49 (dd, J = 16.0, 3.5 Hz, 1 H, 3-H''), 1.38 (s, 3 H, 
CH3), 1.32 (s, 3 H, CH3). 
13C NMR (50.33 MHz) δ (ppm): 168.2 (s, C2), 154.0 (s, CO2CH3), 
108.9 (s, C(CH3)2), 72.1 (d, C4), 71.5 (d, C5), 54.1 (q, OCH3), 46.7 (t, C6), 39.3 (t, C3), 26.1 (q, 
CH3), 24.2 (q, CH3). MS/MS of [M+1]
+ m/z %: 230 (M++1, 4), 171 (100), 139 (37). Anal. Calcd. 
for C10H15NO5: C, 52.40; H, 6.60; N, 6.11. Found: C, 52.35, H, 6.47; N, 5.95. 
 
(±)-140
N O
O
O
Cbz
 
(±)-4,5-O-Isopropylidene-4,5-dihydroxy-2-oxopiperidine-1-carboxylic Acid Benzyl Ester 
((±)-140).   
Prepared as described for (±)-139, starting from (±)-138 (1.09 g, 6.38 mmol) and benzyl 
chloroformate (1.0 mL, 7.0 mmol). After purification by flash chromatography (eluant: n-
hexane-EtOAc, 1:1; Rf 0.22) pure (±)-140 was obtained as a white solid (1.58 g, 81%). 
(±)-140. m.p. 109.9–110.4 °C. 1H NMR (400 MHz) δ (ppm): 7.45–7.41 (m, 2 H, Ph), 7.38–7.27 
(m, 3 H, Ph), 5.32 (AB system, J = 12.5 Hz, 2 H, CH2Ph), 4.64 (ddd, J = 7.6, 3.5, 2.7 Hz, 1 H, 
4-H), 4.54-4.48 (m, 2 H, 5-H, 6-H'), 3.30 (dd, J = 14.6, 2.0 Hz, 1 H, 6-H''), 2.86 (dd, J = 15.8, 
2.7 Hz, 1 H, 3-H'), 2.49 (dd, J = 15.8, 3.5 Hz, 1 H, 3-H''), 1.31 (s, 3 H, CH3), 1.30 (s, 3 H, CH3). 
13C NMR (100.4 MHz) δ (ppm): 168.3 (s, C2), 153.4 (s, NCO2Bn), 135.4 (s, Ph), 128.5 (d, 2 C, 
Ph), 128.2 (d, Ph), 128.0 (d, 2 C, Ph), 109.1 (s, C(CH3)2), 72.2 (d, C4), 71.5 (d, C5), 68.6 (t, 
CH2Ph), 46.7 (t, C6), 39.3 (t, C3), 26.0 (q, CH3), 24.1 (q, CH3). MS (ESI) m/z %: 633 
([2M+Na]+, 100), 328 ([M+Na]+, 12), 306 ([M+1]+, 3). MS/MS of [M+1]+ m/z %: 306 (9), 262 
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(100), 204 (4), 9 (16). Anal. Calcd. for C16H19NO5: C, 62.94; H, 6.27; N, 4.59. Found: C, 63.10, 
H, 6.41; N, 4.49. 
 
N
(±)-141
O
O
OP(O)(OPh)2
CO2Me
 
(±)-3,4-O-Isopropylidene-6-(diphenoxyphosphoryloxy)-3,4-dihydroxy-3,4-dihydro-2H-
pyridine-1-carboxylic Acid Methyl Ester ((±)-141). 
A solution of 0.5 M KHMDS in toluene (10.8 mL, 5.41 mmol) was diluted in anhydrous THF 
(42 mL) and cooled at –78°C. A solution of (±)-139 (993 mg, 4.33 mmol) in anhydrous THF (15 
mL) was then added dropwise, keeping the temperature below –70 °C, and the resulting mixture 
was stirred for 1.5 h. Diphenylchlorophosphate (1.1 mL, 5.41 mmol) was slowly added and, after 
1 h, the mixture was allowed to warm at 0 °C. Aqueous 10% NaOH (100 mL) was slowly added 
and the product extracted with Et2O (3 × 80 mL). The combined organic extracts were washed 
with 10% NaOH (60 mL) and dried over K2CO3 for 30 min. After filtration and evaporation of 
the solvent, the crude was purified over a short pad of silica gel, eluting with n-hexane-EtOAc, 
2:1 buffered with 1% Et3N (Rf 0.29), affording pure (±)-141 as a colourless oil (1.77 g, 89%). 
This was used immediately for the next step. 
(±)-141. 1H NMR (400 MHz) δ (ppm): 7.38–7.32 (m, 4 H, Ph), 7.28–7.17 (m, 6 H, Ph), 5.33 (dd, 
J = 4.5, 2.7 Hz, 1 H, 5-H), 4.68 (ddd, J = 6.4, 4.5, 2.1 Hz, 1 H, 4-H), 4.30 (ddd, J = 6.4, 5.7, 3.1 
Hz,1 H, 3-H), 3.81 (dd, J = 13.5, 5.7 Hz, 1 H, 2-H'), 3.68 (dd, J = 13.5, 3.1 Hz, 1 H, 2-H''), 3.58 
(s, 3 H, OCH3), 1.42 (s, 3 H, CH3), 1.35 (s, 3 H, CH3). 
13C NMR (50.33 MHz) δ (ppm): 154.6 (s, 
CO2Me), 150.3 (s, C6), 143.5 (s, Ph), 143.4 (s, Ph), 129.8 (d, 4 C, Ph), 125.7 (d, 2 C, Ph), 120.1 
(d, 2 C, Ph), 120.0 (d, 2 C, Ph), 109.9 (s, C(CH3)2), 99.8 (d, C5), 73.3 (d, C4), 70.7 (d, C3), 53.4 
(q, OCH3), 48.8 (t, C2), 27.5 (q, CH3), 25.7 (q, CH3). 
 
N
(±)-142
O
O
OP(O)(OPh)2
Cbz
 
(±)-3,4-O-Isopropylidene-6-(diphenoxyphosphoryloxy)-3,4-dihydroxy-3,4-dihydro-2H-
pyridine-1-carboxylic Acid Benzyl Ester ((±)-142). 
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Prepared as described for (±)-141, starting from (±)-140 (1.57 g, 5.15 mmol) and affording, after 
purification over a short pad of silica gel (eluant: n-hexane-EtOAc, 2:1, 1% Et3N; Rf 0.27), pure 
(±)-142 as a colourless oil (2.77 g, 100%). This was used immediately for the next step. 
(±)-142. 1H NMR (400 MHz) δ (ppm): 7.35–7.29 (m, 10 H, Ph), 7.28–7.16 (m, 5 H, Ph), 5.35 
(dd, J = 4.7, 2.6 Hz, 1 H, 5-H), 5.34 (d, J = 12.6 Hz, 1 H, CH2Ph), 5.13 (d, J = 12.6 Hz, 1 H, 
CH2Ph), 4.68 (ddd, J = 6.4, 4.7, 2.0 Hz, 1 H, 4-H), 4.31-4.27 (m, 1 H, 3-H), 3.93 (dd, J = 13.4, 
5.3 Hz, 1 H, 2-H'), 3.64 (dd, J = 13.4, 2.9 Hz, 1 H, 2-H''), 1.32 (s, 6 H, CH3). 
13C NMR (50.33 
MHz) δ (ppm): 154.0 (s, CO2Bn), 150.3 (s, C6), 143.9 (s, 2 C, OPh), 135.5 (s, CH2Ph), 129.8 (d, 
4 C, OPh), 128.4 (d, 2 C, CH2Ph), 128.2 (d, 2 C, CH2Ph), 128.1 (d, CH2Ph), 125.6 (d, 2 C, OPh), 
120.1 (d, 4 C, OPh), 110.0 (s, C(CH3)2), 100.1 (d, C5), 73.4 (d, C4), 70.8 (d, C3), 68.2 (t, 
CH2Ph), 49.0 (t, C2), 27.5 (q, CH3), 25.7 (q, CH3). MS (ESI) m/z %: 560 ([M+Na]
+, 100), 537 
(M+, 98). 
 
(±)-143
N
O
O
CO2Me
CO2Me
 
(±)-4,5-O-Isopropylidene-4,5-dihydroxy-5,6-dihydro-4H-pyridine-1,2-dicarboxylic Acid 
Dimethyl Ester ((±)-143). 
In a round bottom flask was prepared a solution of phosphate (±)-141 (1.77 g, 3.84 mmol), 
Pd(OAc)2 (86 mg, 0.38 mmol) and Ph3P (201 mg, 0.77 mmol) in anhydrous DMF (10 mL) under 
nitrogen atmosphere. The flask was flushed and saturated with carbon monoxide and, after 10 
min, Et3N (1.1 mL, 7.68 mmol) and anhydrous CH3OH (6.2 mL, 154 mmol) were added. The 
mixture was saturated with CO (balloon) and heated at 60 °C (external bath) for 2.5 h. After 
cooling, water (103 mL) was added and the product extracted with Et2O (4 × 100 mL). The 
combined organic extracted were dried over Na2SO4; after filtration and evaporation of the 
solvent, crude (±)-143 was purified by flash chromatography (eluant: n-hexane-EtOAc, 2:1, 1% 
Et3N; Rf 0.27), to afford pure (±)-143 as a white solid (807 mg, 78%). 
(±)-143. m.p. 112.0–113.0 °C. 1H NMR (400 MHz) δ (ppm): 6.20 (d, J = 3.7, 1 H, 3-H), 4.58 
(dd, J = 6.2, 3.7 Hz, 1 H, 4-H), 4.30 (ddd, J = 7.6, 6.2, 4.1 Hz, 1 H, 5-H), 3.95 (dd, J = 13.5, 4.1 
Hz, 1 H, 6-Heq), 3.80 (s, 3 H, OCH3), 3.73 (s, 3 H, OCH3), 3.36 (dd, J = 13.5, 7.6 Hz, 1 H, 6-
Hax), 1.43 (s, 3 H, CH3), 1.38 (s, 3 H, CH3). 
13C NMR (100.32 MHz) δ (ppm): 164.0 (s, CO2Me), 
154.4 (s, NCO2Me), 134.5 (s, C2), 120.0 (d, C3), 109.7 (s, C(CH3)2), 72.5 (d, C4), 69.4 (d, C5), 
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53.5 (q, OCH3), 52.5 (q, OCH3), 46.2 (t, C6), 27.7 (q, CH3), 25.7 (q, CH3). MS (ESI) m/z %: 565 
([2M+Na]+, 100), 294 ([M+Na]+, 86), 272 ([M+1]+, 7). Anal. Calcd. for C12H17NO6: C, 53.13; H, 
6.32; N, 5.16. Found: C, 53.44, H, 6.16; N, 4.95. 
 
(±)-144
N
O
O
Cbz
CO2Me
 
(±)-4,5-O-Isopropylidene-4,5-dihydroxy-5,6-dihydro-4H-pyridine-1,2-dicarboxylic Acid 1-
Benzyl Ester 2-Methyl Ester ((±)-144). 
Prepared as described for (±)-143, starting from phosphate (±)-142 (2.77 g, 5.15 mmol) and 
heating at 60 °C for 5 h. After purification by flash chromatography (eluant: n-hexane-EtOAc, 
3:1, 1% Et3N; Rf 0.29), pure (±)-144 was obtained as a white solid (1.28 g, 72%). 
(±)-144. m.p. 87.5–89.0 °C. 1H NMR (400 MHz) δ (ppm): 7.40–7.29 (m, 5 H, Ph), 6.18 (d, J = 
3.5 Hz, 1 H, 3-H), 5.14 (AB system, J = 12.3 Hz, 2 H, CH2Ph), 4.58 (dd, J = 6.1, 3.5 Hz, 1 H, 4-
H), 4.32-4.27 (m, 1 H, 5-H), 3.97 (dd, J = 13.2, 3.8 Hz, 1 H, 6-Heq), 3.64-3.56 (br s, 3 H, OCH3), 
3.41 (dd, J = 13.2, 7.6 Hz, 1 H, 6-Hax), 1.40 (s, 3 H, CH3), 1.37 (s, 3 H, CH3). 
13C NMR (100.32 
MHz) δ (ppm): 164.0 (s, CO2Me), 153.8 (s, CO2Bn), 135.5 (s, C2), 129.8 (s, Ph), 128.5 (d, 2 C, 
Ph), 128.3 (d, Ph), 128.2 (d, 2 C, Ph), 120.1 (d, C3), 109.7 (s, C(CH3)2), 72.5 (d, C4), 69.4 (d, 
C5), 68.3 (t, CH2Ph), 52.3 (q, OCH3), 46.3 (t, C6), 27.7 (q, CH3), 25.7 (q, CH3). MS (ESI) m/z 
%: 370 ([M+Na]+, 78), 348 ([M+1]+, 100). Anal. Calcd for C18H21NO6: C, 62.24; H, 6.09; N, 
4.03. Found: C, 62.27; H, 5.79; N, 4.26. 
 
N
OH
HO
Cbz
CO2Me
(±)-147  
(±)-4,5-dihydroxy-5,6-dihydro-4H-pyridine-1,2-dicarboxylic Acid 1,2 1-Benzyl Ester 2-
Methyl Ester ((±)-147).  
To a solution of (±)-144 (182 mg, 0.52 mmol) in CHCl3 was added TFA (1 mL) then H2O 
(100µL), and the mixture stirred for 11 min at room temperature. After cooling in an ice bath, the 
reaction mixture was added K2CO3 (1.11 g, 8.0 mmol) and stirred for 3 min. A saturated aqueous 
solution of NHCO3 was added (10 mL). The aqueous phase was extracted with CHCl3 (3 x 5 ml) 
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and the overall organic phases were dried on K2CO3. After filtration and evaporation of the 
solvent, the crude (±)-147, obtained as a 2 : 1 mixture with the unreacted substrate (±)-144, was 
chromatographed (CHCl3-acetone, 2 : 1, Rf = 0.28) to give (±)-147 (104 mg, 0.34 mmol, 65%) as 
a white gummy solid. Unreacted (±)-144 was recovered (35 mg, 20% yield). 
(±)-147. 1H-NMR (400 MHz) δ (ppm): 7.38-7.30 (m, 5 H, Ph), 5.87 (d, J = 3.7 Hz, 1 H, 3-H), 
5.15 (s, 2 H, CH2Ph ), 4.31-4.28 (m, 1 H, 4-H), 3.97-3.91 (m, 1 H, 5-H), 3.83-3.68 (m, 2 H, 6-
Heq), 3.56 (bs, 3 H, CH3), 2.74 (dd, J = 5.86, 42.7 Hz, 2 H, 6-Hax). 
13C NMR (100.32 MHz) δ 
(ppm) 164.7 (s, COMe), 154.4 (s, COBn), 135.3 (s, C-2), 133.3 (s, Ph), 128.4 (m, 4 C, Ph), 120.3 
(s, C-3), 68.5 (s, C-4), 66.1 (s, C-5), 64.6 (s, CH2Bn ), 52.3 (s, OCH3), 47.3 (s, C-6). MS (ESI) 
m/z (%): 308.50 (M+ + 1), 330.33 (M+ + 23) 
 
N
OH
HO
Cbz
CO2Me
(±)-147
N
O
HO
Cbz
O
R
N
OH
Cbz
CO2Me
O
O
R
N
OH
HO
Cbz
N
O
Cbz
O
O
R
O
R
EKR
++
ent-147 149
a:  R= acetate
b : R= butyrate
c : R= stearate
150
a : R= acetate
b : R= butyrate
c : R= stearate
+
151
a : R= acetate
b : R= butyrate
c : R= stearate
CO2Me CO2Me CO2Me
 
General procedure for lipase-catalyzed Kinetic Resolution of (±)-147: 
(4R,5S)-4,5-dihydroxy-5,6-dihydro-4H-pyridine-1,2-dicarboxylic Acid 1,2 1-Benzyl Ester 2-
Methyl Ester (ent-147) and (4S,5R)-4-acyloxy-5-hydroxy-5,6-dihydro-4H-pyridine-1,2-
dicarboxylic Acid 1,2 1-Benzyl Ester 2-Methyl Ester (149) and (4S,5R)-4-hydroxy-5-
acyloxy-5,6-dihydro-4H-pyridine-1,2-dicarboxylic Acid 1,2 1-Benzyl Ester 2-Methyl Ester 
(159) and (4S,5R)-4,5-diacyloxy-5,6-dihydro-4H-pyridine-1,2-dicarboxylic Acid 1,2 1-
Benzyl Ester 2-Methyl Ester (151) 
4 Å MS (130 mg/ mmol substrate) were added to a solution of (±)-147 (176 mg, 0.604 mmol) in 
anhydrous solvent (1.5 mL) at 30 °C, followed by lipase (100 mg/mmol substrate), under N2 
atmosphere. After 20 min, acylating agent (3.5 eq) was added and the reaction was left under 
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vigorous stirring and monitored by HPLC. The reaction was stopped by filtration over a thin 
layer of Celite. After evaporation, the crude product was chromatographed (EtOAc–n-hexane, 
1:2) to give ent-147 (Rf = 0.15) (for ee obtained in each experiment, see Table 3), 149 (Rf-149b = 
0.45), 150 (Rf-150b= 0.61, Rf-150c= 0.66) and 151 (Rf-151c= 0.86). 
 
N
OH
HO
Cbz
CO2Me
147  
(4S,5R)-4,5-dihydroxy-5,6-dihydro-4H-pyridine-1,2-dicarboxylic Acid 1,2 1-Benzyl Ester 2-
Methyl Ester (147) 
To the solution of acylated 149, 150 (and 151 when it is present) in dry MeOH (10 eq), cooled in 
an ice bath, was added MeONa (13 mg, 0.24 mmol), and the mixture stirred for 3.5 h at 0 °C 
under N2 atmosphere. Then glacial acetic acid (14 µL) was added and the solvent was evaporated 
in vaquo without heating. The residue was diluted with water (20 mL), extracted with CHCl3 (3 
× 20 mL) and dried over K2CO3. After filtration and evaporation of the solvent, the crude 147 
was obtained as a colorless oil.  
147. Spectroscopic data as reported above for (±)-147. For ee obtained in each experiments, see 
Table 3 
 
O
OHO
HO
156  
(4S,5R)-4-Hydroxy-5-(hydroxymethyl)dihydrofuran-2(3H)-one [(+)-(156)]. 
Bromine (4.0 mL, 78.0 mmol) was slowly added to a solution of 2-deoxy-D-ribose 155 (2.01 g, 
15.0 mmol) in water (12 mL). The flask was then sealed and the red solution was stirred at room 
temperature for 5 days. After dilution with water (10 mL), Ag2CO3 was added until pH reached 7 
(complete decolourization occurred). The suspension was filtered on a celite pad and the filtrate 
evaporated under vacuum. The residue was purified by flash chromatography (eluent: EtOAc-
MeOH, 10:1; Rf 0.50) affording pure lactone 156 (1.74 g, 88%) as a colourless oil.
[82a, 83] 
156. [α]D
18 +3.05 (c 1.14, CH3OH) [lit.
[83] [α]D
25 +2.17 (c 0.6 , CH3OH); lit.
[97] [α]D
22 +3.50 (c 
0.8, CH3OH)]; [α]D
24 +19.2 (c 1.33, H2O) [lit.
[82a] [α]D
22 +19.9 (c 0.71, H2O)]. 
1H NMR (d6-
DMSO, 400 MHz) δ (ppm): 5.52 (d, J = 0 4.1 Hz, 1 H, CHOH), 5.10 (t, J = 5.5 Hz, 1 H, 
CH2OH), 4.33-4.27 (m, 2 H, 4-H and 5-H), 3.62-3.53 (m, 2 H, CH2OH), 2.85 (dd, J = 17.6, 6.2 
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Hz, 1 H, 3-H), 2.26 (dd, J = 17.6, 2.1 Hz, 1 H, 3-H’); 1H NMR (CD3OD, 400 MHz) δ (ppm): 
4.42 (dt, J = 6.6, 2.3 Hz, 1 H, 4-H), 4.36 (X part of an ABX system, m, 1 H, 5-H), 3.73 (AB part 
of an ABX system, J = 12.5, 3.3 Hz, 2 H, CH2OH), 2.91 (dd, J = 18.0, 6.8 Hz, 1 H, 3-H), 2.37 
(dd, J = 18.0, 2.5 Hz, 1 H, 3-H’). 13C NMR (d6-DMSO, 100.32 MHz) δ (ppm): 177.1 (s, CO), 
89.2 (d, C5), 68.7 (d, C4), 61.7 (t, CH2OH), 38.9 (t, C3);
13C NMR (CD3OD, 100.32 MHz) δ 
(ppm): 178.6 (s, CO), 90.2 (d, C5), 69.7 (d, C4), 62.5 (t, CH2OH), 39.2 (t, C3). MS (ESI) m/z %: 
101 (19, M+-31), 43 (100). C5H8O4 (132.11): calcd C, 45.46; H, 6.10. Found: C, 45.35, H, 6.39. 
 
O
OTsO
HO
157  
(2S,3S)-(3-Hydroxy-5-oxotetrahydrofuran-2-yl)methyl 4-Methylbenzenesulfonate [(+)-
(157)]. 
A solution of lactone 156 (850 mg, 6.4 mmol) in freshly distilled pyridine (20 mL) was cooled at 
-15°C (external) and, after 15 min, TsCl (1.15 eq) was rapidly added and the mixture left under 
stirring at -15°C for 2 h and at 0 °C for 5 h. The solvent was then removed under vacuum and the 
residue taken up in water (20 mL); the product was extracted with EtOAc (4 x 20 mL) and the 
combined organic extracts washed with 0.5 M HCl (2 x 20 mL), water (20 mL) and dried over 
anhydrous Na2SO4. After filtration and evaporation of the solvent, crude 157 was obtained and 
purified by flash chromatography (eluent: n-hexane-EtOAc, 2:3; Rf 0.19), affording pure O-
tosylate 157 as a white solid (990 mg, 54%). 
157. M.p. 56.0-57.9 °C (lit.[84] 56-58 °C). [α]D
20 +36.5 (c 0.89, CHCl3) [lit.
[84] [α]D
20 +39.6 (c 5.3, 
CH2Cl2); lit.
[98] [α]D
20 + 32.1 (c 3.2, CH2Cl2)]. 
1H NMR (400 MHz) δ (ppm): 7.76 (d, J = 8.2 Hz, 
2 H, Ar), 7.37 (d, J = 8.4 Hz, 2 H, Ar), 4.62-4.58 (m, 1 H, 3-H), 4.51-4.48 (m, 1 H, 2-H), 4.29 
(dd, J = 11.3, 3.3 Hz, 1 H, CH2OTs), 4.16 (dd, J = 11.3, 3.5 Hz, 1 H, CH2OTs), 2.90 (dd, J = 
18.2, 7.2 Hz, 1 H, 4-H), 2.64 (br s, 1 H, OH), 2.53 (dd, J = 18.2, 3.7 Hz, 1 H, 4-H’), 2.46 (2, 3 H, 
CH3). 
13C NMR (100.32 MHz) δ (ppm): 174.1 (s, CO), 145.7 (s, Ar), 131.8 (s, Ar), 130.2 (d, 2 
C, Ar), 128.0 (d, 2 C, Ar), 83.6 (d, C2), 68.9 (d, C3), 67.8 (t, CH2OTs), 37.7 (t, C4), 21.7 (q, 
CH3). MS (ESI) m/z %: 286 ([M]
+, 100), 115 (6). C12H14O6S (286.30): calcd C, 50.34; H, 4.93. 
Found: C, 49.94, H, 5.06. 
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O
OBrO
HO
158  
(4S,5S)-5-(Bromomethyl)-4-hydroxydihydrofuran-2(3H)-one [(+)-(158)]. 
A solution of lactone 156 (850 mg, 6.4 mmol) in anhydrous DMF (9.5 mL) was cooled at 0 °C 
and thionyl bromide (595 µL, 7.7 mmol) was dropwise added. After 2 min the cooling bath was 
removed and the orange solution left under stirring for 4.5 h. The reaction was quenched by 
adding anhydrous methanol (332 µL) and, after 10 min, water (95 mL). The product was 
extracted with EtOAc (4 x 80 mL) and the combined organic extracts were dried over anhydrous 
Na2SO4. After filtration and evaporation of the solvent, crude 158 was obtained and purified by 
flash chromatography (eluent: n-hexane-EtOAc, 1:1; Rf 0.25). Pure bromide 158 (587 mg, 47%) 
was so obtained as a colourless oil. The aqueous layer was concentrated under vacuum and the 
residue chromatographed (eluent: EtOAc, Rf 0.21) to give alcohol 156 (262 mg). This was 
treated again with SOBr2 as reported above providing pure 158 (181 mg) in a total yield of 61%. 
158. [α]D
26 +12.5 (c 1.22, EtOAc). 1H NMR (400 MHz) δ (ppm): 4.63–4.58 (m, 1 H, 4-H), 4.58-
4.53 (m, 1 H, 5-H), 3.61 (dd, J = 11.2, 3.9 Hz, 1 H, CH2Br), 3.53 (dd, J = 11.2, 6.0 Hz, 1 H, 
CH2Br), 2.99 (dd, J = 18.4, 7.2 Hz, 1 H, 3-H), 2.58 (dd, J = 18.4, 3.9 Hz, 1 H, 3-H'). 
13C NMR 
(100.32 MHz) δ (ppm): 175.7 (s, CO), 85.6 (d, C5), 70.1 (d, C4), 37.9 (t, CH2Br), 31.5 (t, C3). 
MS (ESI) m/z %: 219 ([M+Na]+, 45), 217 ([M+Na]+, 47). C5H7BrO3 (195.01): calcd C, 30.79; H, 
3.62. Found: C, 30.85, H, 3.93 
 
O
ON3
HO
159  
(4S,5R)-5-Azidomethyl-4-hydroxydihydrofuran-2-one [(+)-(159)].  
From tosylate 157. Tosylate 157 (825 mg, 2.88 mmol) was dissolved into anhydrous acetonitrile 
(12.5 mL) under nitrogen atmosphere; 18-crown-6 ether (152 mg, 0.58 mmol) and NaN3 (280 
mg, 1.5 eq) were rapidly added to this solution and the mixture was heated under reflux. After 7 
h a further amount of NaN3 (0.2 eq) was added and the suspension refluxed until completion (in 
all 15 h). After cooling at room temperature, the suspension was filtered on a Celite pad and the 
filtrate concentrated under vacuum. The residue was purified by flash chromatography (eluent: 
n-hexane-EtOAc, 2:3; Rf 0.23), affording pure azide 159 (401 mg, 87%) as a colourless oil. 
From bromide 158. Bromide 158 (580 mg, 2.97 mmol) was dissolved into anhydrous 
acetonitrile (13 mL) under nitrogen atmosphere; 15-crown-5 ether (118 µL, 0.59 mmol) and 
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NaN3 (387 mg, 2.0 eq) were rapidly added to this solution and the mixture was heated under 
reflux. After 8 h a further amount of NaN3 (0.5 eq) was added and the suspension refluxed until 
completion (20 h; TLC monitoring). After cooling at room temperature, the suspension was 
filtered on a mixed silica gel-celite pad and the filtrate concentrated under vacuum. Azide 159 
(443 mg, 95%) was so obtained as a colourless oil and no further purifications were required. 
159. [α]D
25 +100.5 (c 0.39, CHCl3). 
1H NMR (400 MHz) δ (ppm): 4.51–4.45 (m, 2 H, 4-H, 5-H), 
3.64 (AB part of an ABX system, J = 13.3, 3.9 Hz, 2 H, CH2N3), 2.96 (dd, J = 18.2, 6.8 Hz, 1 H, 
3-H), 2.55 (dd, J = 18.2, 3.9 Hz, 1 H, 3-H'). 13C NMR (100.32 MHz) δ (ppm): 175.8 (s, CO), 
85.5 (d, C5), 69.0 (d, C4), 51.8 (t, CH2N3), 37.8 (t, C3). MS/MS (ESI of [M + 1]
+): m/z (%) = 
158 ([M++1], 100). C5H7N3O3 (157.13): calcd C, 38.22; H, 4.49; N, 26.74. Found: C, 37.96, H, 
4.72; N, 26.56. 
 
N
H
OH
O
HO
137  
(4S,5R)-4,5-Dihydroxypiperidin-2-one (+)-137)  
Azide 159 (840 mg, 5.35 mmol) was dissolved into anhydrous methanol (35 mL) under nitrogen 
atmosphere. Then, 10% Pd/C catalyst (3% mol) was added and the reaction flask flushed first 
with N2 and then with hydrogen and left under hydrogen atmosphere (balloon) at room 
temperature for 24 h. The suspension was filtered on a Celite pad and the filtrate concentrated 
under vacuum, affording pure lactam 137 as a white solid (638 mg, 91%) with spectroscopic data 
identical to those of the racemic compound (EJOC 2012). 
137. M.p. 160.9-162.0 °C. [α]D
23 +17.8 (c 0.62, CH3OH). Spectoscopic data as reported for the 
racemic compound (±)-137 
 
N
H
OH
O
HO
ent-137  
(4S,5R)-4,5-Dihydroxypiperidin-2-one (ent-137) 
Prepared as reported above for (+)-137. Starting from 2-deoxy-L-ribose (ent-155) (700 mg, 5.22 
mmol) pure lactone ent-137 (545 mg, 79%) was obtained as a colourless oil. 
ent-137. [α]D
23 (c 1.04, H2O). Analytical and spectroscopic data as reported above. 
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N
H
138
O
O
O
 
(3aR,7aS)-2,2-Dimethyltetrahydro[1,3]dioxolo[4,5-c]pyridin-6(3aH)-one [(–)-(138)]. 
Lactam (4S,5R)-137 (630 mg, 4.80 mmol) was dissolved in anhydrous methanol (4.3 mL) and a 
catalytic amount of p-toluenesulfonic acid was added (183 mg, 0.96 mmol) followed by 2,2-
dimethoxypropane (10.6 mL, 86 mmol). The mixture was warmed at 55°C for 2.5 h and, after 
cooling, diluted with MeOH (4.5 mL) and neutralized by K2CO3 (73 mg, 0.53 mmol). After 
filtration on a Celite pad and evaporation of the solvent, crude 138 was obtained and purified by 
flash chromatography (eluent: CH2Cl2–MeOH, 20:1; Rf 0.18), affording pure 138 as a white 
powder (756 mg, 92%) with spectroscopic data identical to those of the racemic compound. 
(-)-138. M.p. 118.2-119.2 °C. [α]D
24 –121.9 (c 0.75, CHCl3). Analytical and spectroscopic data 
as reported above for the racemic compound (±)-138 
 
139
N O
O
O
CO2Me
 
(3aR,7aS)-Methyl 2,2-Dimethyl-6-oxotetrahydro[1,3]dioxolo[4,5-c]pyridine-5(4H)-
carboxylate [(–)-(139)]. 
A solution of lactam 138 (750 mg, 4.38 mmol) in dry THF (44 mL) was cooled at –78 °C and a 
1.6 M solution of n-BuLi (2.74 mL, 4.38 mmol) was slowly added, keeping the temperature 
below –70°C during the addition. The mixture was stirred for 15 min and then methyl 
chloroformate (338 µL, 4.38 mmol) was added dropwise; after 10 min, the cooling bath was 
removed and the temperature allowed to warm to 0 °C. Saturated NaHCO3 (20 mL) and water 
(20 mL) were added and the product extracted with dichloromethane (4 × 15 mL). The combined 
organic extracts were dried over Na2SO4, filtered and evaporated in vacuo to give crude 139. 
After purification by flash chromatography (eluent: n-hexane-EtOAc, 1:2; Rf 0.32) pure 139 was 
obtained as a white solid (843 mg, 84%) with spectroscopic data identical to those of the racemic 
compound. 
139. M.p. 70.2-72.1 °C. [α]D
24 –63.9 (c 0.91, CHCl3). Spectoscopic data as reported above for 
racemic (±)-139. 
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N
141
O
O
OP(O)(OPh)2
CO2Me
 
(3aR,7aS)-Methyl 6-(Diphenoxyphosphoryloxy)-2,2-dimethyl-3a,7a-dihydro-4H-
[1,3]dioxolo[4,5-c]pyridine-5(4H)-carboxylate (141). 
Prepared as reported above for the racemic compound, starting from enantiopure 139 (840 mg, 
3.66 mmol), affording pure 141 as a colourless oil (1.68 g, 99%). This was used immediately for 
the next step. Spectroscopic data identical to those of the racemic compound. 
 
N
O
O
CO2Me
CO2Me
143  
(3aR,7aS)-Dimethyl 2,2-Dimethyl-3a,7a-dihydro[1,3]dioxolo[4,5-c]pyridine-5,6(4H)-
dicarboxylate [(+)-(143)]. 
In a round bottom flask was prepared a solution of phosphate 141 (1.68 g, 3.64 mmol), Pd(OAc)2 
(82 mg, 0.36 mmol) and Ph3P (191 mg, 0.73 mmol) in anhydrous DMF (8.6 mL) under nitrogen 
atmosphere. The flask was flushed and saturated with carbon monoxide and, after 10 min, Et3N 
(1.0 mL, 7.28 mmol) and anhydrous CH3OH (5.9 mL, 146 mmol) were added. The mixture was 
saturated with CO (balloon) and heated at 75°C (external bath) for 1 h. After cooling, water (86 
mL) was added and the product extracted with Et2O (4 × 50 mL). The combined organic 
extracted were dried over Na2SO4; after filtration and evaporation of the solvent, crude 143 was 
purified by flash chromatography (eluant: n-hexane-EtOAc, 2:1, 1% Et3N; Rf 0.27), to afford 
pure 143 as a thick colourless oil (770 mg, 78%) and with spectroscopic data identical to those of 
the racemic compound. 
143. [α]D
26 +40.0 (c 1.12, CHCl3). 
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N
O
O
CO2Me
CO2Me
ent-143  
(3aS,7aR)-Dimethyl 2,2-Dimethyl-3a,7a-dihydro[1,3]dioxolo[4,5-c]pyridine-5,6(4H)-
dicarboxylate [(–)-ent-25]     
Prepared as reported for (+)-143, in two steps, starting from (+)-137 (227 mg, 0.99 mmol) and 
affording pure (–)-143 (185 mg, 69%) as colourless oil. 
ent-143. [α]D
25 –39.3 (c 0.78, CHCl3). Analytical and spectroscopic data as reported above. 
 
Attribution of absolute configuration of diol 147 from EKR (Scheme 38)  
Conversion of enantiopure lactam 138 in enamide ester 144: Prepared as reported for (±)-144 
starting from enantiopure 138, affording enantiopure 144 in 52% yield over 3 steps, with 
spectroscopic data identical to those racemic compound and [α]D
22 +33.5 (c 1.02, CHCl3). 
Conversion of diol ent-147 (directly obtained from EKR) in enamide ester ent-144: prepared 
as reported above for 138, starting from ent-147, affording after chromatography (n-hexane-
EtOAc 1:1, Rf = 0.22) pure ent-144 in 62% yield and [α]D
26 -25.3 (c 0.21, CHCl3). 
 
N CO2Me
O
O
160
CO2Me
 
(3aR,6S,7aS)-Dimethyl 2,2-dimethyltetrahydro[1,3]dioxolo[4,5-c]pyridine-5,6(4H)-
dicarboxylate [(–)-(160)]. 
A suspension of NaHCO3 (155 mg, 1.84 mmol, 2.5 eq) and 10% Pd/C (126 mg, 0.12 mmol, 0.16 
eq) in EtOAc (19.4 mL) was flushed with H2 and vigorously stirred under H2 atmosphere for 30 
min. A solution of 143 (200 mg, 0.74 mmol) in EtOAc (1.7 mL mL) was then added and the 
resulting mixture flushed with H2 and stirred under H2 (balloon) at room temperature for 4 h. 
After filtration on a Celite pad, the filtrate was concentrated under vacuum to give pure 160 as a 
colourless oil (195 mg, 97%) with spectroscopic data identical to those of the racemic 
compound. 
160. [α]D
25 –7.1 (c 0.93, CHCl3). 
1H NMR (400 MHz) (1.3:1 mixture of rotamers) δ (ppm): 4.54 
(t, J = 6.4 Hz, 1 H, 2-H, major), 4.40 (t, J = 6.8 Hz, 1 H, 2-H, minor), 4.29–4.15 (m, 2 H, 4-H, 5-
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H, both rotamers + 1 H, 6-Heq minor), 3.99 (dd, J = 13.9, 6.2 Hz, 1 H, 6-Heq, major), 3.74 (s, 3 
H, CO2CH3), 3.72 (s, 3 H, NCO2CH3, major), 3.68 (s, 3 H, NCO2CH3, minor), 3.33 (dd, J = 
13.9, 8.2 Hz, 1 H, 6-Hax, major), 3.26 (dd, J = 13.7, 8.2 Hz, 1 H, 6-Hax, minor), 2.38–2.16 (m, 2 
H, 3-H', 3-H''), 1.43 (s, 3 H, CH3), 1.32 (s, 3 H, CH3). C12H19NO6 (273.28): calcd C, 51.06; H, 
7.14; N, 4.96. Found: C, 50.92; H, 7.18; N, 4.72. 
 
N
H
OH
CO2H
HO
10 HCl  
(2S,4S,5R)-4,5-Dihydroxypipecolic Acid [(–)-10·HCl]. 
A 25 mM solution of compound 160 (187 mg, 0.68 mmol) in aqueous 4 N HCl  was heated 
under reflux for 24 h. After cooling, the solvent was concentrated under vacuum. The residue 
was triturated with cold diethyl ether and then dried under vacuum until constant weight. Pure 
acid (–)-10 was so obtained as hydrochloride (135 mg, quantitative). 
White solid. 
(–)-10. M.p. 167 °C (dec.). [α]D
24 –29.0 (c 0.54, H2O); [α]D
28 –25.3 (c 0.54, 2N HCl). 1H NMR 
(400 MHz, D2O) δ (ppm): 4.15 (br s, 1 H, 5-H), 4.10 (dd, J = 12.1, 3.7 Hz, 1 H, 2-H), 4.04 (ddd, 
J = 10.9, 4.3,  2.9 Hz, 1 H, 4-H), 3.51 (dd, J = 13.5, 3.9 Hz, 1 H, 6-Heq), 3.25 (dd, J = 13.9, 1.8 
Hz, 1 H, 6-Hax), 2.36 (dt, J = 13.7, 4.1 Hz, 1 H, 3-Heq), 2.19-2.10 (m, 1 H, 3-Hax). 
13C NMR 
(100.4 MHz, D2O) δ (ppm): 170.5 (s, CO), 66.7 (d, C-5), 64.4 (d, C-4), 55.3 (d, C-2), 46.7 (t, C-
6), 27.6 (t, C-3); MS/MS (ESI of [M + 1]+): m/z (%) = 162 ([M++1], 2), 144 (53), 116 (100), 98 
(25). C6H13NO4Cl (197.62): calcd C, 36.47; H, 6.63; N, 7.12. Found: C, 36.38; H,6.85; N, 7.03 
 
N CO2Me
O
O
CO2Me
161
N CO2Me
O
O
CO2Me
ent-160  
(3aS,6R,7aR)-Dimethyl 2,2-dimethyltetrahydro[1,3]dioxolo[4,5-c]pyridine-5,6(4H)-
dicarboxylate [(+)-ent-(160)] and (3aS,6S,7aR)-Dimethyl 2,2-
dimethyltetrahydro[1,3]dioxolo[4,5-c]pyridine-5,6(4H)-dicarboxylate [(–)-161] 
A solution of (–)-ent-143 (185 mg, 0.68 mmol) in anhydrous THF (2.5 mL) was cooled at –10 
°C and Super-Hydride (1 M solution in THF, 820 µL, 0.82 mmol) was slowly added. After 70 
min, the temperature was raised to 0 °C and the mixture stirred for 5 min, before being cooled 
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again at –10 °C and quenched by satd NaHCO3 solution (8 mL). The product was extracted with 
CH2Cl2 (5 x 15 mL); the combined organic extracts were washed once with water (25 mL) and 
dried over anhydrous Na2SO4. After filtration and evaporation of the solvent, the crude 2.6 : 1 
mixture of 161 and ent-160 was obtained. The two diastereoisomers were separated by flash 
chromatography (eluent: n-hexane-EtOAc, 2:1), affording pure 161 (126 mg, 68%) and ent-160 
(41 mg, 22%) both as a thick colourless oil. 
(+)-ent-160. [α]D
25 +8.0 (c 0.64, CHCl3). 
(–)-161. [α]D
27 –113.4 (c 0.96, CHCl3). 
1H NMR (400 MHz) (1.4:1 mixture of rotamers) δ 
(ppm): 4.52 (dd, J = 11.9, 5.7 Hz, 1 H, 2-H, major), 4.47-4.42 [m, 2 H, 2-H (minor) and 4-H 
(both rotamers)], 4.31 (dm, J = 8.0 Hz, 1 H, 5-H, minor), 4.28 (dm, J = 7.8 Hz, 1 H, 5-H, major), 
4.20 (dd, J = 14.6, 2.0 Hz,1 H, 6-Heq minor), 4.07 (dd, J = 15.0, 2.0 Hz, 1 H, 6-Heq, major), 3.72 
(s, 3 H, CO2CH3, major), 3.71 (s, 3 H, CO2CH3, minor),  3.70 (s, 3 H, NCO2CH3, major), 3.67 (s, 
3 H, NCO2CH3, minor), 3.14 (dd, J = 15.0, 2.0 Hz, 1 H, 6-Hax, major), 3.09 (dd, J = 14.6, 1.8 
Hz, 1 H, 6-Hax, minor), 2.38–2.28 (m, 1 H, 3-H), 1.78–1.69 (m, 1 H, 3-H’), 1.37 (s, 3 H, CH3), 
1.30 (s, 3 H, CH3). 
13C NMR (100.4 MHz) δ (ppm): 13C NMR (100.4 MHz) (mixture of 
rotamers) δ (ppm): 173.1 (s, CO2Me), 156.7 and 156.3 (s, NCO2Me), 108.5 and 108.4 (s, 
C(CH3)2), 72.6 and 72.5 (d, C-4), 69.7 (d, C-5), 52.9 and 52.8 (d, C-2), 52.2 (q, OCH3), 50.9 and 
50.8 (q, OCH3), 42.4 and 42.1 (t, C-6), 27.9 and 27.6 (t, C-3), 26.2 and 26.1 (q, CH3), 24.2 and 
24.1 (q, CH3). MS/MS (ESI of [M + 1]
+): m/z (%) = 274 ([M+ + 1], 3), 242 (45), 216 (100), 214 
(22), 184 (7), 156 (5). C12H19NO6 (273.28): calcd C, 51.06; H, 7.14; N, 4.96. Found: C, 50.88; H, 
7.28; N, 4.80 
 
N
H
OH
CO2H
HO
11 HCl  
(2S,4R,5S)-4,5-Dihydroxypipecolic Acid [(–)-11·HCl]. 
Prepared as reported for (–)-10, starting from 161 (145 mg, 0.53 mmol) and obtaining pure (–)-
11 as hydrochloride (104 mg, 99%). 
White solid. 
11. Mp = 253 °C (dec.);  [α]D
25 –10.7 (c 0.53, 2N HCl); 1H NMR (400 MHz, D2O) δ (ppm): 4.20 
(dd, J = 10.9, 3.9 Hz, 1 H, 2-H), 4.13–3.99 (br m, 1 H, 4-H), 3.98 (ddd, J = 9.8, 4.1,  2.7 Hz, 1 
H, 5-H), 3.33 (dd, J = 12.5, 4.3 Hz, 1 H, 6-Heq), 3.19 (dd, J = 12.5, 10.0 Hz, 1 H, 6-Hax), 2.39 
(ddd, J = 15.0, 5.9, 4.1 Hz, 1 H, 3-Heq), 2.11-2.04 (ddd, J = 15.0, 11.0, 2.5 Hz, 1 H, 3-Hax). 
13C 
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NMR (100.4 MHz, D2O) δ (ppm): 171.1 (s, CO), 66.7 (d, C-5), 64.6 (d, C-4), 51.7 (d, C-2), 42.3 
(t, C-6), 29.8 (t, C-3); MS/MS (ESI of [M + 1]+): m/z (%) = 162 ([M++1], 21), 144 (100), 116 
(25), 98 (69). C6H13NO4Cl (197.62): calcd C, 36.47; H, 6.63; N, 7.12. Found: C, 36.34; H, 6.88; 
N, 6.99. 
 
N
H
CO2H
OH
HO
ent-10  
(2R,4R,5S)-4,5-Dihydroxypipecolic Acid [(+)-ent-10·HCl] 
Prepared as reported for (–)-10, starting from ent-160 (18 mg, 0.065 mmol) and obtaining pure 
(+)-ent-10 as hydrochloride (13 mg, quantitative). 
(+)-ent-10. [α]D
24 +26.1 (c 0.65, 2N HCl) 
 
N O
TBSO
CO2Me
165  
(5S)-Methyl 5-(tert-Butyldimethylsilanyloxy)-2-oxopiperidine-1-carboxylate [(+)-(165)] 
Prepared as reported for (–)-115, starting from 164 (2.22 g, 9.68 mmol) and affording, after 
purification by flash chromatography (n-hexane-EtOAc, 2:1; Rf 0.25), pure (+)-165 (1.98 g, 
71%) as a white solid. 
(+)-165. M.p. 64.1–65.0 °C (lit.[92g] m.p. 68 °C). [α]D
21 +17.2 (c 1.07, CHCl3) {lit.
[92g] [α]D
20 
+10.9 (c 1.0. MeOH)}. 1H NMR (CDCl3, 400 MHz) δ (ppm): 4.20–4.15 (m, 1 H, 5-H), 3.86 (s, 3 
H, OCH3), 3.75 (ddd, J = 13.3, 4.7, 1.6 Hz, 1 H, 6-H), 3.68 (dd, J = 13.3, 3.7 Hz, 1 H, 6-H’), 
2.75 (ddd, J = 17.4, 9.6, 6.8 Hz, 1 H, 3-H), 2.46 (dt, J = 17.4, 6.0 Hz, 1 H, 3-H’), 2.05–1.92 (m, 1 
H, 4-H), 1.90–1.81 (m, 1 H, 4-H), 0.87 [s, 9 H, SiC(CH3)3], 0.08 [s, 6 H, Si(CH3)2]. 
13C NMR 
(CDCl3, 100.4 MHz) δ (ppm): 170.8 (s, CO), 154.9 (s, NCO2Me), 64.1 (d, C-5), 53.9 (q, OCH3), 
52.9 (t, C-6), 30.8 (t, C-3), 28.6 (t, C-4), 25.6 [(q, 3 C, SiC(CH3)3], 17.8 [(s, SiC(CH3)3], –4.9 
[(q, 2 C, Si(CH3)2]. MS/MS (ESI of [M + 1]
+) m/z (%): 288 ([M+ + 1], 19), 256 (65), 156 (86), 
147 (27), 114 (100). C13H25NO4Si (287.49): calcd C, 54.32; H, 8.77; N, 4.87. Found: C, 54.26; 
H, 8.50; N, 4.88. 
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N O
TBSO
Cbz
166  
(5S)-Benzyl 5-(tert-Butyldimethylsilanyloxy)-2-oxopiperidine-1-carboxylate [(+)-(166)] 
Prepared as described for (±)-139, starting from 164 (2.22 g, 9.68 mmol) and benzyl 
chloroformate, and affording, after purification by flash chromatography (n-hexane-EtOAc, 4:1; 
Rf 0.21), pure (+)-166 (1.98 g, 71%) as a white solid. 
(+)-166. M.p. 35.6–36.8 °C. [α]D
23 +12.4 (c 0.80, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm):  
7.44-7.41 (m, 2H, Ph), 7.38-7.29 (m, 3 H, Ph), 5.29 (s, 2 H, CH2Bn), 4.19-4.15 (m, 1 H, 5-H), 
3.75 (ddd, J = 13.3, 4.7, 1.6 Hz, 1 H, 6-H), 3.68 (dd, J = 13.3, 3.7 Hz, 1 H, 6-H’), 2.76 (ddd, J = 
17.2, 9.4, 6.6 Hz, 1 H, 3-H), 2.46 (ddd, J = 17.2, 6.2, 5.7 Hz, 1 H, 3-H’), 2.00-1.92 (m, 1 H, 4-
H), 1.90-1.82 (m, 1 H, 4-H’), 0.86 [s, 9 H, SiC(CH3)3], 0.07 [s, 3 H, Si(CH3)2], 0.06 [s, 3 H, 
Si(CH3)2]. 
13C NMR (CDCl3, 100.4 MHz) δ (ppm): 170.7 (s, CO), 154.1 (s, NCO2Bn), 135.5 (s, 
Carom), 128.2 (d, 2 C, Carom), 128.2 (d, 2 C, Carom), 68.5 (s, CH2Ph), 64.2 (s, C-5), 52.9 (s, C-6), 
30.9 (s, C-3), 28.9 (s, C-4), 25.6 (s, [(s, 3 C, SiC(CH3)3]), 18.0 [(s, SiC(CH3)3], -4.9 [(d, 2 C, 
Si(CH3)2]. MS/MS (ESI of [M + 23]
+) m/z (%): 386 [M + 23]+, 37), 342 (100). C19H29NO4Si 
(363.52): calcd C, 62.78; H, 8.04; N, 3.85. Found: C, 62.40; H, 7.67; N, 3.98. 
 
N OPO(OPh)2
TBSO
CO2Me
167  
(3S)-Methyl 6-[(diphenoxyphosphoryl)oxy]-3-(tert-butyldimethylsilanyloxy)-3,4-
dihydropyridine-1(2H)-carboxylate (167) 
Prepared as reported for 123, starting from 165 (1.97 g, 6.85 mmol) and affording, after 
purification by chromatography (EtOAc-n-hexane, 1:3, + 1% Et3N; Rf 0.55), phosphate 167 
(3.52 g, 99%) as a pale yellow oil which was immediately used in the next step. 
167. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.37–7.32 (m, 4 H, CHarom), 7.28–7.13 (m, 6 H, 
CHarom),  5.04 (q, J = 3.1 Hz, 1 H, 3-H), 4.04–3.99 (m, 1 H, 5-H), 3.76 (dd, J = 12.5, 5.6 Hz, 1 H, 
6-H),  3.55 (s, 3 H, OCH3), 3.40 (dd, J = 12.5, 2.1 Hz, 1 H, 6-H'), 2.36 (dq, J = 18.1, 4.3 Hz, 1 H, 
4-H), 2.06 (dq, J = 18.1, 3.5 Hz, 1 H, 4-H'), 0.86 [s, 9 H, SiC(CH3)3], 0.06 [s, 3 H, Si(CH3)2], 
0.05 [s, 3 H, Si(CH3)2]. 
13C NMR (CDCl3, 100.4 MHz) δ (ppm): 155.3 (s, CO), 150.5 (s, 2 C, 
Carom), 139.6 (s, C-2), 129.8 (d, 4 C, Carom), 125.5 (d, 2 C, Carom), 120.1 (d, 4 C, Carom), 98.2 (d, 
C-3), 64.7 (d, C-5), 53.0 (q, OCH3), 51.4 (t, C-6), 32.0 (t, C-4), 25.6 [(q, 3 C, SiC(CH3)3], 18.0 
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[(s, SiC(CH3)3], –5.00 [(q, 2 C, Si(CH3)2]. MS/MS (ESI of [M + 1]
+) m/z (%): 520 ([M+ + 1], 
11), 476 (100), 379 (10), 344 (8). 
 
N OPO(OPh)2
TBSO
Cbz
168  
(3S)-Benzyl 6-[(diphenoxyphosphoryl)oxy]-3-(tert-butyldimethylsilanyloxy)-3,4-
dihydropyridine-1(2H)-carboxylate (168) 
Prepared as reported for 123, starting from 166 (1.97 g, 6.85 mmol) and affording, after 
purification by chromatography (EtOAc-n-hexane, 1:4, + 1% Et3N; Rf 0.22), phosphate 168 
(3.52 g, 99%) as a pale yellow oil which was immediately used in the next step. 
168. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.36-7.23 (m, 10 H, Ph), 7.19-7.15 (m, 5 H, Ph), 5.06 
(AB system, 2 H, CH2Bn), 4.04-3.99 (m, 1 H, 5-H), 3.76 (dd, J = 12.7, 6.1 Hz, 1 H, 6-H), 3.44 
(dd, J = 12.7, 2.1 Hz, 1 H, 6-H’), 2.38 (dq, J = 18.2, 4.3 Hz, 1 H, 4-H), 2.07 (dq, J = 18.2, 3.9 
Hz, 1 H, 4-H’), 0.85 [s, 9 H, SiC(CH3)3], 0.05 [s, 3 H, Si(CH3)2], 0.04 [s, 3 H, Si(CH3)2]. 
13C 
NMR (CDCl3, 100.4 MHz) δ (ppm): 154.6 (s, CO), 150.3 (d, NCOBn), 139.5 (d, C-2), 135.8 (s, 
Carom), 129.7 (s), 128.4 (s), 128.0 (s, 2 C, Carom), 125.2 (d, 2 C, Carom), 120.1 (t, 4-C, Carom), 98.5 
(d, C-3), 67.9 (s, CH2Bn), 64.7 (s, C-5), 51.5 (s, C-6), 32.0 (s, C-4), 25.7 [(s, 3 C, SiC(CH3)3], 
18.0 [(s, SiC(CH3)3], -5.0 [(s, 2 C, Si(CH3)2]. MS/MS (ESI of [M + 1]
+) m/z (%): 596 ([M+ + 1], 
100), 499 (50), 272 (80). 
 
N CO2Me
TBSO
CO2Me
169  
(5S)-Dimethyl 5-(tert-Butyldimethylsilanyloxy)-5,6-dihydropyridine-1,2(4H)-dicarboxylate 
[(+)-169] 
Prepared as reported for 124, starting from phosphate 167 (3.52 g, 6.77 mmol) and affording, 
after purification by chromatography (EtOAc-n-hexane, 1:4;  Rf 0.27), pure 169 (1.83 g, 82%) as 
a thick pale yellow oil. 
169. [α]D
19 +5.27 (c 0.99, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 6.06 (t, J = 3.9 Hz, 1 H, 
3-H), 4.06–4.02 (m, 1 H, 5-H), 3.77 (s, 3 H, OCH3), 3.70 (s, 3 H, OCH3), 3.59 (dd, J = 12.7, 6.2 
Hz, 1 H, 6-H), 3.52 (dd, J = 12.7, 2.7 Hz, 1 H, 6-H’), 2.44 (ddd, J = 19.3, 5.5, 3.7 Hz, 1 H, 4-H), 
2.13 (dt, J = 19.3, 4.3 Hz, 1 H, 4-H’), 0.86 [s, 9 H, SiC(CH3)3], 0.07 [s, 6 H, Si(CH3)2]. 
13C NMR 
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(CDCl3, 100.4 MHz) δ (ppm): 164.7 (s, CO), 155.2 (s, NCO), 132.1 (s, C-2), 121.4 (d, C-3), 64.5 
(d, C-5), 53.1 (q, OCH3), 52.1 (q, OCH3), 49.7 (t, C-6), 33.2 (t, C-4), 25.6 [(q, 3 C, SiC(CH3)3], 
18.0 [(s, SiC(CH3)3], –5.00 [(q, 2 C, Si(CH3)2]. MS m/z (%): 329 (M
+, 100), 298 (7). 
C15H27NO5Si (329.46): calcd C 54.68; H 8.26; N 4.25. Found: C 54.87; H 8.27; N 4.13. 
 
N CO2Me
TBSO
Cbz
170  
(5S)-1-Benzyl 2-methyl 5-(tert-Butyldimethylsilanyloxy)-5,6-dihydropyridine-1,2(4H)-
dicarboxylate [(+)-170] 
In a round bottom flask was prepared a solution of phosphate 168 (1.68 g, 3.25 mmol), Pd(OAc)2 
(73 mg, 0.33 mmol) and Ph3P (170 mg, 0.65 mmol) in anhydrous DMF (7.7 mL) under nitrogen 
atmosphere. The flask was flushed and saturated with carbon monoxide and, after 10 min, Et3N 
(0.9 mL, 6.5 mmol) and anhydrous CH3OH (5.9 mL, 146 mmol) were added. The mixture was 
saturated with CO (balloon) and heated at 60°C (external bath) for 8 h. After cooling, water (80 
mL) was added and the product extracted with Et2O (4 × 50 mL). The combined organic 
extracted were dried over Na2SO4; after filtration and evaporation of the solvent, crude 170 was 
purified by flash chromatography (eluant: n-hexane-EtOAc, 6:1, Rf 0.11), to afford pure 170 as a 
thick colourless oil (800 mg, 60%) and with spectroscopic data identical to those of the racemic 
compound. 
170: [α]D
21 -10.6 (c 1.16, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.37-7.29 (m, 5 H, Ph), 
6.04 (t, J = 3.9 Hz, 1 H, 3-H), 5.12 (AB system, 2 H, CH2Bn), 4.05-4.02 (m, 1 H, 5-H), 3.60 (m, 
2 H, 6-H + 6 H’), 3.54 (m, 3 H, OCH3), 2.45 (ddd, J = 19.3, 5.5, 3.7 Hz, 1 H, 4-H), 2.14 (dt, J = 
19.3, 4.1 Hz, 1 H, 4-H’), 0.86 [s, 9 H, SiC(CH3)3], 0.06 [s, 6 H, Si(CH3)2]. 
13C NMR (CDCl3, 
100.4 MHz) δ (ppm): 164.7 (s, CO), 154.6 (s, NCO), 135.8 (s, Carom), 132.0 (s, C-2), 128.3 (t, 4 
C, Carom), 121.5 (s, C-3), 68.0 (s, CH2Bn), 64.6 (s, C-5), 51.9 (s, C-5), 49.8 (s, C-6), 33.3 (s, C-
4), 25.7  [(s, 3 C, SiC(CH3)3], 18.0 [(s, SiC(CH3)3], -4.9 [(q, 2 C, Si(CH3)2]. MS (ESI) m/z (%): 
428 ([M+ + 23], 33) 406 ([M+ + 1], 66). 
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173  
(4R,5R)-Dimethyl 4-Acetyloxy-5-(tert-Butyldimethylsilanyloxy)-5,6-dihydropyridine-
1,2(4H)-dicarboxylate [(–)-173] 
A solution of 169 (906 mg, 2.75 mmol), N-bromosuccinimide (622 mg, 3.49 mmol) and a 
catalytic amount of AIBN (77 mg, 0.47 mmol) in a 9:1 mixture of CCl4 and CHCl3 (99 mL) was 
refluxed under vigorous stirring for 1.5 h. After cooling, the mixture was diluted with CHCl3 (80 
mL), washed with water (90 mL) and concentrated under vacuum to give crude bromide 171 as a 
yellow oil that was immediately used for the next step without further purification. 
(–)-171. 
1H NMR (CDCl3, 400 MHz) δ (ppm): 6.09 (dd, J = 4.3, 1.0 Hz, 1 H, 3-H), 4.33–4.30 
(m, 1 H, 4-H), 4.27-4.24 (m, 1 H, 5-H), 4.11(dd, J = 12.1, 4.14.7 Hz, 1 H, 6-H), 3.80 (s, 3 H, 
OCH3), 3.70 (s, 3 H, OCH3), 3.53 (d, J = 12.1, Hz, 1 H, 6-H'), 0.83 [s, 9 H, SiC(CH3)3], 0.08 [s, 
6 H, Si(CH3)2] 
 
Silver acetate (688 g, 4.13 mmol) was added to a solution of 171 (898 mg, 2.20 mmol) in glacial 
CH3CO2H (115 mL) and the resulting mixture stirred at room temperature for 15 min. The 
suspension was then filtered on a celite pad and the filtrate diluted with Et2O (300 mL), washed 
with satd NaHCO3 to neutralization (6 x 150 mL) and dried over anhydrous Na2SO4. After 
filtration and evaporation of the solvent, crude 173 was obtained and purified by flash 
chromatography (EtOAc-n-hexane, 1:4, Rf 0.30), affording pure 173 (1.03 g, 75% over two 
steps) as a thick pale yellow oil.  
(–)-173. [α]D
25 –149.6 (c 1.06, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 5.90 (dd, J = 4.1, 
1.4 Hz, 1 H, 3-H), 4.96–4.94 (m, 1 H, 4-H), 4.08 (dd, J = 13.3, 4.5 Hz, 1 H, 6-H), 3.91-3.89 (m, 
1 H, 5-H), 3.79 (s, 3 H, OCH3), 3.71 (s, 3 H, OCH3), 3.19 (dd, J = 13.3, 1.4 Hz, 1 H, 6-H’), 2.06 
(s, 3 H, CH3CO), 0.83 [s, 9 H, SiC(CH3)3], 0.11 [s, 3 H, Si(CH3)2], 0.07 [s, 3 H, Si(CH3)2]. 
13C 
NMR (CDCl3, 100.4 MHz) δ (ppm): 169.5 (s, CH3CO), 164.4 (s, CO), 155.0 (s, NCO), 135.1 (s, 
C-2), 115.4 (d, C-3), 67.9 (d, C-4), 67.3 (d, C-5), 53.3 (q, OCH3), 52.4 (q, OCH3), 47.0 (t, C-6), 
25.4 [(q, 3 C, SiC(CH3)3], 20.9 (q, CH3CO), 17.7 [(s, SiC(CH3)3], –5.0 [(q, 1 C, Si(CH3)2], –5.3 
[(q, 1 C, Si(CH3)2]. MS/MS (ESI of [M + 23]
+) m/z (%): 410 ([M+ + 23], 12), 350 (8), 328 (83), 
296 (41), 292 (100). C17H29NO7Si (387.50): calcd C 52.69; H 7.54; N 3.61. Found: C 52.83; H 
7.87; N 3.43 
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174  
(4R,5R)-1-Benzil 2-Methyl 4-Acetyloxy-5-(tert-Butyldimethylsilanyloxy)-5,6-
dihydropyridine-1,2(4H)-dicarboxylate [(+)-174] 
Prepared as reported for (-)-173, starting from 170 (262 mg, 0.65 mmol) and affording, after 
purification by chromatography (EtOAc-n-hexane, 1:10;  Rf 0.27), pure 174 (1.83 g, 82%) as a 
thick pale yellow oil. 
(+)-174. [α]D
23 +103.7 (c 0.82, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.37-7.28 (m, 5 H, 
Ph), 5.87 (dd, J = 4.1, 1.4, 1 H, 3-H), 5.13 (AB system, 2 H, CH2Bn), 4.97-4.95 (m, 1 H, 4-H), 
4.12-4.09 (m, 1 H, 6-Heq), 3.93-3.90 (m, 1 H, 5-H), 3.53 (br s, 3 H, CO2CH3), 3.21 (d, J = 13.3, 1 
H, 6-Hax), 2.06 (s, 3 H, OCH3), 0.83 [s, 9 H, SiC(CH3)3], 0.10 [s, 3 H, Si(CH3)2], 0.06 [s, 3 H, 
Si(CH3)2]. 
13C NMR (CDCl3, 100.4 MHz) δ (ppm): 169.5 (s, CH3CO), 164.5 (s, CO), 154.4 (s, 
NCO), 135.3 (s, Carom), 135.1 (s, C-2), 128.4 (d, 4 C, Carom), 115.4 (s, C-3), 68.4 (s, CH2Bn), 68.1 
(s, C-4), 67.4 (s, C-5), 52.2 (OCH3), 47.1 (s, C-6), 25.5 [(s, 3 C, SiC(CH3)3], 21.0 (s, CH3CO), 
17.8 [(s, SiC(CH3)3], -5.0 [(s, 1 C, Si(CH3)2], -5.2 [(s, 1 C, Si(CH3)2]. MS/MS (ESI of [M + 23]
+) 
m/z (%): 486 ([M+ + 23], 50), 360 (100), 29 (53). 
 
N CO2Me
TBSO
CO2Me
OH
175  
(4R,5R)-Dimethyl 5-(tert-Butyldimethylsilanyloxy)-4-hydroxy-5,6-dihydropyridine-1,2(4H)-
dicarboxylate [(–)-175] 
A solution of 173 (1.03 g, 2.66 mmol) in anhydrous MeOH (29 mL) was cooled at 0 °C and 
MeONa (144 mg, 2.66 mmol) was rapidly added. The mixture was stirred at 0 °C for 1 h, 
acidified by addition of glacial acetic acid (380 µL, 6.65 mmol) and the solvent removed under 
vacuum without heating. The residue was diluted with water (260 mL) and the product extracted 
with Et2O (5 × 110 mL); the combined organic extracts were dried over Na2SO4. After filtration 
and evaporation of the solvent, crude 175 was obtained and purified by chromatography (EtOAc-
n-hexane, 1:2; Rf 0.20) to give pure 175 (670 mg, 73%) as a thick colourless oil. 
175. [α]D
21 –111.4 (c 1.13, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 5.96 (dd, J = 3.9, 1.2 
Hz, 1 H, 3-H), 3.99 (dd, J = 12.9, 4.5 Hz, 1 H, 6-Heq), 3.92–3.89 (m, 1 H, 4-H), 3.88–3.86 (m, 1 
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H, 5-H), 3.79 (s, 3 H, OCH3), 3.70 (s, 3 H, OCH3), 3.24 (dd, J = 12.9, 1.4 Hz, 1 H, 6-H'), 0.84 [s, 
9 H, SiC(CH3)3], 0.09 [s, 3 H, Si(CH3)2], 0.07 [s, 3 H, Si(CH3)2]. 
13C NMR (CDCl3, 100.4 MHz) 
δ (ppm): 164.8 (s, CO), 155.1 (s, NCO), 133.5 (s, C-2), 119.2 (d, C-3), 69.9 (d, C-4), 67.1 (d, C-
5), 53.2 (q, OCH3), 52.4 (q, OCH3), 46.4 (t, C-6), 25.5 [(q, 3 C, SiC(CH3)3], 17.9 [(s, 
SiC(CH3)3], –5.0 [(q, 1 C, Si(CH3)2], –5.1 [(q, 1 C, Si(CH3)2]. MS/MS (ESI of [M + 1]
+) m/z 
(%): 346 ([M+ + 1], 21), 328 (47), 314 (100), 296 (17). C15H27NO6Si (345.46): calcd C 52.15; H 
7.88; N 4.05. Found: C 52.08; H 8.05; N 3.95 
 
N CO2Me
TBSO
Cbz
OH
176  
(4R,5R)-1-Benzil 2-Methyl 5-(tert-Butyldimethylsilanyloxy)-4-hydroxy-5,6-
dihydropyridine-1,2(4H)-dicarboxylate [(–)-176] 
Prepared as reported for 175, starting from 174 (262 mg, 0.65 mmol) and affording, after 
purification by chromatography (EtOAc-n-hexane, 1:10;  Rf 0.27), pure 176 (1.83 g, 82%) as a 
thick pale yellow oil 
176. [α]D
20 -110.1 (c 1.15, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 7.37-7.29 (m, 5 H, Ph), 
5.93 (dd, J = 3.7, 1.2, 1H, 3-H), 5.12 (AB system, 2 H, CH2Bn), 4.02 (dd, J = 12.7, 9.2, 1 H, 6-
Heq) 3.91-3.89 (m, 2 H, 4-H + 5-H), 3.53 (br s, 3 H, OCH3), 3.27 (d, J = 12.9, 1 H, 6-Hax), 0.84 
[s, 9 H, SiC(CH3)3], 0.08 [s, 3 H, Si(CH3)2], 0.06 [s, 3 H, Si(CH3)2]. 
13C NMR (CDCl3, 100.4 
MHz) δ (ppm): 164.8 (s, CO), 154.4 (s, NCO), 135.4 (s, Carom), 133.5 (s, C-2), 128.4 (t, 4 C, 
Carom), 119.2 (s, C-3), 69.9 (s, CH2Bn), 68.3 (s, C-4), 67.3 (s, C-5), 52.2 (s, OCH3), 46.5 (s, C-6), 
25.6 [(s, 3 C, SiC(CH3)3], 17.9 [(s, SiC(CH3)3], -5.0 [(s, 2 C, Si(CH3)2]. MS (ESI) m/z (%): 444 
[M + 23]+, 32), 421 ([M]+, 10), 378 (5). 
 
N CO2Me
OH
TBSO
CO2Me
178  
(2S,4R,5R)-Dimethyl 5-(tert-Butyldimethylsilyloxy)-4-hydroxypiperidine-1,2-dicarboxylate 
[(–)-178]  
Prepared as reported for (–)-160, starting from 175 (650 mg, 1.88 mmol) and leaving the mixture 
under stirring and hydrogen atmosphere for 24 h. After filtration on a celite pad and removal of 
Experimental 
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the solvent under vacuum, a crude 3:1 mixture of 178 and 177 was obtained. The major 
diastereoisomer 178 (346 mg, 53%) was obtained in pure form by flash chromatography (eluent: 
n-hexane-Et2O, 2:3; Rf 0.25), as a thick colourless oil. The fraction containing the mixture of 
both isomers 178 and 177 was further chromatographed to give another amount of pure 178 (117 
mg; overall yield 71%).  
178. [α]D
25 –39.6 (c 0.95, MeOH). 1H NMR (400 MHz) (1.1:1 mixture of rotamers) δ (ppm): 
5.01 (d, J = 6.2 Hz, 1 H, 2-H, major), 4.85 (d, J = 6.2 Hz, 1 H, 2-H, minor), 4.21 (dd, J = 13.0, 
3.9 Hz, 1 H, 6-Heq, minor), 4.03 (dd, J = 13.8, 3.5 Hz, 1 H, 6-Heq, major), 3.75 and 3.70 (s, 6 H, 
CO2CH3 and NCO2CH3, both rotamers), 3.41–3.35 (m, 2 H, 4-H and 5-H), 2.85 (dd, J = 13.8, 
10.1 Hz, 1 H, 6-Hax, major), 2.77 (dd, J = 13.0, 10.1 Hz, 1 H, 6-Hax, minor), 2.53–2.47 (m, 1 H, 
3-Heq), 2.33 (dd, J = 14.6, 1.2 Hz, 1 H, OH), 1.74–1.66 (m, 1 H, 3-Hax), 0.90 [s, 9 H, SiC(CH3)3], 
0.12 [s, 6 H, Si(CH3)2]. 
13C NMR (100.4 MHz) δ (ppm): 13C NMR (100.4 MHz) (mixture of 
rotamers) δ (ppm): 171.2 and 171.1 (s, CO2Me), 156.4 and 155.9 (s, NCO2Me), 73.2 and 73.1 (d, 
C-4), 71.4 (d, C-5), 53.9 and 53.7 (d, C-2), 53.2 and 53.1 (q, OCH3), 52.6 and 52.5 (q, OCH3), 
46.2 and 46.1 (t, C-6), 32.0 and 31.7 (t, C-3), 25.7 [(q, 3 C, SiC(CH3)3], 18.0 [(s, SiC(CH3)3], –
4.5 [(q, 1 C, Si(CH3)2], –4.7 [(q, 1 C, Si(CH3)2]. MS/MS (ESI of [M + 1]
+) m/z (%): 348 ([M+ + 
1], 27), 316 (100), 288 (72). C15H29NO6Si (347.48): calcd C, 51.85; H, 8.41; N, 4.03. Found: C, 
51.51; H, 8.60; N, 4.35. 
 
N
H
OH
CO2H
HO
9 HCl  
(2S,4R,5R)-4,5-Dihydroxypipecolic Acid [(–)-9·HCl] 
Prepared as reported for (–)-10, starting from 178 (410 mg, 1.18 mmol) and obtaining pure (–)-9 
as hydrochloride (233 mg, quantitative). 
(–)-9. M.p. 252 °C (dec.);  [α]D
21 –18.2  (c 0.57, 2N HCl); 1H NMR (400 MHz, D2O) δ (ppm): 
4.17 (dd, J = 11.5, 4.1 Hz, 1 H, 2-H), 4.06–4.01 (br m, 1 H, 4-H), 3.97–3.92 (br m, 1 H, 5-H), 
3.43 (dd, J = 13.5, 2.0 Hz, 1 H, 6-Heq), 3.30 (dd, J = 13.5, 3.5 Hz, 1 H, 6-Hax), 2.32–2.17 (m, 2 
H, 3-H). 13C NMR (100.4 MHz, D2O) δ (ppm): 174.2 (s, CO), 67.4 (d, C-4), 67.1 (d, C-5), 54.8 
(d, C-2), 47.0 (t, C-6), 30.3 (t, C-3). MS/MS (ESI of [M + 1]+) m/z (%): 162 ([M+ + 1], 7), 144 
(16), 126 (5), 116 (100), 98 (19). C6H13NO4Cl (197.62): calcd C, 36.47; H, 6.63; N, 7.12. Found: 
C, 36.26; H, 6.85; N, 7.00. 
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cis-179  
2-Benzyl 1-Methyl (1S,4R,5R,6R)-4-(tert-Butyldimethylsilanyloxy)-5-hydroxy-2-
azabicyclo[4.1.0]heptane-1,2-dicarboxylate [(–)-179] 
To a solution of 2,4,6-trichlorophenol (33 mg, 0.167 mmol) in anhydrous CH2Cl2 (1.9 mL), 
cooled to –40 °C, was added Et2Zn (167 µL of a 1 M solution in hexane, 0.167 mmol) under 
nitrogen atmosphere. The mixture was left under stirring for 15 min, then CH2I2 (101 µL, 1.26 
mmol) was added dropwise and, after another 15 min at –40 °C, a solution of alcohol 176 (35 
mg, 0.083 mmol) in CH2Cl2 (300 µL) was added dropwise. The cooling bath was removed and 
reaction mixture was left under stirring for 22 h. The suspension was then cooled in a ice bath 
and a 10% solution of citric acid (3 mL) was added dropwise under vigorous stirring. The 
cooling bath was removed and when the solution became clear, the layers were separated, the 
aqueous layer extracted with  CH2Cl2 (4 × 3  mL) and the combined organic layers washed with 
a 10% solution of Na2CO3 (2 × 3 mL) and dried over Na2SO4. After filtration and evaporation of 
the solvent, crude cis-179 was obtained and purified by chromatography (n-exane-EtOAc 5:2, Rf 
0.18), to give compound cis-179 (23 mg, 95%) as a colorless oil. 
179. [α]D
24 –27.3 (c 0.88, CHCl3); 
1H NMR (400 MHz, 1.7:1 mixture of rotamers) δ (ppm): 
7.36-7.29 (m, 5 H, Ph), 5.29 (part A of an AB system, J = 12.5, 1 H, CH2Bn, major), 5.21 (part 
A of an AB system, J = 12.3, 1 H, CH2Bn, minor), 5.11 (part B of an AB system, J = 12.5, 1 H, 
CH2Bn, minor), 5.04 (part B of an AB system, J = 12.5, 1 H, CH2Bn, major), 4.07-4.04 (m, 1 H, 
5-H both rotamers), 3.96 (dd, J =12.3, 4.0, 1 H, 3-H, major), 3.82 (dd, J = 12.3, 4.1, 1 H, 3-H, 
minor rotamer), 3.70 (s, 3 H, OCH3, minor), 3.51 (s, 3 H, OCH3, major), 3.39-3.33 (m, 1 H, 4-H, 
major) 3.32-3.26 (m, 1 H, 4-H, minor), 2.75 (dd, J = 12.9, 9.8, 1 H, 3-H’, minor), 2.72 (dd, J = 
12.9, 9.8, 1 H, 3-H’, major), 2.10-2.01 (m, 2 H, 6-H + OH), 1.95 (dd, J = 10.1, 5.5, 1 H, 7-Hexo, 
minor), 1.89 (dd, J = 10.1, 5.5, 1 H, 7-Hexo, major), 1.12-1.08 (m, 1 H, 7-Hendo, both rotamers), 
0.88 [s, 9 H, SiC(CH3)3, major], 0.84 [s, 9 H, SiC(CH3)3 minor], 0.11 [s, 3 H, Si(CH3)2, major], 
0.10 [s, 3 H, Si(CH3)2, major], 0.03 [s, 3 H, Si(CH3)2, minor], -0.01 [s, 3 H, Si(CH3)2 minor].  
 
13C NMR (100.4 MHz, CHCl3) (mixture of rotamers) δ (ppm): 171.9 and 171.3 (s, CO), 156.0 
and 155.5 (s, NCO), 136.4 and 136.1 (s, 1 H, Carom), 128.4 and 128.2 (t, 2 C, Carom), 72.1 and 
71.9 (s, CH2Bn), 70.1 and 70.9 (s, C-5), 67.6 and 67.4 (s, C-4), 52.6 and 52.4 (s, OCH3), 47.5 
and 47.0 (s, C-1), 41.8 and 41.0 (s, C-3), 29.1 and 28.7 (s, C-6), 25.6 [(d, 3 C, SiC(CH3)3], 21.2 
and 20.8 (s, C-7), 17.9 [(s, SiC(CH3)3], -4.6 and -4.7 and -4.8 [(s, 2 C, Si(CH3)2]. 
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MS (ESI) m/z (%): 436 ([M+ + 1], 100) 
 
N
H
HO
CO2Me
OH
cis-112  
1-Methyl (1S,4R,5R,6R)-4,5-Dihydroxy-2-azabicyclo[4.1.0]heptane-1-carboxylate (cis-112) 
Compound cis 179 (26 mg, 0.06 mmol) was dissolved in acetonitrile (2.7 mL) and, after cooling 
at 0 °C, a 3 N solution of HCl (2.7 mL) was added dropwise. The cooling bath was removed and 
the mixture left under stirring 1 h. A satd solution of NaHCO3 (20 mL) was slowly added until 
pH 7, the aqueous layer extracted with EtOAc (6 × 20 mL) and the combined organic layers 
dried over Na2SO4, filtered and concentrated. Chromatography (Et2O, Rf 0.23) gave diol 180 (14 
mg, 73%) as a colorless oil. 
180. 1H NMR (400 MHz, mixture of rotamers) δ (ppm): 7.36-7.28 (m, 5 H, Ph), 5.25 (part A of 
an AB system, J = 12.6 Hz, 1 H, CH2Bn, major), 5.19 (part A of an AB system, J = 12.3 Hz, 1 
H, CH2Bn, minor), 5.12 (part B of an AB system, J = 12.3 Hz, 1 H, CH2Bn, minor), 5.04 (part B 
of an AB system, J = 12.6 Hz, 1 H, CH2Bn, major), 4.07-3.95 (br, 2 H, 5-H + 3-H, both 
rotamers), 3.70 (s, 3 H, OCH3, minor), 3.53 (s, 3 H, OCH3, major), 3.33-3.29 (m, 1 H, 4-H, both 
rotamers), 2.83-2.66 (m, 1 H, 3-H’, both rotamers), 2.11-2.02 (m, 1 H, 6-H), 1.98-1.87 (m, 1 H, 
7-Hexo, both rotamers), 1.10-1.06 (m, 1 H, 7-Hendo, both rotamers). 
To a solution of alcohol 180 (14 mg, 0.04 mmol) in ethyl acetate (1.5 mL) was added, under 
nitrogen atmosphere, 10% Pd/C (7 mg) and the resulting suspension stirred under an H2 
atmosphere (balloon) at room temperature for 4.5 h. After filtration over a Celite layer and 
evaporation of the solvent, pure cis (+)-112 (118 mg) was obtained in quantitative yield as a 
colorless oil 
cis-112. [α]D
21 –60.1 (c 0.96, CHCl3); 
1H NMR (400 MHz) δ (ppm): 4.02-3.99 (br, 1 H, 3-H), 
3.72 (s, 3 H, OCH3), 3.68-3.38 (br, 1 H, 3-H’), 3.08-2.85 (br, 3 H, OH, NH), 2.56-2.50 (m, 1 H, 
5-H), 2.18-2.11 (m, 1 H, 7-H), 1.57 (dd, J = 10.2, 4.9 Hz, 1 H, 7-H), 1.13-1.10 (m, 1 H, 7-H’). 
13C NMR (100.4 MHz, CHCl3) δ (ppm): 174.2 (s, CO), 71.7 (s, C-4), 71.0 (s, C-5), 48.0 (s, 
OCH3), 42.9 (s, C-1), 29.7 (s, C-3) 28.3 (s, C-6), 22.7 (s, C-7). MS (ESI) m/z (%): 188 ([M
+ + 1], 
100) 
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181   
(4R,5R)-2-Benzyl 1-Methyl 4,5-Bis-(tertbutyldimethylsilanoxy)-5,6-dihydropyridine 
1,2(4H)-dicarboxylate (181) 
To a stirred solution of 176 (55 mg, 0.13 mmol) in anhydrous DMF (0.6 mL) were added 
imidazole (27 mg, 0.39 mmol) and TBSCl (39 mg, 0.26 mmol) and it was stirred 2.5 h at 38 °C 
(external bath) under N2 atmosphere. After cooling to room temperature, water (5 mL) was 
added and the solution extracted with Et2O (5 × 6 mL). The combined organic layers dried over 
Na2SO4. After filtration and evaporation of the solvent, the crude 181 was chromatographed 
(EtOAc-n-hexane, 1:8, Rf 0.41) to give 181 (72 mg, 99%) as a white solid. 
181. M.p. 96.0-97.1°C;  [α]D
21 –146.3  (c 1,12 CHCl3); 
1H NMR (400 MHz, CHCl3) δ (ppm): 
7.36-7.28 (m, 5 H, Ph) 5.82 (dd, J = 4.1, 1.4 Hz, 1 H, 3-H), 5.14-5.04 (m, 2 H, CH2Ph), 4.14-
4.12 (m, 1 H, 6-Heq), 3.80-3.79 (m, 2 H, 4-H + 5-H), 3.50 (br s, 3 H, OCH3), 3.15 (d, J = 13.1 
Hz, 1 H, 6-Hax), 0.87 [s, 9 H, SiC(CH3)3], 0.83 [s, 9 H, SiC(CH3)3], 0.10 [s, 3 H, Si(CH3)2], 0.09 
[s, 3 H, Si(CH3)2], 0.06 [s, 3 H, Si(CH3)2], 0.04 [s, 3 H, Si(CH3)2].
 13C NMR (100.4 MHz, 
CHCl3) δ (ppm): 164.8 (s, CO), 154.4 (s, NCO), 135.2 (s, Carom), 132.1 (s, C-2), 128.4 (t, 4 C, 
Carom), 120.4 (s, C-3), 70.0 (s, CH2Bn), 67.8 (s, C-4), 66.5 (s, C-5), 51.9 (s, OCH3), 45.7 (s, C-6), 
25.5 [(s, 3 C, SiC(CH3)3], 25.3 [(s, 3 C, SiC(CH3)3], 17.7 [(s, SiC(CH3)3], 17.6 [(s, SiC(CH3)3] -
4.7 [(s, 1 C, Si(CH3)2], -4.9 [(s, 1 C, Si(CH3)2], -5.1 [(s, 1 C, Si(CH3)2], -5.2 [(s, 1 C, Si(CH3)2]. 
MS/MS (ESI of [M+ + 23]) m/z (%): 360 (100), 228 (89). 
C27H45NO6Si2 (535.82) calcd C, 60.52; H, 8.47; N, 2.61. Found C, 60.31; H, 8.32, N, 3.00 
 
N
TBSO
Cbz
CO2Me
OTBS
182 (dr 6 : 1)  
2-Benzyl 1-Methyl (1R,4R,5R,6S)-4,5-Bis-(tert-Butyldimethylsilanyloxy)-2-
azabicyclo[4.1.0]heptane-1,2-dicarboxylate [(–)-182] 
Cyclopropanation by dimethylsulfoxonium methylide of 181. Dry DMSO (0.7 mL) was 
added to NaH (60% in weight in mineral oil, 8 mg, 0.19 mmol) previously washed with dry n-
hexane (2 × 1 mL) under nitrogen atmosphere. To the resulting suspension was added 
trimethylsulfoxonium iodide (38 mg, 0.17 mmol) in three portions and the mixture was left 40 
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min under stirring  at room temperature. After cooling with a water bath at 15 °C, a solution of 
181 (62 mg, 0.12 mmol) in DMSO-DMF 1:1 (400 µL) was added dropwise. The water bath was 
removed and the reaction mixture was left under stirring for 4 h. Water (6 mL) was added and 
the mixture extracted with Et2O (7 × 5 mL), dried over Na2SO4, filtered and concentrated. 
Chromatography (EtOAc-n-hexane, 1:10, Rf 0.10) gave compound 183 (43 mg, 82%) as a 6:1 
mixture of trans and cis isomers.  
183. 1H NMR (CDCl3, 400 MHz, trans isomer, 1.7:1 mixture of rotamers) δ (ppm): 7.37-7.27 
(m, 5 H, Ph), 5.28 (part A of an AB system, J = 12.5 Hz, 1 H, CH2Ph, minor rotamer), 5.23 (part 
A of an AB system, J = 12.7 Hz, 1 H, CH2Ph, major rotamer), 5.05 (part B of an AB system, J = 
12.5 Hz, 1 H, CH2Ph, major rotamer), 4.98 (part B of an AB system, J = 12.3, 1 H, CH2Ph, 
minor rotamer) 3.92 (s + dd, 13.1, 3.1 Hz, 2 H, 5-H, both rotamers + 3-H, major), 3.71 (s, 3 H, 
OCH3, minor), 3.56 (s, 3 H, OCH3, major), 3.22 (d, J = 13.1 Hz, 1 H, 3-H’, minor), 3.10 (d, J = 
13.1 Hz, 1 H, 3-H’, major), 1.81 (dd, J = 10.5, 4.5 Hz, 1 H, 7-Hexo, minor), 1.72 (dd, J = 10.7, 
4.3, 1 H, 7-Hexo, major), 1.42-1.37 (m, 1 H, 7-Hendo, both rotamers), 0.88 [s, 9 H, SiC(CH3)3, 
major], 0.87 [s, 9 H, SiC(CH3)3, minor], 0.81 [s, 9 H, SiC(CH3)3, major], 0.79 [s, 9 H, 
SiC(CH3)3, minor], 0.10 [s, 3 H, Si(CH3)2 major], 0.08 [s, 3 H, Si(CH3)2, both rotamers], 0.07 [s, 
3 H, Si(CH3)2, major], 0.05 [s, 3 H, Si(CH3)2, major], 0.04 [s, 3 H, Si(CH3)2, major], 0.01 [s, 3 H, 
Si(CH3)2, minor], -0.08 [s, 3 H, Si(CH3)2, monor]. 
 
N
H
HO
CO2Me
OH
ent-116  (dr 6 : 1)  
1-Methyl (1R,4R,5R,6S)-4,5-Dihydroxy-2-azabicyclo[4.1.0]heptane-1-carboxylate 
The mixture of trans and cis 182 (79 mg, 0.22 mmol) was treated as reported for 180, affording, 
after chromatography (EtOAc, Rf 0.27), diol 183 as a 6 : 1 mixture with the cis isomer (10 mg, 
44%) as a white solid. 
183. 
1H NMR (200 MHz, CDCl3) (trans isomer, mixture or rotamers δ (ppm) : 7.36-7.28 (m, 5 
H, Ph), 5.12 (AB system, 2 H, CH2Bn) 3.94-3.70 (m, 2 H, 5-H + 3-H), 3.70 (s, 3 H, OCH3, 
minor), 3.53 (s, 3 H, OCH3, major), 3.34-3.28 (m, 1 H, 3-H’, both rotamers), 2.33 (br s, 2 H, 
OH), 1.94 (dd, J = 10.4, 4.9 Hz, 1 H, 7-H, minor), 1.85 (dd, J = 10.4, 4.7 Hz, 1 H, 7-H, major), 
1.79-1.70 (m, 1 H, 6-H’, both rotamers), 1.30-1.23 (m, 1 H, 7-H’, both rotamers). 
Diol 183 was treated as reported for cis-112, affording pure ent-116 in 83% yield (6:1 ratio with 
the cis isomer) as a pale yellow oil. 
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ent-116.1H NMR (400 MHz, CDCl3) (trans isomer) δ (ppm): 4.02-4.01 (br, 1 H, 5-H), 3.72 (s, 3 
H, OCH3), 3.62-3.60 (br, 1 H, 3-H), 3.03 (dd, J = 12.7, 2.3 Hz, 1 H, 4-H), 2.67 (dd, J = 12.7, 4.9 
Hz, 1 H, 3-H’), 2.43-2.42 (br, 3 H, NH, OH), 1.62-1.67 (m, 1 H, 6-H), 1.53 (dd, J = 10.7, 4.7 Hz, 
1 H, 7-H’).  
  
N CO2Me
TBSO
CO2Me
184  
(2S,5S)-Dimethyl 5-(tert-Butyldimethylsilanyloxy)piperidine-1,2-dicarboxylate [(–)-184]. 
Prepared as reported for (–)-160, starting from 169 (920 mg, 2.79 mmol) and leaving the mixture 
under stirring and hydrogen atmosphere for 21 h. After filtration on a celite pad and removal of 
the solvent under vacuum, the so obtained crude 184 was purified by flash chromatography 
(eluent: n-hexane-EtOAc, 6:1; Rf 0.24), affording pure 184 (878 mg, 95%) as a colourless oil, in 
mixture with a small amount of the trans diastereoisomer. 
184. [α]D
30 –24.5 (c 0.74, MeOH) {lit.[92g] [α]D
20 –15.4 (c 1.0, MeOH)}  1H NMR (400 MHz) 
(1.3:1 mixture of rotamers, dr 8:1) δ (ppm): 4.88 (d, J = 4.4 Hz, 1 H, 2-H, major), 4.72 (d, J = 
5.1 Hz, 1 H, 2-H, minor), 4.17 (dd, J = 12.9, 4.9 Hz, 1 H, 6-Heq, minor), 3.99 (dd, J = 12.9, 4.9 
Hz, 1 H, 6-Heq, major), 3.74 and 3.70 (s, 6 H, CO2CH3 and NCO2CH3, both rotamers), 3.60–3.51 
(m, 1 H, 5-H), 2.75 (dd, J = 12.9, 10.5 Hz, 1 H, 6-Hax, major), 2.67 (dd, J = 12.9, 10.5 Hz, 1 H, 
6-Hax, minor), 2.31–2.23 (m, 1 H, 3-Heq), 1.88–1.81 (m, 1 H, 4-Heq), 1.74–1.62 (m, 1 H, 3-Hax), 
1.31–1.19 (m, 1 H, 4-Hax), 0.87 [s, 9 H, SiC(CH3)3], 0.07 [s, 3 H, Si(CH3)2], 0.06 [s, 3 H, 
Si(CH3)2]  ppm. 
13C NMR (100.4 MHz) δ (ppm): 13C NMR (100.4 MHz) (mixture of rotamers) δ 
(ppm): 171.6 (s, CO2Me), 156.7 and 156.2 (s, NCO2Me), 67.4.2 and 67.2 (d, C-5), 53.7 and 53.4 
(d, C-2), 53.1 (q, OCH3), 52.4 and 52.3 (q, OCH3), 48.5 and 48.3 (t, C-6), 31.1 and 31.0 (t, C-3), 
25.8 [(q, 3 C, SiC(CH3)3], 25.4 and 25.0 (C-4), 18.1 [(s, SiC(CH3)3], –4.7 [(q, 2 C, Si(CH3)2]. 
MS (ESI) m/z (%): 332 ([M+ + 1], 100). C15H29NO5Si (331.48): calcd C, 54.35; H, 8.82; N, 4.23. 
Found: C, 54.19; H, 9.02; N, 3.99. 
 
N CO2Me
HO
CO2Me
185  
(2S,5S)-Dimethyl 5-Hydroxypiperidine-1,2-dicarboxylate [(–)-185]. 
A solution of compound 169 (878 mg, 2.65 mmol) in acetonitrile (80 mL) was cooled at 0 °C 
and aqueous 3 N HCl was dropwise added (80 mL). After 10 min the ice bath was removed and 
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the mixture was left under stirring at room temperature for 2 h. Satd NaHCO3 solution was then 
slowly added until complete neutralization and the product extracted with EtOAc (5 x 160 mL). 
The combined organic extracts were dried over anhydrous Na2SO4. After filtration and 
evaporation of the solvent, crude 185 was obtained and purified by flash chromatography 
(eluent: n-hexane-EtOAc, 2:3; Rf 0.35), affording pure compound 185 as a single diasteroisomer 
(448 mg, 78%). Colourless oil. 
185. [α]D
24 –40.3 (c 0.42, MeOH) {lit.[92g] [α]D
20 –24.1 (c 1.0, MeOH)}.  1H NMR (400 MHz) 
(1.3:1 mixture of rotamers) δ (ppm): 4.88 (d, J = 5.5 Hz, 1 H, 2-H, major), 4.73 (d, J = 4.9 Hz, 1 
H, 2-H, minor), 4.27 (br d, J = 12.3 Hz, 1 H, 6-Heq, minor), 4.13 (br d, J = 12.5 Hz, 1 H, 6-Heq, 
major), 3.74 (s, 3 H, CO2CH3), 3.73 and 3.69 (s, 3 H, NCO2CH3), 3.67–3.59 (m, 1 H, 5-H), 2.20 
(br t, J = 11.9, 1 H, 6-Hax, major), 2.71 ( br t, J = 11.7, 1 H, 6-Hax, minor), 2.29 (br d, J = 14.1 
Hz, 1 H, 3-Heq), 2.01–1.93 (m, 2 H, OH and 4-Heq), 1.77–1.68 (m, 1 H, 3-Hax), 1.28–1.18 (m, 1 
H, 4-Hax) 
 
N
H
CO2H
HO
6 HCl.  
(2S,5S)-5-Hydroxypipecolic Acid [(–)-6·HCl] 
Prepared as reported for (–)-10, starting from (–)-185 (100 mg, 0.46 mmol) and obtaining pure (–
)-6 as hydrochloride (83 mg, 99%). 
(–)-6. [α]D
23 –20.8 (c 1.6, H2O) {lit.
[92g] [α]D
20 –21.9 (c 1.0, H2O)}. 
1H NMR (400 MHz, D2O) δ 
(ppm): 4.22 (br s, 1 H, 5-Heq), 4.02 (dd, J = 11.7, 3.7 Hz, 1 H, 2-Hax), 3.38 (dt, J = 13.5, 1.9 Hz, 
1 H, 6-Heq), 3.25 (dd, J = 13.5, 1.6 Hz, 1 H, 6-Hax), 2.22-1.83 (m, 4 H, 3-H and 4-H) 
 
N CO2Me
HO
CO2Me
N CO2Me
HO
CO2Me
ent-185 187  
(2R,5R)-Dimethyl 5-Hydroxypiperidine-1,2-dicarboxylate [(+)-ent-185] and (2S,5R)-
Dimethyl 5-Hydroxypiperidine-1,2-dicarboxylate [(–)-187]  
Reduction of ent-169 (520 mg, 1.58 mmol) was performed as reported for 169 affording, after 
chromatographic purification, a 1.5:1 mixture of ent-184 and 186 (392 mg, 75%). 
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Removal of the O-silyl group was performed on the mixture as reported above for (–)-185, 
affording, after chromatographic separation, pure ent-185 (138 mg, 54%) and (–)-187 (74 mg, 
29%), both as colourless oil. 
Ent-185. [α]D
23 +39.1 (c 0.91, MeOH). 
187. Rf 0.21. [α]D
24 –49.1 (c 0.58, MeOH). 1H NMR (400 MHz) (1.2:1 mixture of rotamers) δ 
(ppm): 4.98 (br d, J = 4.7 Hz, 1 H, 2-H, major), 4.85 (br s, 1 H, 2-H, minor), 4.15 (br d, J = 14.4 
Hz, 1 H, 6-Heq, minor), 4.03 (br, 1 H, 5-Heq), 3.98 (br d, J = 13.7 Hz, 1 H, 6-Heq, major), 3.74 (s, 
3 H, CO2CH3), 3.73 and 3.71 (s, 3 H, NCO2CH3), 3.26 (br d, J = 13.7, 1 H, 6-Hax, major), 3.17 ( 
br d, J = 14.4, 1 H, 6-Hax, minor), 2.25–2.12 (m, 1 H, 3-H), 2.10–1.95 (m, 1 H, 4-H), 1.85–1.63 
(m, 2 H, OH and 4-H'), 1.58–1.45 (m, 1 H, 3-H'). 
 
N
H
CO2H
HO
ent-6  HCl (100%).  
(2R,5R)-5-Hydroxypipecolic Acid [(+)-ent-6·HCl] 
Prepared as reported for (–)-10, starting from ent-185 (138 mg, 0.64 mmol) and obtaining pure 
(+)-ent-6 as hydrochloride (115 mg, quantitative). 
(+)-ent-6. [α]D
24 +21.2 (c 1.1, H2O). Spectroscopic data identical to those of (–)-6 
 
N
H
CO2H
HO
7  HCl.  
(2S,5R)-5-Hydroxypipecolic Acid [(–)-7·HCl] 
Prepared as reported for (–)-10, starting from 187 (74 mg, 0.34 mmol) and obtaining pure (–)-7 
as hydrochloride (62 mg, quantitative). 
[α]D
23 –9.5 (c 0.59, H2O) {lit.
[99] [α]D
20 –9.7 (c 0.9, H2O); lit.
[92g] for (2R,5S) [α]D
20 +8.6 (c 1.0, 
H2O)}. 
1H NMR (400 MHz, D2O) δ (ppm): 4.05–3.98 (m, 2 H, 2-H and 5-H), 3.54 (dd, J = 12.5, 
4.1 Hz, 1 H, 6-Heq), 2.94 (dd, J = 12.5, 9.4 Hz, 1 H, 6-Hax), 2.46–2.38 (m, 1 H, 3-H), 2.18–2.11 
(m, 1 H, 4-H), 1.96–1-85 (m, 1 H, 3-H'), 1.72-1.62 (m, 4-H') ppm 
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N
HO
Cbz
CO2Me
188  
1-Benzyl 2-Methyl (S)-5-Hydroxy-5,6-dihydropyridine-1,2(4H)-dicarboxylate [(–)-188] 
Prepared as reported for 180, starting from 170 (100 mg, 0.25 mmol). After purification by flash 
chromatography (eluant: n-hexane-EtOAc, 1:1; Rf 0.17) pure 188 was obtained as a white solid 
(60 mg, 83%). 
188. M.p. 87.8 - 89.2 °C;  [α]D
25 –14.6  (c 0.65, CHCl3); 
1H NMR (400 MHz, CDCl3) δ (ppm): 
7.38-7.29 (m, 5 H, Ph), 6.06 (t, J = 3.9 Hz, 1 H, 3-H), 5.19 (part A of an AB system, J = 12.2 Hz, 
1 H, CH2Bn), 5.12 (part B of an AB system, J = 12.2, 1 H, CH2Bn), 4.18-4.17 (m, 1 H, 5-H), 
3.82 (dd, J = 13.1, 6.1 Hz, 1 H, 6-H), 3.59-3.55 (m, 4 H, 6-H’ + OCH3), 2.54 (ddd, J = 9.6, 5.7, 
3.71 Hz, 1-H, 4-H), 2.22 (dt, J = 19.9, 4.1 Hz, 1-H, 4-H’). 13C NMR (100.4 MHz, CDCl3) δ 
(ppm): 164.5 (s, CO), 154.9 (s, NCO), 135.7 (s, Carom), 132.1 (s, C-2), 128.5 (s, 2 C, Carom), 
128.3 (s, 2 C, Carom), 128.2 (s, Carom), 121.0 (s, C-3), 68.2 (s, CH2Bn), 64.1 (s, C-5), 52.0 (s, 
OCH3), 49.4 (s, C-6), 32.1 (C-4). MS (ESI) m/z (%): 292 ([M
+ + 1], 28), 248 (12). C15H17NO5 
(291.30) calcd C, 61.85; H, 5.88; N, 4.81; found C, 62.11; H, 5.62; N, 4.62  
 
N
HO
Cbz
CO2Me
cis-189  
2-Benzyl 1-Methyl (1R,4S,6S)-4-Hydroxy-2-azabicyclo[4.1.0]heptane-1,2dicarboxylate [(+)-
cis-188] 
To a solution of 188 (44 mg, 0.15 mmol) in anhydrous CH2Cl2 (1.5 mL), cooled to –15 °C, 
Et2Zn (450 µL of a 1 M solution in hexane, 0.45 mmol) then CH2I2 (72 µL, 0.90 mmol) were 
added dropwise under N2 atmosphere. The cooling bath was removed and reaction mixture was 
left under stirring for 1 h at room temperature, then refluxed for 18h. The suspension was then 
cooled in a ice bath and a 10% solution of citric acid (4 mL) was added dropwise under vigorous 
stirring. The cooling bath was removed and when the solution became clear, the layers were 
separated, the aqueous layer extracted with  CH2Cl2 (3 × 4  mL) and the combined organic layers 
were dried over Na2SO4. After filtration and evaporation of the solvent, crude cis-189 was  
purified by chromatography (n-hexane/EtOAn, 1 : 1; Rf 0.21), which give compound cis-189 (19 
mg, 41%) was obtained as a colorless oil. 
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cis-189. [α]D
25 +22.7  (c 0.92, CHCl3); 
1H NMR (400 MHz, CDCl3) (2.8:1 mixture of rotamers) 
δ (ppm): 7.36-7.25 (m, 5 H, Ph), 5.26 (part A of an AB system, J = 12.5 Hz, 1 H, CH2Bn), 5.09 
(part B of an AB system, J = 12.5 Hz, 1 H, CH2Bn), 4.64-3.88 (m, 2 H, 4-H, both rotamers + 3-
H, major rotamer), 3.85 (dd, J = 12.3, 4.1, 1 H, 6-H, minor rotamer), 3.69 (s, 3 H, OCH3, minor), 
3.55 (s, 3 H, OCH3, major), 3.07 (dd, J = 13.7, 2.5, 1 H, 3-H’, minor), 2.91-2.71 (m, 1 H, 3-H’, 
major), 2.16-1.91 (m, 2 H, 5-H + 7-H, both rotamers), 1.85 (dd, J = 10.2, 4.7 Hz, 1 H, 6-H, both 
rotamers), 1.72-1.60 (m, 1 H, 5-H’, both rotamers), 1.28-1.20 (m, 1 H, 7-H’, both rotamers). 13C 
NMR (100.4 MHz, CDCl3) (mixture of rotamers) δ (ppm): 172.9 and 172.5 (s), 157.7 and 156.6 
(s), 136.7 and 136.6 (s), 128.3 and 127.8 (q), 67.3 (s), 64.9 (s), 52.4 and 52.2 (s), 47.4 and 46.8 
(s), 38.7 and 38.4 (s), 28.8 and 27.9 (s), 24.0 and 23.7 (s), 22.5 and 22.2 (s). MS/MS (ESI of [M 
+ 1]+) m/z (%): 306 ([M + 1]+, 3), 262 (100).  
 
N
H
HO
CO2Me
cis-111  
1-Methyl-(1R,4S,6S)-4-Hydroxy-2-azabicyclo[4.1.0]heptane 1-carboxylate [(+)-cis-111]  
Prepared as reported for (+)-cis-110, starting from cis-189 (17 mg, 0.06 mmol) and obtaining 
pure (+)-cis-111 as a pale yellow oil (10 mg, 96%). 
cis-111. [α]D
24 +91.0  (c 0.91, CHCl3); 
1H NMR (400 MHz, CDCl3) δ (ppm): 3.88-3.85 (m, 1 H, 
4-H), 3.71 (s, 3 H, OCH3), 2.83 (ddd, J = 12.7, 3.9, 1.4 Hz, 1 H, 3-H), 2.69-2.65 (m, 3 H, 3-H’ + 
OH + NH), 2.10-1.98 (m, 2 H, 5-H + 7-H), 1.64-1.54 (m, 5-H’ + 6-H), 1.15 (dd, J = 7.03, 3.5 
Hz, 1 H, 7-H’). 13C NMR (100.4 MHz, CDCl3) δ (ppm): 175.4 (s, CO), 64.0 (s), 52.4 (s), 47.5 
(s), 39.5 (s), 28.7 (s), 26.1 (s), 19.6 (s). MS (ESI) m/z (%) 172 ([M]+, 100) 
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